CUMULATIVE SUPPLEMENT 12

JAN'91-DEC'91

APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

11TH EDITION

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION

Prepared By
Division of Drug Information Resources
Office of Management
Center for Drug Evaluation and Research, FDA

SUBCRIBE NOW!

Available in March 1992

New 12th Edition

APPROVED DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

12TH EDITION
1992

CONTENTS

- Prescription Drug Product List
- OTC Drug Product List
- Drug Products with Approval under Section 505 of the Act Administered by the Division of Blood and Blood Products List
- Discontinued Drug Product List
- Orphan Drug Product Designations
- Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution
- Biopharmaceutic Guidance Availability
- ANDA Suitability Petitions
- Patent and Exclusivity Information

See Subscription Form Inside Back Cover

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

11TH EDITION

Cumulative Supplement

December 1991

CONTENTS

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

11TH EDITION

CUMULATIVE SUPPLEMENT 12

DECEMBER 1991

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 11th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Division of Blood and Blood Products and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Division of Blood and Blood Products lists.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product, along with the application number and product number (FDA's internal file number). All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Additions new to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >ADD> to the left of the line on which new information exists. The >ADD> symbol is then dropped in subsequent Cumulative Supplements for that item. A newly approved product is also identified by a lozenge (⌑) to the right of its strength which remains throughout all Cumulative Supplements for this edition.

Deletions new to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >DLT> (DELETE) to the left of the line containing overstruck print. The >DLT> symbol is dropped in subsequent Cumulative Supplements for that item. The overstruck print remains in the Prescription Drug Product List and OTC Drug Product Lists in all Cumulative Supplements for this edition. However, the overstruck print in the Patent and Exclusivity Data is dropped in subsequent Cumulative Supplements.

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the " ∋ " symbol to designate their non-marketed status. All products having a " ∋ " symbol in the 12th Cumulative Supplement of the 11th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 12th Edition.

1.2 PRODUCTS REQUIRING REVISED LABELING FOR FULL APPROVAL

Drug products in this category (1) initially received approval only on the basis of safety before effectiveness studies were required, or (2) were conditionally approved under the temporary exemption that allowed these products to be marketed while effectiveness studies were being conducted. Listed below are those drugs which are now required to revise their labeling and provide additional information necessary for full approval on the basis of requirements listed in the Federal Register. As approval is granted by the Agency for a specific product, based on additional information submitted by the applicant, the product will be included in the appropriate Drug Product List.

Products	Federal Register Reference
Nitroglycerin (capsule, controlled release;oral)	SEP 7, 1984 (49 FR 35428)
Nitroglycerin (tablet, controlled release;oral)	SEP 7, 1984 (49 FR 35428)
Nitroglycerin (tablet, controlled release;buccal)	JUL 5, 1985 (50 FR 27688)
Tranylcypromine Sulfate	MAR 22, 1984 (49 FR 10708)

1.3 CHANGE OF A THERAPEUTIC EQUIVALENCY CODE FOR A DRUG ENTITY

Methylphenidate Hydrochloride:

In Cumulative Supplement 4 of the Approved Drug Products with Therapeutic Equivalence Evaluations, 11th Edition, the Agency proposed to change the therapeutic equivalence code for methylphenidate hydrochloride oral tablets from a drug product not presenting a bioequivalence problem **AA** to a drug product with a potential bioequivalence problem **BP**.

The Agency solicited comments from interested persons to be received no later than 60 days from the first day in Cumulative Supplement 4 or April 1, 1991. The proposal did not elicit any comments from the readers.

The therapeutic equivalence code for the drug entity in this dosage form will be changed to reflect it has a potential for a bioequivalence problem. An acceptable bioequivalence study, among other things, will be required before an approval is granted for a methylphenidate tablet application.

As mentioned in the 4th Cumulative Supplement proposal for a change in the code for methylphenidate hydrochloride oral tablets, the Agency commissioned a bioequivalence study under its extramural contract research program to study the two approved methylphenidate oral immediate-release tablets. The study demonstrated that the two drug products were bioequivalent. This supplement will reflect that finding by coding the two products as **AB**.

1.4 THE B* THERAPEUTIC EQUIVALENCE CODE

Drug products requiring further FDA investigation and review to determine therapeutic equivalence.

The code **B*** is assigned to products that were previously assigned an **A** or **B** code if FDA receives new information that raises a significant question regarding therapeutic equivalence that can be resolved only through further Agency investigation and/or review of data and information submitted by the applicant. The **B*** code signifies that the Agency will take no position regarding the therapeutic equivalence of the product until the Agency completes its investigation and review.

1.5 APPLICANT (NAME) CHANGES

Because it is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name, the cumulation of these transfers and name changes will be identified in this section only. Where only partial approved product lines are transferred between applicants, each approved product involved will appear as an applicant name change in the Cumulative Supplement.

APPLICANT (NAME) CHANGES

FORMER APPLICANT (NAME)	NEW APPLICANT (NAME)	ABBREVIATED NAME
CORD LABORATORIES INC	GENEVA PHARMACEUTICALS INC	GENEVA
FOREST LABORATORIES INC	FOREST LABORATORIES INC	FOREST LABS
FOREST PHARMACEUTICALS INC	FOREST PHARMACEUTICALS INC	FOREST PHARMS
GIST BROCADES	BROCADES PHARMA bv	BROCADES PHARMA
ICI PHARMACEUTICALS PR INC	IPR PHARMACEUTICALS INC	IPR
KENDALL MCGAW PHARMACEUTICALS	GENSIA PHARMACEUTICALS INC	GENSIA

APPLICANT (NAME) CHANGES

FORMER APPLICANT (NAME)	NEW APPLICANT (NAME)	ABBREVIATED NAME
PHARMACIA LABORATORIES DIV PHARMACIA INC	KABI PHARMACIA	KABI
REID ROWELL INC	SOLVAY PHARMACEUTICALS	SOLVAY

1.6 REVISED TRADE NAME SELECTION CRITERIA

The following is a revision to the main volume of the *Approved Drug Products with Therapeutic Equivalence Evaluations*, 11th Edition's Section 1.4, Practitioner's Responsibilities.

> To relate trade name (proprietary name) information on a product label to that on the List, the following should be noted: if the applicant is the marketer, its name appears on the List and on the label; if the Agency is aware of a corporate relationship between the applicant and the marketer, the trade name (proprietary name) of the drug product (established drug name if no trade name exists) appears on the List. If a corporate relationship exists between an application holder and a marketer and both firms are distributing the drug product, the FDA reserves the right to select the trade name of either the marketer or the application holder to appear on the List. If there is no known corporate relationship between the applicant and the marketer, the established drug name appears on the List.

1.7 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under sections 505 and 507 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 1990) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 1990	JUN 1991	SEP 1991	DEC 1991
DRUG PRODUCTS LISTED	10123	9900	9869	9584
SINGLE SOURCE	2030 (20.1%)	2110 (21.3%)	2103 (21.4%)	2187 (22.8%)
MULTISOURCE	8093 (79.9%)	7790 (78.7%)	7766 (78.6%)	7397 (77.2%)
THERAPEUTICALLY EQUIVALENT	7222 (71.3%)	6937 (70.1%)	6914 (70.0%)	6580 (68.7%)
NOT THERAPEUTICALLY EQUIVALENT	752 (7.4%)	702 (7.1%)	706 (7.2%)	664 (6.9%)
EXCEPTIONS[1]	119 (1.2%)	151 (1.5%)	146 (1.4%)	153 (1.6%)
NEW MOLECULAR ENTITIES APPROVED	--	4	3	17
NUMBER OF APPLICANTS	400	417	418	430

[1]Amino acid-containing products of varying composition (see Introduction, page 1-8 of the List).

ACETAMINOPHEN; CODEINE PHOSPHATE

CAPSULE; ORAL

	PROVAL #3			
AA	SOLVAY	325MG;30MG		N85685 001
	@ SOLVAY	325MG;30MG		N85685 001
	TYLENOL W/ CODEINE NO. 3			
AA	JOHNSON RW	300MG;30MG		N87422 001
	@ JOHNSON RW	300MG;30MG		N87422 001
	TYLENOL W/ CODEINE NO. 4			
	JOHNSON RW	300MG;60MG		N87421 001
	@ JOHNSON RW	300MG;60MG		N87421 001

TABLET; ORAL

	ACETAMINOPHEN AND CODEINE PHOSPHATE			
	MIKART	650MG;60MG¤		N89363 001 SEP 25, 1991
> DLT >	ACETAMINOPHEN AND CODEINE PHOSPHATE NO. 2			
> DLT > AA	AM THERAP	300MG;15MG		N89478 001 MAR 03, 1987
> DLT > AA	AM THERAP	300MG;15MG		N89481 001 MAR 03, 1987
> ADD >	@ AM THERAP	300MG;15MG		N89478 001 MAR 03, 1987
> ADD >	@	300MG;15MG		N89481 001 MAR 03, 1987
> DLT >	ACETAMINOPHEN AND CODEINE PHOSPHATE NO. 3			
> DLT > AA	AM THERAP	300MG;30MG		N89479 001 MAR 03, 1987
> DLT > AA		300MG;30MG		N89482 001 MAR 03, 1987
> ADD >	@ AM THERAP	300MG;30MG		N89479 001 MAR 03, 1987
> ADD >	@	300MG;30MG		N89482 001 MAR 03, 1987
> DLT >	ACETAMINOPHEN AND CODEINE PHOSPHATE NO. 4			
> DLT > AA	AM THERAP	300MG;60MG		N89480 001 MAR 03, 1987
> DLT > AA		300MG;60MG		N89483 001 MAR 03, 1987
> ADD >	@ AM THERAP	300MG;60MG		N89480 001 MAR 03, 1987
> ADD >	@	300MG;60MG		N89483 001 MAR 03, 1987
	ACETAMINOPHEN W/ CODEINE PHOSPHATE			
AA	PARKE/DAVIS	300MG;60MG		N87306 001
	@ WARNER CHILCOTT	300MG;60MG		N87306 001

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL

	TYLENOL W/ CODEINE		
AA	JOHNSON RW	325MG;15MG	N85056 002
AA		325MG;30MG	N85056 003
		325MG;7.5MG	N85056 001
		325MG;60MG	N85056 004
	@ JOHNSON RW	325MG;7.5MG	N85056 001
	@	325MG;15MG	N85056 002
	@	325MG;30MG	N85056 003
	@	325MG;60MG	N85056 004

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

	HYDROCODONE BITARTRATE AND ACETAMINOPHEN		
AA	MIKART	500MG;2.5MG	N89698 001 AUG 25, 1989
AA		500MG;7.5MG	N89699 001 AUG 25, 1989
		500MG;2.5MG	N89698 001 AUG 25, 1989
		500MG;7.5MG	N89699 001 AUG 25, 1989
AA	PHARM BASICS	500MG;5MG	N89291 001 MAY 29, 1987
	@ PHARM BASICS	500MG;5MG	N89291 001 MAY 29, 1987
AA	WATSON	500MG;2.5MG¤	N81079 001 AUG 30, 1991
AA		500MG;7.5MG¤	N81080 001 AUG 30, 1991
AA		750MG;7.5MG¤	N81083 001 AUG 30, 1991
	VICODIN ES		
AA	KNOLL	750MG;7.5MG	N89736 001 DEC 09, 1988
		750MG;7.5MG	N89736 001 DEC 09, 1988

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

	TYLOX-325		
	JOHNSON RW	325MG;5MG	N88246 001 NOV 08, 1984
	@ JOHNSON RW	325MG;5MG	N88246 001 NOV 08, 1984

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

/AB/	/BOLAR/	/325MG;50MG/	/N70398/001/	/DEC/18,/1986/
/AB/		/650MG;100MG/	/N70399/001/	/DEC/18,/1986/
	∂ BOLAR	325MG;50MG	N70398 001	DEC 18, 1986
	∂	650MG;100MG	N70399 001	DEC 18, 1986
>DLT> /B*/	/CHELSEA/	/325MG;50MG/	/N71336/001/	/DEC/11,/1986/
>DLT> /B*/		/650MG;100MG/	/N71337/001/	/DEC/11,/1986/

ACETAZOLAMIDE

TABLET; ORAL
ACETAZOLAMIDE

	∂ ALRA	250MG	N83320 001
/∂/	/BANMAX/	/250MG/	/N83320/001/
/AB/	/BOLAR/	/250MG/	/N84498/002/
	∂ BOLAR	250MG	N84498 002

ACETIC ACID, GLACIAL

SOLUTION/DROPS; OTIC
/DRLEX/

/AT/	/NORWICH/EATON/	/2%/	/N86845/001/
	∂ NORWICH EATON	2%	N86845 001

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS; OTIC
/DRLEX 'HC/

/AT/	/NORWICH/EATON/	/2%;1%/	/N86844/001/
	∂ NORWICH EATON	2%;1%	N86844 001

ACETOHEXAMIDE

TABLET; ORAL
ACETOHEXAMIDE

/AB/	/PHARM/BASICS/	/250MG/	/N70753/001/	/NOV/03,/1986/
/AB/		/500MG/	/N70754/001/	/NOV/03,/1986/
B*	PHARM BASICS	250MG	N70753 001	NOV 03, 1986
B*		500MG	N70754 001	NOV 03, 1986

ACETOPHENAZINE MALEATE

/TABLET;/ORAL/
/TINDAL/

/BP/	/SCHERING/	/20MG/	/N12254/002/
	∂ SCHERING	20MG	N12254 002

ACETYLCYSTEINE

SOLUTION; INHALATION, ORAL
ACETYLCYSTEINE

/AN/	/QUAD/	/10%/	/N71740/001/ /AUG/11,/1987/
/AN/		/20%/	/N71741/001/ /AUG/11,/1987/
	∂ QUAD	10%	N71740 001 AUG 11, 1987
	∂	20%	N71741 001 AUG 11, 1987

ACYCLOVIR

TABLET; ORAL
ZOVIRAX

	BURROUGHS WELLCOME	400MG*	N20089 001 APR 30, 1991
		800MG*	N20089 002 APR 30, 1991

ALBUTEROL SULFATE

SOLUTION; INHALATION
ALBUTEROL SULFATE

AN	COPLEY	EQ 0.5% BASE*	N73307 001 NOV 27, 1991

ALBUTEROL SULFATE

TABLET; ORAL
ALBUTEROL SULFATE

> DLT >	/AB/	/AM THERAP/	/EQ 2MG BASE/	/N72449/001/	/FEB/01,/1989/
> DLT >			/EQ 4MG BASE/	/N72450/001/	/FEB/01,/1989/
> ADD >		ə AM THERAP	EQ 2MG BASE	N72449 001	FEB 01, 1989
> ADD >		ə	EQ 4MG BASE	N72450 001	FEB 01, 1989
	AB	COPLEY	EQ 2MG BASE¤	N72966 001	NOV 22, 1991
	AB		EQ 4MG BASE¤	N72967 001	NOV 22, 1991
	AB	DANBURY	EQ 2MG BASE¤	N72629 001	JAN 31, 1991
	AB		EQ 4MG BASE¤	N72630 001	JAN 31, 1991
	AB	MYLAN	EQ 2MG BASE¤	N72893 001	JAN 17, 1991
	AB		EQ 4MG BASE¤	N72894 001	JAN 17, 1991
	AB	WATSON	EQ 2MG BASE¤	N72764 001	AUG 28, 1991
	AB		EQ 4MG BASE¤	N72765 001	AUG 28, 1991

ALCOHOL

INJECTABLE; INJECTION
/ALCOHOL 5% IN DEXTROSE 5%/

/AP/	/CUTTER/	/5ML/100ML/	/N83483/001/	
	ə CUTTER	5ML/100ML	N83483 001	

ALGLUCERASE

INJECTABLE; INJECTION
CEREDASE

GENZYME	80 UNITS/ML¤	N20057 003	APR 05, 1991

ALLOPURINOL

TABLET; ORAL
ALLOPURINOL

	/AB/	/BOLAR/	/300MG/	/N18241/002/	/NOV/16,/1984/
		ə BOLAR	300MG	N18241 002	NOV 16, 1984
> DLT >	/AB/	/CHELSEA/	/100MG/	/N18785/001/	/SEP/28,/1984/
> DLT >	/AB/		/300MG/	/N18785/002/	/SEP/28,/1984/
> ADD >		ə CHELSEA	100MG	N18785 001	SEP 28, 1984
> ADD >		ə	300MG	N18785 002	SEP 28, 1984
	/AB/	/PUREPAC/	/100MG/	/N70579/001/	/APR/14,/1986/
	/AB/		/300MG/	/N70580/001/	/APR/14,/1986/
		ə PUREPAC	100MG	N70579 001	APR 14, 1986
		ə	300MG	N70580 001	APR 14, 1986

ALPRAZOLAM

TABLET; ORAL
XANAX

/Ə/UPJOHN/	/2MG/	/N18276/004/	/NOV/27,/1985/
UPJOHN	2MG	N18276 004	NOV 27, 1985

AMANTADINE HYDROCHLORIDE

SYRUP; ORAL
AMANTADINE HCL

AA	COPLEY	50MG/5ML¤	N73115 001	AUG 23, 1991

AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL
AMILORIDE HCL AND HYDROCHLOROTHIAZIDE

> DLT >	/AB/	/BARR/	/5MG;50MG/	/N71111/001/	/MAY/10,/1988/
> ADD >	AB	BARR	EQ 5MG ANHYDROUS;50MG	N71111 001	MAY 10, 1988

AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

AMILORIDE HCL AND HYDROCHLOROTHIAZIDE

> DLT >	/AB/	/BIOCRAFT/	/5MG;50MG/	/N70795/001/	
> DLT >				/JUL/15,/1987/	
> ADD >	AB	BIOCRAFT	EQ 5MG ANHYDROUS;50MG	N70795 001	
> ADD >				JUL 15, 1987	
> DLT >	/AB/	/GENEVA/	/5MG;50MG‡/	/N73357/001/	
> DLT >				/NOV/27,/1991/	
> ADD >	AB	GENEVA	EQ 5MG ANHYDROUS;50MG‡	N73357 001	
> ADD >				NOV 27, 1991	
> DLT >	/AB/	/MYLAN/	/5MG;50MG‡/	/N73209/001/	
> DLT >				/OCT/31,/1991/	
> ADD >	AB	MYLAN	EQ 5MG ANHYDROUS;50MG‡	N73209 001	
> ADD >				OCT 31, 1991	
> DLT >	/AB/	/ROYCE/	/5MG;50MG‡/	/N73334/001/	
> DLT >				/JUL/19,/1991/	
> ADD >	AB	ROYCE	EQ 5MG ANHYDROUS;50MG‡	N73334 001	
> ADD >				JUL 19, 1991	

HYDRO-RIDE

> DLT >	/AB/	/PAR/	/5MG;50MG/	/N70347/001/	
> DLT >				/AUG/06,/1986/	
> ADD >	AB	PAR	EQ 5MG ANHYDROUS;50MG	N70347 001	
> ADD >				AUG 06, 1986	

MODURETIC 5-50

> DLT >	/AB/	/MSD/	/5MG;50MG/	/N18201/001/	
> ADD >	AB	MSD	EQ 5MG ANHYDROUS;50MG	N18201 001	

AMINO ACIDS

INJECTABLE; INJECTION

> ADD >		AMINOSYN II 10% IN PLASTIC CONTAINER			
> ADD >		ABBOTT	10%‡	N20015 001	
> ADD >				DEC 19, 1991	
> ADD >		AMINOSYN II 15% IN PLASTIC CONTAINER			
> ADD >		ABBOTT	15%‡	N20041 001	
> ADD >				DEC 19, 1991	

AMINOCAPROIC ACID

INJECTABLE; INJECTION

AMINOCAPROIC ACID

	/AP/	/QUAD/	/250MG/ML/	/N70694/001/	
				/MAR/04,/1986/	
		∂ QUAD	250MG/ML	N70694 001	
				MAR 04, 1986	

AMINOHIPPURATE SODIUM

INJECTABLE; INJECTION

AMINOHIPPURATE SODIUM

	/AP/	/MSD/	/20%/	/N05619/001/	
		MSD	20%	N05619 001	
	/AP/	/QUAD/	/20%/	/N89821/001/	
				/JUL/14,/1988/	
		∂ QUAD	20%	N89821 001	
				JUL 14, 1988	

AMINOPHYLLINE

INJECTABLE; INJECTION

AMINOPHYLLINE

	AP	GENSIA	25MG/ML‡	N81142 001	
				SEP 25, 1991	
	/AP/	/INTL/MEDICATION/	/25MG/ML/	/N87867/001/	
				/NOV/10,/1983/	
	/AP/		/25MG/ML/	/N87868/001/	
				/NOV/10,/1983/	
		∂ INTL MEDICATION	25MG/ML	N87867 001	
				NOV 10, 1983	
		∂	25MG/ML	N87868 001	
				NOV 10, 1983	
	/AP/	/SOLOPAK/	/25MG/ML/	/N88429/001/	
				/MAY/30,/1985/	
		∂ SOLOPAK	25MG/ML	N88429 001	
				MAY 30, 1985	

TABLET; ORAL

AMINOPHYLLINE

> DLT >	/AB/	/DURAMED/	/100MG/	/N88182/001/	
> DLT >				/MAR/31,/1983/	
> DLT >	/AB/		/200MG/	/N88183/001/	
> DLT >				/MAR/31,/1983/	
> ADD >		∂ DURAMED	100MG	N88182 001	
> ADD >				MAR 31, 1983	
> ADD >		∂	200MG	N88183 001	
> ADD >				MAR 31, 1983	
	BD	LANNETT	100MG	N84588 001	
	BD		200MG	N84588 002	
		/∂/	/100MG/	/N84588/001/	
		/∂/	/200MG/	/N84588/002/	

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

/AMITID/

/AB/	/SQUIBB/	/10MG/	/N86454/001/	
/AB/		/25MG/	/N86454/002/	
/AB/		/50MG/	/N86454/003/	
/AB/		/75MG/	/N86454/004/	
/AB/		/100MG/	/N86454/005/	
	∂ SQUIBB	10MG	N86454 001	
	∂	25MG	N86454 002	
	∂	50MG	N86454 003	
	∂	75MG	N86454 004	
	∂	100MG	N86454 005	

AMITRIPTYLINE HCL

/AB/	/BARR/	/10MG/	/N85744/001/	
/AB/		/25MG/	/N85627/001/	
/AB/		/50MG/	/N85745/001/	
/AB/		/75MG/	/N85743/001/	
/AB/		/100MG/	/N85742/002/	
			/MAY/11,/1982/	
/AB/		/150MG/	/N89423/001/	
			/FEB/17,/1987/	
	∂ BARR	10MG	N85744 001	
	∂	25MG	N85627 001	
	∂	50MG	N85745 001	
	∂	75MG	N85743 001	
	∂	100MG	N85742 002	
			MAY 11, 1982	
	∂	150MG	N89423 001	
			FEB 17, 1987	

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HCL

/AB/	/PHARM/BASICS/	/EQ 12.5MG BASE;5MG/	/N70477/001/	
			/JAN/12,/1988/	
/AB/		/EQ 25MG BASE;10MG/	/N70478/001/	
			/JAN/12,/1988/	
B*	PHARM BASICS	EQ 12.5MG BASE;5MG	N70477 001	
			JAN 12, 1988	
B*		EQ 25MG BASE;10MG	N70478 001	
			JAN 12, 1988	

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL

PERPHENAZINE AND AMITRIPTYLINE HCL

/AB/	/BOLAR/	/10MG;2MG/	/N70373/001/		
			/AUG/25,/1986/		
/AB/		/10MG;4MG/	/N70375/001/		
			/AUG/25,/1986/		
/AB/		/25MG;2MG/	/N70374/001/		
			/AUG/25,/1986/		
/AB/		/25MG;4MG/	/N70376/001/		
			/AUG/25,/1986/		
/AB/		/50MG;4MG/	/N70377/001/		
			/NOV/04,/1986/		
	∂ BOLAR	10MG;2MG	N70373 001		
			AUG 25, 1986		
	∂	10MG;4MG	N70375 001		
			AUG 25, 1986		
	∂	25MG;2MG	N70374 001		
			AUG 25, 1986		
	∂	25MG;4MG	N70376 001		
			AUG 25, 1986		
	∂	50MG;4MG	N70377 001		
			NOV 04, 1986		
>DLT>	/B*/ /CHELSEA/	/10MG;2MG/	/N71384/001/		
>DLT>			/NOV/03,/1986/		
>DLT>	/B*/	/10MG;4MG/	/N71386/001/		
>DLT>			/NOV/03,/1986/		
>DLT>	/B*/	/25MG;2MG/	/N71385/001/		
>DLT>			/NOV/03,/1986/		
>DLT>	/B*/	/25MG;4MG/	/N71387/001/		
>DLT>			/NOV/03,/1986/		
	/B*/	/50MG;4MG/	/N71558/001/		
			/MAR/02,/1987/		
	∂ CHELSEA	50MG;4MG	N71558 001		
			MAR 02, 1987		
	AB ROYCE	10MG;2MG[M]	N73007 001		
			OCT 17, 1991		
	AB	10MG;4MG[M]	N73009 001		
			OCT 17, 1991		
	AB	25MG;2MG[M]	N73008 001		
			OCT 17, 1991		
	AB	25MG;4MG[M]	N73010 001		
			OCT 17, 1991		

AMOXAPINE

TABLET; ORAL
AMOXAPINE

AB	GENEVA	25MG¤	N72943 001 JUN 28, 1991	
AB		50MG¤	N72944 001 JUN 28, 1991	
AB		100MG¤	N72878 001 JUN 28, 1991	
AB		150MG¤	N72879 001 JUN 28, 1991	

AMPICILLIN SODIUM

INJECTABLE; INJECTION
AMPICILLIN SODIUM

/AP/	/INTL/MEDICATION/	/EQ 1GM BASE/VIAL/	/N62634/002/ /JAN/09,/1987/	> DLT >
/AP/		/EQ 2GM BASE/VIAL/	/N62634/003/ /JAN/09,/1987/	> DLT >
	∂ INTL MEDICATION	EQ 1GM BASE/VIAL	N62634 002 JAN 09, 1987	> DLT >
	∂	EQ 2GM BASE/VIAL	N62634 003 JAN 09, 1987	> DLT >

POLYCILLIN-N

AP	BRISTOL	EQ 10GM BASE/VIAL	N61395 006	> ADD >

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL
/PENBRITIN/

/AB/	/WYETH/AYERST/	/EQ 250MG BASE/	/N60908/001/	> ADD >
/AB/		/EQ 500MG BASE/	/N60908/002/	> ADD >
	∂ WYETH AYERST	EQ 250MG BASE	N60908 001	> ADD >
	∂	EQ 500MG BASE	N60908 002	> ADD >

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION
M,V,I,-12 LYOPHILIZED

/AP/	/ARMOUR/	/100MG/VIAL;0.06MG/VIAL;/ /0.005MG/VIAL;15MG/VIAL;5UGM/VIAL;/ /0.4MG/VIAL;40MG/VIAL;4MG/VIAL;/ /3.6MG/VIAL;3MG/VIAL;1MG/VIAL;/ /10MG/VIAL/	/N18933/002/ /AUG/08,/1985/	> DLT >

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN E

	/INJECTABLE;/INJECTION/			> ADD >
	/BEROCCA/PN/			> ADD >
	/ROCHE/	/50MG/ML;0.03MG/ML;0.0025MG/ML;/ /7.5MG/ML;100/IU/ML;0.2MG/ML;/ /20MG/ML;2MG/ML;1.8MG/ML;1.5MG/ML;/ /1,650/IU/ML;5/IU/ML/	/N06071/003/ /OCT/10,/1985/	> ADD >
	∂ ROCHE	50MG/ML;0.03MG/ML;0.0025MG/ML; 7.5MG/ML;100 IU/ML;0.2MG/ML; 20MG/ML;2MG/ML;1.8MG/ML;1.5MG/ML; 1,650 IU/ML;5 IU/ML	N06071 003 OCT 10, 1985	> ADD >

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION
M,V,I,-12

AP	ASTRA	10MG/ML;0.006MG/ML;0.5UGM/ML; 1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML; 0.4MG/ML;0.36MG/ML;0.3MG/ML; 330 UNITS /ML;1 IU/ML	N08809 004 AUG 08, 1985	> ADD >
/AP/	/USV/	/10MG/ML;0.006MG/ML;0.5UGM/ML;/ /1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML;/ /0.4MG/ML;0.36MG/ML;0.3MG/ML;/ /330 UNITS /ML;1 IU/ML/	/N08809/004/ /AUG/08,/1985/	> ADD >

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

MVC PLUS

/AP/	/ASCOT/	/10MG/ML;0.006MG/ML;0.5UGM/ML;/ /1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML;/ /0.4MG/ML;0.36MG/ML;0.3MG/ML;/ /330 UNITS /ML;1 IU/ML/	/N18439/002/ /AUG/08,/1985/	
AP	STERIS	10MG/ML;0.006MG/ML;0.5UGM/ML; 1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML; 0.4MG/ML;0.36MG/ML;0.3MG/ML; 330 UNITS /ML;1 IU/ML	N18439 002 AUG 08, 1985	

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

/BUTALBITAL W/ ASPIRIN AND CAFFEINE/

/AB/	/CHELSEA/	/325MG;50MG;40MG/	/N86231/002/ /FEB/12,/1985/	

BUTALBITAL, ASPIRIN AND CAFFEINE

AB	CHELSEA	325MG;50MG;40MG	N86231 002	FEB 12, 1985

TABLET; ORAL

/BUTALBITAL W/ ASPIRIN AND CAFFEINE/

/AB/	/CHELSEA/	/325MG;50MG;40MG/	/N86237/002/ /MAR/23,/1984/	

BUTALBITAL, ASPIRIN AND CAFFEINE

AB	CHELSEA	325MG;50MG;40MG	N86237 002	MAR 23, 1984

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL

HORGESIC

> DLT >	/AB/	/3M/	/385MG;30MG;25MG/	/N13416/003/ /OCT/27,/1982/	
> DLT >					
> ADD >		3M	385MG;30MG;25MG	N13416 003	OCT 27, 1982
> ADD >					

HORGESIC FORTE

> DLT >	/AB/	/3M/	/770MG;60MG;50MG/	/N13416/004/ /OCT/27,/1982/	
> DLT >					
> ADD >		3M	770MG;60MG;50MG	N13416 004	OCT 27, 1982
> ADD >					

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL

/ORPHENGESIC/

> DLT >	/B*/	/PAR/	/385MG;30MG;25MG/	/N71642/001/ /JUN/23,/1987/

/ORPHENGESIC/FORTE/

> DLT >	/B*/	/PAR/	/770MG;60MG;50MG/	/N71643/001/ /JUN/23,/1987/

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

COMPOUND 65

@ ALRA	389MG;32.4MG;65MG	N84553 002	AUG 17, 1983
/@/BANMAX/	/389MG;32.4MG;65MG/	/N84553/002/ /AUG/17,/1983/	

ASPIRIN; CARISOPRODOL

TABLET; ORAL

/CARISOPRODOL COMPOUND/

/AB/	/BOLAR/	/325MG;200MG/	/N88809/001/ /OCT/03,/1985/	
@ BOLAR		325MG;200MG	N38809 001	OCT 03, 1985

ASPIRIN; MEPROBAMATE

TABLET; ORAL

/MEPROBAMATE AND ASPIRIN/

> DLT >					
> DLT >	/AB/	/PAR/	/325MG;200MG/	/N89126/001/ /AUG/19,/1986/	
> DLT >					
> ADD >		@ PAR	325MG;200MG	N89126 001	AUG 19, 1986
> ADD >					

ATENOLOL

TABLET; ORAL

ATENOLOL

> ADD >	AB	DANBURY	50MG*	N73352 001
> ADD >				DEC 27, 1991
> ADD >	AB		100MG*	N73353 001
> ADD >				DEC 27, 1991

ATENOLOL

TABLET; ORAL
ATENOLOL

AB	GENEVA	50MG¤	N73025 001 SEP 17, 1991		
AB		100MG¤	N73026 001 SEP 17, 1991		
> ADD > AB	LEDERLE	50MG¤	N73542 001 DEC 19, 1991		
> ADD > AB		100MG¤	N73543 001 DEC 19, 1991		

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL
DIPHENOXYLATE HCL AND ATROPINE SULFATE

/AA/	/HEATHER/	/0.025MG;2.5MG/	/N86798/001/
	∂ HEATHER	0.025MG;2.5MG	N86798 001
	/LONOXATE/		
/AA/	/CORD/	/0.025MG;2.5MG/	/N85311/002/
	LONOX		
AA	CORD	0.025MG;2.5MG	N85311 002

ATROPINE SULFATE; EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION
ENLON-PLUS

ANAQUEST	0.14MG/ML;10MG/ML¤	N19677 001 NOV 06, 1991
	0.14MG/ML;10MG/ML¤	N19678 001 NOV 06, 1991

AZITHROMYCIN

CAPSULE; ORAL
ZITHROMAX

PFIZER	250MG¤	N50670 001 NOV 01, 1991

BACITRACIN

INJECTABLE; INJECTION
BACITRACIN

> DLT >/AP/	/QUAD/	/10,000 UNITS/VIAL/	/N62696/001/	/APR/17,/1987/
> DLT >				
> DLT >/AP/		/50,000 UNITS/VIAL/	/N62696/002/	/APR/17,/1987/
> DLT >				
> ADD >	∂ QUAD	10,000 UNITS/VIAL	N62696 001 APR 17, 1987	
> ADD >				
> ADD >	∂	50,000 UNITS/VIAL	N62696 002 APR 17, 1987	
> ADD >				

BACLOFEN

TABLET; ORAL
BACLOFEN

AB	DANBURY	10MG¤	N72824 001 SEP 18, 1991
AB		20MG¤	N72825 001 SEP 18, 1991
/AB/	/PHARM/BASICS/	/10MG/	/N71260/001/ /MAY/06,/1988/
/AB/		/20MG/	/N71261/001/ /MAY/06,/1988/
B*	PHARM BASICS	10MG	N71260 001 MAY 06, 1988
B*		20MG	N71261 001 MAY 06, 1988

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL
LOTENSIN

CIBA	EQ 5MG BASE¤	N19851 001 JUN 25, 1991
	EQ 10MG BASE¤	N19851 002 JUN 25, 1991
	EQ 20MG BASE¤	N19851 003 JUN 25, 1991
	EQ 40MG BASE¤	N19851 004 JUN 25, 1991

BENOXINATE HYDROCHLORIDE

> DLT >	/SOLUTION/DROPS;/OPHTHALMIC/			
> DLT >	/BENOXINATE HCL/			
> DLT >/AT/	/BARNES/HIND/	/0.4%/	/N84149/001/	
> ADD >	∂ SOLA BARNES HIND	0.4%	N84149 001	

BENZTROPINE MESYLATE

TABLET; ORAL

	BENZTROPINE MESYLATE		
/AA/	/PHARM/BASICS/	/0.5MG/	/N89211/001/ /JUN/14,/1988/
/AA/		/1MG/	/N89212/001/ /JUN/14,/1988/
/AA/		/2MG/	/N89213/001/ /JUN/14,/1988/
B*	PHARM BASICS	0.5MG	N89211 001 JUN 14, 1988
B*		1MG	N89212 001 JUN 14, 1988
B*		2MG	N89213 001 JUN 14, 1988

BERACTANT

SUSPENSION; INTRATRACHEAL

SURVANTA		
ROSS	25MG/ML*	N20032 001 JUL 01, 1991

BETHANECHOL CHLORIDE

INJECTABLE; INJECTION

	/BETHANECHOL CHLORIDE/		
/AP/	/QUAD/	/5MG/ML/	/N89815/001/ /APR/12,/1988/
ə	QUAD	5MG/ML	N89815 001 APR 12, 1988

	URECHOLINE		
/AP/	/MSD/	/5MG/ML/	/N06536/001/
	MSD	5MG/ML	N06536 001

TABLET; ORAL

	BETHANECHOL CHLORIDE		
/AA/	/BOLAR/	/5MG/	/N85230/002/
/AA/		/10MG/	/N85228/001/
/AA/		/25MG/	/N85229/001/
/AA/		/50MG/	/N87397/001/
ə	BOLAR	5MG	N85230 002
ə		10MG	N85228 001
ə		25MG	N85229 001
ə		50MG	N87397 001
	DUVOID		
/AA/	/NORWICH/EATON/	/10MG/	/N86262/001/
/AA/		/25MG/	/N85882/002/
/AA/		/25MG/	/N86263/001/
/AA/		/50MG/	/N85882/003/

BETHANECHOL CHLORIDE

TABLET; ORAL

	DUVOID		
AA	ROBERTS	10MG	N86262 001
AA		25MG	N86263 001
AA		50MG	N85882 003

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION

	BRETYLIUM TOSYLATE		
/AP/	/QUAD/	/50MG/ML/	/N71181/001/ /FEB/16,/1988/
ə	QUAD	50MG/ML	N71181 001 FEB 16, 1988

	BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER		
	/ABBOTT/	/800MG/100ML/	/N19008/001/ /APR/16,/1986/
ə	ABBOTT	800MG/100ML	N19008 001 APR 16, 1986

BROMPHENIRAMINE MALEATE

TABLET; ORAL

	BROMPHENIRAMINE MALEATE		
/AA/	/PAR/	/4MG/	/N87009/001/
ə	PAR	4MG	N87009 001
/AA/	/VITARINE/	/4MG/	/N85850/001/
ə	VITARINE	4MG	N85850 001

BROMPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

	/ELIXIR;/ORAL/		
	/BIPHETAP/		
	/PHARM/BASICS/	/4MG/5ML;25MG/5ML/	/N88687/001/ /SEP/26,/1984/
ə	PHARM BASICS	4MG/5ML;25MG/5ML	N88687 001 SEP 26, 1984

BUPRENORPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

	BUPRENEX		
	/NORWICH/EATON/	/EQ/0.3MG/BASE/ML/	/N18401/001/
	R AND C	EQ 0.3MG BASE/ML	N18401 001

BUPROPION HYDROCHLORIDE

TABLET; ORAL
WELLBUTRIN
/BURROUGHS/WELLCOME/ /50MG/ /N18644/001/
/DEC/30,/1985/
@ BURROUGHS WELLCOME 50MG N18644 001
DEC 30, 1985

BUTABARBITAL SODIUM

TABLET; ORAL
BUTABARBITAL SODIUM
/AA/ /CORD/ /15MG/ /N84292/003/
/FEB/09,/1982/
/AA/ /30MG/ /N84272/002/
@ CORD 15MG N84292 003
FEB 09, 1982
@ 30MG N84272 002
/AA/ /WHITE/TOWNE/PAULSEN// /15MG/ /N83325/002/
@ WHITE TOWNE PAULSEN 15MG N83325 002

BUTORPHANOL TARTRATE

>ADD> SPRAY, METERED; NASAL
>ADD> STADOL
>ADD> BRISTOL MYERS SQUIBB 1MG/INH¤ N19890 001
>ADD> DEC 12, 1991

CALCITONIN, SALMON

INJECTABLE; INJECTION
CALCIMAR
AP RHONE POULENC RORER 200 IU/ML N17769 001
MIACALCIN
AP SANDOZ 200 IU/ML¤ N17808 002
MAR 29, 1991

CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION; IRRIGATION
BSS PLUS
AT ALCON 0.154MG/ML;0.92MG/ML;0.184MG/ML; 0.2MG/ML;0.38MG/ML;2.1MG/ML; 7.14MG/ML;0.42MG/ML N18469 001

CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION; IRRIGATION
ENDOSOL PLUS
AT ENTRAVISION 0.154MG/ML;0.92MG/ML;0.184MG/ML; 0.2MG/ML;0.38MG/ML;2.1MG/ML; 7.14MG/ML;0.42MG/ML¤ N20079 001
NOV 27, 1991

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

/INJECTABLE;/INJECTION/
/ACETATED/RINGER'S/IN/PLASTIC/CONTAINER/
/MCGAW/ /20MG/100ML;30MG/100ML;380MG/100ML;/ /600MG/100ML/ /N18725/001/
/NOV/29,/1982/
@ MCGAW 20MG/100ML;30MG/100ML;380MG/100ML; 600MG/100ML N18725 001
NOV 29, 1982

CALCIUM GLUCEPTATE

INJECTABLE; INJECTION
CALCIUM GLUCEPTATE
/AP/ /ABBOTT/ /EQ 90MG CALCIUM/5ML/ /N83159/001/
@ ABBOTT EQ 90MG CALCIUM/5ML N83159 001

CARBAMAZEPINE

TABLET; ORAL
CARBAMAZEPINE
/AB/ /PHARM/BASICS/ /200MG/ /N70300/001/
/MAY/15,/1986/
B* PHARM BASICS 200MG N70300 001
MAY 15, 1986

CARBIDOPA; LEVODOPA

TABLET, EXTENDED RELEASE; ORAL
SINEMET CR
MSD 50MG;200MG¤ N19856 001
MAY 30, 1991

CARISOPRODOL

TABLET; ORAL
CARISOPRODOL

/AA/	/BOLAR/	/350MG/	/N85433/001/	> ADD >	AP	HANFORD	EQ 500MG BASE/VIAL¤	N63214 001
	∂ BOLAR	350MG	N85433 001	> ADD >				DEC 27, 1991
AA	MUTUAL PHARM	350MG¤	N89346 001	> ADD >	AP		EQ 500MG BASE/VIAL¤	N63216 001
			OCT 17, 1991	> ADD >				DEC 27, 1991
				> ADD >	AP		EQ 1GM BASE/VIAL¤	N63207 001
				> ADD >				DEC 27, 1991
				> ADD >	AP		EQ 1GM BASE/VIAL¤	N63208 001
				> ADD >				DEC 27, 1991
				> ADD >	AP		EQ 10GM BASE/VIAL¤	N63209 001
				> ADD >				DEC 27, 1991

CEFADROXIL

CAPSULE; ORAL
ULTRACEF

/AB/	/BRISTOL/	/EQ 500MG BASE/	/N62378/001/					
			/MAR 16, 1982/					
	∂ BRISTOL	EQ 500MG BASE	N62378 001					
			MAR 16, 1982					

POWDER FOR RECONSTITUTION; ORAL
ULTRACEF

/AB/	/BRISTOL/	/EQ 125MG BASE/5ML/	/N62376/001/	> ADD >		CEFPROZIL		
			/MAR 16, 1982/	> ADD >		POWDER FOR RECONSTITUTION; ORAL		
/AB/		/EQ 250MG BASE/5ML/	/N62376/002/	> ADD >		CEFZIL		
			/MAR 16, 1982/	> ADD >		BRISTOL MYERS SQUIBB	125MG/5ML¤	N50665 001
/AB/		/EQ 500MG BASE/5ML/	/N62376/003/	> ADD >				DEC 23, 1991
			/MAR 16, 1982/	> ADD >			250MG/5ML¤	N50665 002
	∂ BRISTOL	EQ 125MG BASE/5ML	N62376 001	> ADD >				DEC 23, 1991
			MAR 16, 1982	> ADD >		TABLET; ORAL		
	∂	EQ 250MG BASE/5ML	N62376 002	> ADD >		CEFZIL		
			MAR 16, 1982	> ADD >		BRISTOL MYERS SQUIBB	250MG¤	N50664 001
	∂	EQ 500MG BASE/5ML	N62376 003	> ADD >				DEC 23, 1991
			MAR 16, 1982	> ADD >			500MG¤	N50664 002
				> ADD >				DEC 23, 1991

TABLET; ORAL
ULTRACEF

/AB/	/BRISTOL/	/EQ 1GM BASE/	/N62408/001/					
			/AUG 31, 1982/					
	∂ BRISTOL	EQ 1GM BASE	N62408 001					
			AUG 31, 1982					

CEFAZOLIN SODIUM

INJECTABLE; INJECTION
ANCEF IN PLASTIC CONTAINER

	BAXTER	EQ 10MG BASE/ML¤	N63002 001
			MAR 28, 1991
		EQ 20MG BASE/ML¤	N63002 002
			MAR 28, 1991

CEFAZOLIN SODIUM

INJECTABLE; INJECTION
CEFAZOLIN SODIUM

> ADD >	AP	HANFORD	EQ 500MG BASE/VIAL¤	N63214 001				
> ADD >				DEC 27, 1991				
> ADD >	AP		EQ 500MG BASE/VIAL¤	N63216 001				
> ADD >				DEC 27, 1991				
> ADD >	AP		EQ 1GM BASE/VIAL¤	N63207 001				
> ADD >				DEC 27, 1991				
> ADD >	AP		EQ 1GM BASE/VIAL¤	N63208 001				
> ADD >				DEC 27, 1991				
> ADD >	AP		EQ 10GM BASE/VIAL¤	N63209 001				
> ADD >				DEC 27, 1991				

CEFPROZIL

POWDER FOR RECONSTITUTION; ORAL
CEFZIL

	BRISTOL MYERS SQUIBB	125MG/5ML¤	N50665 001	
			DEC 23, 1991	
		250MG/5ML¤	N50665 002	
			DEC 23, 1991	

TABLET; ORAL
CEFZIL

	BRISTOL MYERS SQUIBB	250MG¤	N50664 001
			DEC 23, 1991
		500MG¤	N50664 002
			DEC 23, 1991

CEPHALEXIN

CAPSULE; ORAL
/CEPHALEXIN MONOHYDRATE/

> DLT >	/∂/VITARINE/	/EQ 250MG BASE/	/N62159/001/	
> DLT >	/∂/	/EQ 500MG BASE/	/N62159/002/	
> ADD >	CEPHALEXIN MONOHYDRATE			
> ADD > B*	VITARINE	EQ 250MG BASE	N62159 001	
> ADD > B*		EQ 500MG BASE	N62159 002	

POWDER FOR RECONSTITUTION; ORAL
CEPHALEXIN

AB	SQUIBB MARK	EQ 125MG BASE/5ML¤	N62986 001	
			APR 18, 1991	

CEPHALOTHIN SODIUM

INJECTABLE; INJECTION
/CEPHALOTHIN/

/AP/	/INTL/MEDICATION/	/EQ 1GM BASE/VIAL/	/N62426/002/ /MAY/03,/1985/
/AP/		/EQ 2GM BASE/VIAL/	/N62426/003/ /MAY/03,/1985/
/AP/		/EQ 4GM BASE/VIAL/	/N62426/004/ /MAY/03,/1985/
		/EQ/500MG/BASE/VIAL/	/N62426/001/ /MAY/03,/1985/
	∂ INTL MEDICATION	EQ 500MG BASE/VIAL	N62426 001 MAY 03, 1985
	∂	EQ 1GM BASE/VIAL	N62426 002 MAY 03, 1985
	∂	EQ 2GM BASE/VIAL	N62426 003 MAY 03, 1985
	∂	EQ 4GM BASE/VIAL	N62426 004 MAY 03, 1985

CEPHALOTHIN SODIUM W/ DEXTROSE IN PLASTIC CONTAINER

BAXTER	EQ 20MG BASE/ML¤	N62422 005 JUL 16, 1991
	EQ 40MG BASE/ML¤	N62422 006 JUL 16, 1991

CEPHRADINE

CAPSULE; ORAL
/VELOSEF '250'/

/AB/	/ERSANA/	/250MG/	/N50548/001/
	∂ ERSANA	250MG	N50548 001

/VELOSEF '500'/

/AB/	/ERSANA/	/500MG/	/N50548/002/
	∂ ERSANA	500MG	N50548 002

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL
CHLORDIAZEPOXIDE HCL

/AB/	/SUPERPHARM/	/5MG/	/N88987/001/ /APR/25,/1985/
/AB/		/10MG/	/N88986/001/ /APR/25,/1985/
/AB/		/25MG/	/N88988/001/ /APR/25,/1985/
	∂ SUPERPHARM	5MG	N88987 001 APR 25, 1985
	∂	10MG	N88986 001 APR 25, 1985
	∂	25MG	N88988 001 APR 25, 1985
	LYGEN		
	∂ ALRA	5MG	N85107 001
	∂	10MG	N85009 001
	∂	25MG	N85108 001
	/∂/BANMAX/	/5MG/	/N85107/001/
	/∂/	/10MG/	/N85009/001/
	/∂/	/25MG/	/N85108/001/

CHLOROTHIAZIDE

TABLET; ORAL
CHLOROTHIAZIDE

/AB/	/BOLAR/	/250MG/	/N85165/001/
/AB/		/500MG/	/N84026/001/ /SEP/01,/1982/
	∂ BOLAR	250MG	N85165 001
	∂	500MG	N84026 001 SEP 01, 1982
/B*/	/CHELSEA/	/500MG/	/N86796/001/ /AUG/15,/1983/
	∂ CHELSEA	500MG	N86796 001 AUG 15, 1983

CHLOROTHIAZIDE; RESERPINE

TABLET; ORAL
/CHLOROTHIAZIDE/W//RESERPINE/

/BP/	/BOLAR/	/500MG;0.125MG/	/N88151/001/ /JUN/09,/1983/
	∂ BOLAR	500MG;0.125MG	N88151 001 JUN 09, 1983

CHLORPHENIRAMINE MALEATE

INJECTABLE; INJECTION
CHLORPHENIRAMINE MALEATE

/AP/	/LEMMON/	/10MG/ML/	/N83593/001/
AP	STERIS	10MG/ML	N83593 001

TABLET; ORAL
/ANTAGONATE/

/AA/	/MILES/	/4MG/	/N83381/001/
	ə MILES	4MG	N83381 001

CHLORPHENIRAMINE MALEATE

> ADD >	ə ELKINS SINN	4MG	N80938 001
> DLT >	/ə/QUANTUM/PHARMICS/	/4MG/	/N80938/001/
/AA/	/VITARINE/	/4MG/	/N85837/001/
	ə VITARINE	4MG	N85837 001

/PHENETRON/

/AA/	/LANNETT/	/4MG/	/N80846/001/
	ə LANNETT	4MG	N80846 001

CHLORPROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
CHLORPROMAZINE HCL

/AP/	/LEMMON/	/25MG/ML/	/N85591/001/
AP	STERIS	25MG/ML	N85591 001

CHLORPROPAMIDE

TABLET; ORAL
CHLORPROPAMIDE

/AB/	/BOLAR/	/100MG/	/N88608/001/ /APR/12,/1984/
/AB/		/250MG/	/N88568/001/ /APR/12,/1984/
	ə BOLAR	100MG	N88608 001 APR 12, 1984
	ə	250MG	N88568 001 APR 12, 1984
> DLT >/AB/	/DURAMED/	/100MG/	/N88918/001/ /OCT/16,/1984/
> DLT > /AB/		/250MG/	/N88919/001/ /OCT/16,/1984/
> DLT > > ADD >	ə DURAMED	100MG	N88918 001 OCT 16, 1984
> ADD > > ADD >	ə	250MG	N88919 001 OCT 16, 1984

CHLORPROPAMIDE

TABLET; ORAL
CHLORPROPAMIDE

/AB/	/PHARM/BASICS/	/100MG/	/N88708/001/ /AUG/30,/1984/
/AB/		/250MG/	/N88709/001/ /AUG/30,/1984/
B*	PHARM BASICS	100MG	N88708 001 AUG 30, 1984
B*		250MG	N88709 001 AUG 30, 1984

CHLORTHALIDONE

TABLET; ORAL
CHLORTHALIDONE

/AB/	/BOLAR/	/25MG/	/N87050/001/
/AB/		/50MG/	/N87029/001/
	ə BOLAR	25MG	N87050 001
	ə	50MG	N87029 001
/AB/	/SUPERPHARM/	/25MG/	/N87473/001/ /FEB/09,/1983/
	ə SUPERPHARM	25MG	N87473 001 FEB 09, 1983

CHLORZOXAZONE

TABLET; ORAL
CHLORZOXAZONE

AA	DANBURY	500MG*	N81019 001 JUL 29, 1991

CITRIC ACID; GLUCONOLACTONE; MAGNESIUM CARBONATE

SOLUTION; IRRIGATION
RENACIDIN

> ADD > > ADD > > ADD >	GUARDIAN LABS	6.602GM/100ML;0.198GM/100ML; 3.177GM/100ML	N19481 001 OCT 02, 1990
> DLT > > DLT >	/UNITED/GUARDIAN/	/6.602GM/100ML;0.198GM/100ML;/ /3.177GM/100ML/	/N19481/001/ /OCT/02,/1990/

CLARITHROMYCIN

TABLET; ORAL
BIAXIN
ABBOTT 250MG¤ N50662 001
OCT 31, 1991
500MG¤ N50662 002
OCT 31, 1991

CLEMASTINE FUMARATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
TAVIST D
/DORSEY/ /EQ 1MG BASE;75MG/ /N18298 001/
/DEC 15, 1982/
SANDOZ EQ 1MG BASE;75MG N18298 001
DEC 15, 1982

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL
CLINDAMYCIN HCL
AB DANBURY EQ 75MG BASE¤ N63082 001
JUL 31, 1991
AB EQ 150MG BASE¤ N63083 001
JUL 31, 1991

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION
CLINDAMYCIN PHOSPHATE
/AP/ /LEMMON/ /EQ 150MG BASE/ML/ /N62900 001/
/JUN 08, 1988/
/AP/ /EQ 150MG BASE/ML/ /N63079 001/
/MAR 05, 1990/
>DLT >/AP/ /QUAD/ /EQ 150MG BASE/ML/ /N62877 001/
>DLT > /MAR 15, 1988/
>ADD > ∂ QUAD EQ 150MG BASE/ML N62877 001
>ADD > MAR 15, 1988
AP STERIS EQ 150MG BASE/ML N62900 001
JUN 08, 1988
AP EQ 150MG BASE/ML N63079 001
MAR 05, 1990

CLIOQUINOL; HYDROCORTISONE

CREAM; TOPICAL
VIOFORM-HYDROCORTISONE
CIBA 3%;0.5% N10412 002
3%;1% N10412 001

OINTMENT; TOPICAL
VIOFORM-HYDROCORTISONE
∂ CIBA 3%;0.5% N10412 004
3%;1% N10412 003

CLOFIBRATE

CAPSULE; ORAL
CLOFIBRATE
AB NOVOPHARM 500MG¤ N72600 001
JUL 25, 1991

CLONIDINE HYDROCHLORIDE

TABLET; ORAL
CLONIDINE HCL
/AB/ /BOLAR/ /0.1MG/ /N70395 001/
/MAR 23, 1987/
/AB/ /0.2MG/ /N70396 001/
/MAR 23, 1987/
/AB/ /0.3MG/ /N70397 001/
/MAR 23, 1987/
∂ BOLAR 0.1MG N70395 001
MAR 23, 1987
∂ 0.2MG N70396 001
MAR 23, 1987
∂ 0.3MG N70397 001
MAR 23, 1987
/AB/ /DURAMED/ /0.1MG/ /N71103 001/
/AUG 14, 1986/
/AB/ /0.2MG/ /N71102 001/
/AUG 14, 1986/
/AB/ /0.3MG/ /N71101 001/
/AUG 14, 1986/
∂ DURAMED 0.1MG N71103 001
AUG 14, 1986
∂ 0.2MG N71102 001
AUG 14, 1986
∂ 0.3MG N71101 001
AUG 14, 1986

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL

CLORAZEPATE DIPOTASSIUM

>DLT >/AB/	/AM/THERAP/	/3.75MG/	/N71429/001/		
>DLT >			/JAN/08,/1987/		
>DLT >/AB/		/7.5MG/	/N71430/001/		
>DLT >			/JAN/08,/1987/		
>DLT >/AB/		/15MG/	/N71431/001/		
>DLT >			/JAN/08,/1987/		
>ADD >	ə AM THERAP	3.75MG	N71429 001		
>ADD >			JAN 08, 1987		
>ADD >	ə	7.5MG	N71430 001		
>ADD >			JAN 08, 1987		
>ADD >	ə	15MG	N71431 001		
>ADD >			JAN 08, 1987		
/AB/	/PHARM/BASICS/	/3.75MG/	/N71242/001/		
			/MAY/20,/1987/		
/AB/		/7.5MG/	/N71243/001/		
			/MAY/20,/1987/		
/AB/		/15MG/	/N71244/001/		
			/MAY/20,/1987/		
B*	PHARM BASICS	3.75MG	N71242 001		
			MAY 20, 1987		
B*		7.5MG	N71243 001		
			MAY 20, 1987		
B*		15MG	N71244 001		
			MAY 20, 1987		
/AB/	/PUREPAC/	/3.75MG/	/N71924/001/		
			/APR/25,/1988/		
	ə PUREPAC	3.75MG	N71924 001		
			APR 25, 1988		
/AB/	/SEARLE/	/3.75MG/	/N71727/001/		
			/DEC/18,/1987/		
/AB/		/7.5MG/	/N71728/001/		
			/DEC/18,/1987/		
/AB/		/15MG/	/N71729/001/		
			/DEC/18,/1987/		
	ə SEARLE	3.75MG	N71727 001		
			DEC 18, 1987		
	ə	7.5MG	N71728 001		
			DEC 18, 1987		
	ə	15MG	N71729 001		
			DEC 18, 1987		

CLORAZEPATE DIPOTASSIUM

TABLET; ORAL

CLORAZEPATE DIPOTASSIUM

/AB/	/AM/THERAP/	/3.75MG/	/N71747/001/		
			/JUN/09,/1987/		
/AB/		/7.5MG/	/N71748/001/		
			/JUN/09,/1987/		
/AB/		/15MG/	/N71749/001/		
			/JUN/09,/1987/		
	ə AM THERAP	3.75MG	N71747 001		
			JUN 09, 1987		
	ə	7.5MG	N71748 001		
			JUN 09, 1987		
	ə	15MG	N71749 001		
			JUN 09, 1987		

CLOTRIMAZOLE

CREAM; VAGINAL

		GYNE-LOTRIMIN			
>ADD >	BX	SCHERING	1%		N18052 001
		MYCELEX-G			
>ADD >	BX	MILES	1%		N18230 001
>DLT >			/1%/		/N18230/001/

TABLET; VAGINAL

		GYNE-LOTRIMIN			
>ADD >	BX	SCHERING	100MG		N17717 001
		MYCELEX-G			
>ADD >	BX	MILES	100MG		N18182 001
>DLT >			/100MG/		/N18182/001/

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL

		HISTAFED C			
>ADD >	AA	CENCI	10MG/5ML;30MG/5ML;		
>ADD >			1.25MG/5ML		N89018 001
>ADD >					JUL 23, 1986
>DLT >/AA/	/LIFE/LABS/	/10MG/5ML;30MG/5ML;/			
>DLT >		/1.25MG/5ML/			/N89018/001/
>DLT >					/JUL/23,/1986/

COLCHICINE; PROBENECID

TABLET; ORAL

/PROBENECID/W//COLCHICINE/

/BP/	/BOLAR/	/0.5MG;500MG/	/N83221/001/

COLCHICINE; PROBENECID

TABLET; ORAL
/PROBENECID/W/COLCHICINE/
∂ BOLAR 0.5MG;500MG N83221 001

COPPER

INTRAUTERINE DEVICE; INTRAUTERINE
> ADD > COPPER T MODEL TCU 380A
> ADD > POPULATION COUNCIL APPROX 309MG COPPER¤ N18680 001
> ADD > NOV 15, 1984
> DLT > /INTRAUTERINE/COPPER/CONTRACEPTIVE/
> DLT > /POPULATION/COUNCIL/ /APPROX/176MG/COPPER/ /N18680/002/
> DLT > /APR/29,/1988/

CORTISONE ACETATE

INJECTABLE; INJECTION
CORTISONE ACETATE
/BP/ /LEMMON/ /25MG/ML/ /N85677/001/
/BP/ /50MG/ML/ /N85677/002/
BP STERIS 25MG/ML N85677 001
BP 50MG/ML N85677 002

TABLET; ORAL
CORTISONE ACETATE
> ADD > ∂ ELKINS SINN 25MG N80836 001
> DLT > /∂/QUANTUM/PHARMICS/ /25MG/ /N80836/001/

CYANOCOBALAMIN

INJECTABLE; INJECTION
COBAVITE
/AP/ /LEMMON/ /0.1MG/ML/ /N83013/001/
/AP/ /1MG/ML/ /N83064/001/
AP STERIS 0.1MG/ML N83013 001
AP 1MG/ML N83064 001
CYANOCOBALAMIN
AKORN 1MG/ML N87969 001
NOV 10, 1983
/AP/ /LEMMON/ /0.1MG/ML/ /N83120/001/
/AP/ /1MG/ML/ /N83120/002/
/AP/ /LYPHOMED/ /0.03MG/ML/ /N80510/003/
/AP/ /0.1MG/ML/ /N80510/001/
/AP/ /1MG/ML/ /N80510/002/
∂ LYPHOMED 0.03MG/ML N80510 003
∂ 0.1MG/ML N80510 001
∂ 1MG/ML N80510 002
AP STERIS 0.1MG/ML N83120 001
AP 1MG/ML N83120 002

CYANOCOBALAMIN

INJECTABLE; INJECTION
/DODECAMIN/
/AP/ /AKORN/ /1MG/ML/ /N87969/001/
/NOV/10,/1983/

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL
CYCLOBENZAPRINE HCL
AB GENEVA 10MG¤ N72854 001
NOV 19, 1991
AB MYLAN 10MG¤ N73144 001
MAY 31, 1991
AB WATSON 10MG¤ N73143 001
NOV 27, 1991

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
AK-PENTOLATE
AT AKORN 1% N85555 001
/CYCLOPENTOLATE HCL/
/AT/ /AKORN/ /1%/ /N85555/001/
CYCLOPENTOLATE HCL
> DLT >/AT/ /BARNES/HIND/ /1%/ /N84150/001/
> ADD > ∂ SOLA BARNES HIND 1% N84150 001
AT STERIS 1%¤ N89162 001
JAN 24, 1991

CYPROHEPTADINE HYDROCHLORIDE

SYRUP; ORAL
CYPROHEPTADINE HCL
/AA/ /NASKA/ /2MG/5ML/ /N89021/001/
/DEC/21,/1987/
∂ NASKA 2MG/5ML N89021 001
DEC 21, 1987

TABLET; ORAL
CYPROHEPTADINE HCL
/AA/ /BOLAR/ /4MG/ /N85245/001/
∂ BOLAR 4MG N85245 001
> DLT >/AA/ /DURAMED/ /4MG/ /N88232/001/
> DLT > /OCT/25,/1983/
> ADD > ∂ DURAMED 4MG N88232 001
> ADD > OCT 25, 1983

CYTARABINE

INJECTABLE; INJECTION
CYTARABINE

/AP/	/QUAD/	/100MG/VIAL/	/N71248/001/	/DEC/30,/1987/
/AP/		/500MG/VIAL/	/N71249/001/	/DEC/30,/1987/
	∂ QUAD	100MG/VIAL	N71248 001	DEC 30, 1987
	∂	500MG/VIAL	N71249 001	DEC 30, 1987

DACARBAZINE

INJECTABLE; INJECTION
DACARBAZINE

/AP/	/QUAD/	/100MG/VIAL/	/N70821/001/	/OCT/09,/1986/
/AP/		/200MG/VIAL/	/N70822/001/	/OCT/09,/1986/
	∂ QUAD	100MG/VIAL	N70821 001	OCT 09, 1986
	∂	200MG/VIAL	N70822 001	OCT 09, 1986
		/500MG/VIAL/	/N71563/001/	/MAY/06,/1988/
	∂	500MG/VIAL	N71563 001	MAY 06, 1988

DANAZOL

CAPSULE; ORAL
/DANAZOL/

>DLT>					
>DLT>	/B*/	/AM/THERAP/	/200MG/	/N71569/001/	/DEC/30,/1987/
>DLT>					
>ADD>		∂ AM THERAP	200MG	N71569 001	DEC 30, 1987
>ADD>					

DANOCRINE

>DLT>	/AB/	/STERLING/	/200MG/	/N17557/002/
>ADD>		STERLING	200MG	N17557 002

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
CERUBIDINE

>DLT>	/AP/	/RHONE/POULENC/	/EQ 20MG BASE/VIAL/	/N61876/001/
>ADD>	AP	RHONE POULENC RORER	EQ 20MG BASE/VIAL	N61876 001

DESERPIDINE; METHYCLOTHIAZIDE

TABLET; ORAL
ENDURONYL

/BP/	/ABBOTT/	/0.25MG;5MG/	/N12775/001/	
	ABBOTT	0.25MG;5MG	N12775 001	

ENDURONYL FORTE

/BP/	/ABBOTT/	/0.5MG;5MG/	/N12775/002/	
	ABBOTT	0.5MG;5MG	N12775 002	

/METHYCLOTHIAZIDE/AND/DESERPIDINE/

/BP/	/BOLAR/	/0.25MG;5MG/	/N88486/001/	/AUG/10,/1984/
/BP/		/0.5MG;5MG/	/N88452/001/	/AUG/10,/1984/
	∂ BOLAR	0.25MG;5MG	N88486 001	AUG 10, 1984
	∂	0.5MG;5MG	N88452 001	AUG 10, 1984

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL
DESIPRAMINE HCL

/AB/	/PHARM/BASICS/	/25MG/	/N71864/001/	/SEP/09,/1987/
/AB/		/50MG/	/N71865/001/	/SEP/09,/1987/
/AB/		/75MG/	/N71866/001/	/SEP/09,/1987/
/AB/		/100MG/	/N71867/001/	/SEP/09,/1987/
B*	PHARM BASICS	25MG	N71864 001	SEP 09, 1987
B*		50MG	N71865 001	SEP 09, 1987
B*		75MG	N71866 001	SEP 09, 1987
B*		100MG	N71867 001	SEP 09, 1987

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL

DESIPRAMINE HCL

> ADD >	AB	VITARINE	25MG	N71601 001 JUN 05, 1987	
> ADD >					
> ADD >	AB		50MG	N71588 001 JUN 05, 1987	
> ADD >					
> ADD >	AB		75MG	N71602 001 OCT 05, 1987	
> ADD >					
> ADD >	AB		100MG	N71766 001 OCT 05, 1987	
> ADD >					
> DLT >		/∂/	/25MG/	/N71601/001/ /JUN/05,/1987/	
> DLT >					
> DLT >		/∂/	/50MG/	/N71588/001/ /JUN/05,/1987/	
> DLT >					
> DLT >		/∂/	/75MG/	/N71602/001/ /OCT/05,/1987/	
> DLT >					
> DLT >		/∂/	/100MG/	/N71766/001/ /OCT/05,/1987/	
> DLT >					

DESMOPRESSIN ACETATE

SOLUTION; NASAL

CONCENTRAID

BX	FERRING	0.01%	N19776 001 DEC 26, 1990	
		/0.01%/	/N19776/001/ /DEC/26,/1990/	

DDAVP

BX	RHONE POULENC RORER	0.01%	N17922 001	
		/0.01%/	/N17922/001/	

DEXAMETHASONE

TABLET; ORAL

DEXAMETHASONE

/BP/	/BOLAR/	/0.75MG/	/N84457/001/	
∂ BOLAR		0.75MG	N84457 001	
/BP/	/CORD/	/0.75MG/	/N80399/001/	
∂ CORD		0.75MG	N80399 001	

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

/DEXACEN-4/

/AP/	/CENTRAL/PHARMS/	/EQ 4MG PHOSPHATE/ML/	/N84342/001/
∂ CENTRAL PHARMS		EQ 4MG PHOSPHATE/ML	N84342 001

DEXAMETHASONE SODIUM PHOSPHATE

/AP/	/LEMMON/	/EQ 4MG PHOSPHATE/ML/	/N84355/001/

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

DEXAMETHASONE SODIUM PHOSPHATE

/AP/	/QUAD/	/EQ 4MG PHOSPHATE/ML/	/N89280/001/ /MAR/18,/1987/	
/AP/		/EQ 10MG PHOSPHATE/ML/	/N89281/001/ /MAR/18,/1987/	
/AP/		/EQ 20MG PHOSPHATE/ML/	/N89282/001/ /MAR/18,/1987/	
/AP/		/EQ 24MG PHOSPHATE/ML/	/N89372/001/ /MAR/18,/1987/	
∂ QUAD		EQ 4MG PHOSPHATE/ML	N89280 001 MAR 18, 1987	
∂		EQ 10MG PHOSPHATE/ML	N89281 001 MAR 18, 1987	
∂		EQ 20MG PHOSPHATE/ML	N89282 001 MAR 18, 1987	
∂		EQ 24MG PHOSPHATE/ML	N89372 001 MAR 18, 1987	
AP	STERIS	EQ 4MG PHOSPHATE/ML	N84355 001	

HEXADROL

/AP/	/ORGANON/	/EQ 20MG PHOSPHATE/ML/	/N14694/004/	
	ORGANON	EQ 20MG PHOSPHATE/ML	N14694 004	

SOLUTION/DROPS; OPHTHALMIC

DEXAIR

AT	BAUSCH AND LOMB	EQ 0.1% PHOSPHATE	N88433 001 DEC 15, 1983
/AT/	/PHARMAFAIR/	/EQ 0.1% PHOSPHATE/	/N88433/001/ /DEC/15,/1983/

> DLT >		/DEXAMETHASONE SODIUM PHOSPHATE/		
> DLT >	/AT/	/BARNES/HIND/	/EQ 0.1% PHOSPHATE/	/N84170/001/
> DLT >	/AT/		/EQ 0.1% PHOSPHATE/	/N84173/001/
> ADD >		∂ SOLA BARNES HIND	EQ 0.1% PHOSPHATE	N84170 001
> ADD >		∂	EQ 0.1% PHOSPHATE	N84173 001

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

> DLT >		/PROMETHAZINE DM/		
> DLT >	/AA/	/PHARM/BASICS/	/15MG/5ML;6.25MG/5ML/	/N88864/001/ /JAN/04,/1985/
> DLT >				
> ADD >		PROMETHAZINE W/ DEXTROMETHORPHAN		
> ADD >	AA	PHARM BASICS	15MG/5ML;6.25MG/5ML	N88864 001 JAN 04, 1985
> ADD >				

DEXTROSE

INJECTABLE; INJECTION

DEXTROSE 10% IN PLASTIC CONTAINER

/AP/	/CUTTER/	/10GM/100ML/	/N18504/001/	
	∂ CUTTER	10GM/100ML	N18504 001	

DEXTROSE 50% IN PLASTIC CONTAINER

AP	BAXTER	50GM/100ML¤	N20047 001	JUL 02, 1991

> DLT > /DEXTROSE 60%/
> DLT >/AP/ /MCGAW/ /60GM/100ML/ /N17995/002/ /SEP/22,/1982/
> DLT >
> ADD > ∂ MCGAW 60GM/100ML N17995 002 SEP 22, 1982
> ADD >

DEXTROSE 60% IN PLASTIC CONTAINER

AP	BAXTER	60GM/100ML¤	N20047 002	JUL 02, 1991
> DLT >/AP/	/MCGAW/	/60GM/100ML/	/N17995/001/	
> ADD >	∂ MCGAW	60GM/100ML	N17995 001	

DEXTROSE 70% IN PLASTIC CONTAINER

AP	BAXTER	70GM/100ML¤	N20047 003	JUL 02, 1991

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5%, SODIUM CHLORIDE 0,45% AND POTASSIUM CHLORIDE 0,22% IN PLASTIC CONTAINER

/AP/	/MCGAW/	/5GM/100ML;220MG/100ML;/ /450MG/100ML/	/N18268/002/	
	MCGAW	5GM/100ML;220MG/100ML; 450MG/100ML	N18268 002	

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% AND SODIUM CHLORIDE 0,2% IN PLASTIC CONTAINER

/AP/	/CUTTER/	/5GM/100ML;200MG/100ML/	/N18399/001/	
	∂ CUTTER	5GM/100ML;200MG/100ML	N18399 001	

DEXTROSE 5% AND SODIUM CHLORIDE 0,3% IN PLASTIC CONTAINER

/AP/	/ABBOTT/	/5GM/100ML;300MG/100ML/	/N17799/001/	
	ABBOTT	5GM/100ML;300MG/100ML	N17799 001	
/AP/	/CUTTER/	/5GM/100ML;300MG/100ML/	/N18501/001/	
	∂ CUTTER	5GM/100ML;300MG/100ML	N18501 001	

DEXTROSE 5% AND SODIUM CHLORIDE 0,45% IN PLASTIC CONTAINER

/AP/	/CUTTER/	/5GM/100ML;450MG/100ML/	/N18400/001/	
	∂ CUTTER	5GM/100ML;450MG/100ML	N18400 001	

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION

/DIATRIZOATE 66/

/AP/	/INTL/MEDICATION/	/52%;8%/	/N88166/001/	/JUN/17,/1983/
	∂ INTL MEDICATION	52%;8%	N88166 001	JUN 17, 1983

DIATRIZOATE SODIUM

INJECTABLE; INJECTION

/MD-50/

/AP/	/MALLINCKRODT/	/50%/	/N87075/001/	
	∂ MALLINCKRODT	50%	N87075 001	

DIAZEPAM

INJECTABLE; INJECTION

DIAZEPAM

/AP/	/LEMMON/	/5MG/ML/	/N70911/001/	/AUG/28,/1986/
/AP/		/5MG/ML/	/N70912/001/	/AUG/28,/1986/
/AP/		/5MG/ML/	/N70930/001/	/DEC/01,/1986/
AP	STERIS	5MG/ML	N70911 001	AUG 28, 1986
AP		5MG/ML	N70912 001	AUG 28, 1986
AP		5MG/ML	N70930 001	DEC 01, 1986

TABLET; ORAL

DIAZEPAM

> DLT >/AB/	/CHELSEA/	/2MG/	/N70456/001/	/NOV/01,/1985/
> DLT >				
> DLT >/AB/		/5MG/	/N70457/001/	/NOV/01,/1985/
> DLT >				
> DLT >/AB/		/10MG/	/N70458/001/	/NOV/01,/1985/
> DLT >				
> ADD >	∂ CHELSEA	2MG	N70456 001	NOV 01, 1985
> ADD >	∂	5MG	N70457 001	NOV 01, 1985
> ADD >				
> ADD >	∂	10MG	N70458 001	NOV 01, 1985
> ADD >				

DIAZEPAM

TABLET; ORAL
DIAZEPAM

>DLT >/AB/	/DURAMED/	/2MG/	/N70894/001/	
>DLT >			/AUG/27,/1986/	
>DLT >/AB/		/5MG/	/N70895/001/	
>DLT >			/AUG/27,/1986/	
>DLT >/AB/		/10MG/	/N70896/001/	
>DLT >			/AUG/27,/1986/	
>ADD >	∂ DURAMED	2MG	N70894 001	
>ADD >			AUG 27, 1986	
>ADD >	∂	5MG	N70895 001	
>ADD >			AUG 27, 1986	
>ADD >	∂	10MG	N70896 001	
>ADD >			AUG 27, 1986	
	/∂/SUPERPHARM/	/2MG/	/N70642/001/	
			/DEC/11,/1985/	
	/∂/	/5MG/	/N70643/001/	
			/DEC/11,/1985/	
	/∂/	/10MG/	/N70644/001/	
			/DEC/11,/1985/	

DICLOFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC
VOLTAREN

CIBA	0.1%¤	N20037 001	
		MAR 28, 1991	

DICYCLOMINE HYDROCHLORIDE

CAPSULE; ORAL
DICYCLOMINE HCL

/AB/	/BOLAR/	/10MG/	/N83179/001/	
			/FEB/12,/1986/	
	∂ BOLAR	10MG	N83179 001	
			FEB 12, 1986	

TABLET; ORAL
DICYCLOMINE HCL

/AB/	/BOLAR/	/20MG/	/N84361/001/	
			/FEB/06,/1986/	
	∂ BOLAR	20MG	N84361 001	
			FEB 06, 1986	

DIDANOSINE

POWDER FOR RECONSTITUTION; ORAL
VIDEX

BRISTOL MYERS SQUIBB	10MG/ML¤	N20156 001	
		OCT 09, 1991	
	100MG/PACKET¤	N20155 003	
		OCT 09, 1991	
	167MG/PACKET¤	N20155 004	
		OCT 09, 1991	
	250MG/PACKET¤	N20155 005	
		OCT 09, 1991	
	375MG/PACKET¤	N20155 006	
		OCT 09, 1991	

TABLET, CHEWABLE; ORAL
VIDEX

BRISTOL MYERS SQUIBB	25MG¤	N20154 002	
		OCT 09, 1991	
	50MG¤	N20154 003	
		OCT 09, 1991	
	100MG¤	N20154 004	
		OCT 09, 1991	
	150MG¤	N20154 005	
		OCT 09, 1991	

DIETHYLSTILBESTROL

TABLET; ORAL
STILBESTROL

/BP/	/TABLICAPS/	/0.5MG/	/N83004/001/	
	TABLICAPS	0.5MG	N83004 001	
	/STILBETIN/			
/BP/	/SQUIBB/	/0.5MG/	/N04056/008/	
/BP/		/1MG/	/N04056/009/	
/BP/		/5MG/	/N04056/010/	
		/0.1MG/	/N04056/007/	
		/0.25MG/	/N04056/017/	
	∂ SQUIBB	0.1MG	N04056 007	
	∂	0.25MG	N04056 017	
	∂	0.5MG	N04056 008	
	∂	1MG	N04056 009	
	∂	5MG	N04056 010	

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

>ADD>	CARDIZEM CD			
>ADD>	MARION MERRELL DOW	180MG¤	N20062 002	
>ADD>			DEC 27, 1991	
>ADD>		240MG¤	N20062 003	
>ADD>			DEC 27, 1991	
>ADD>		300MG¤	N20062 004	
>ADD>			DEC 27, 1991	

INJECTABLE; INJECTION

CARDIZEM			
MARION MERRELL DOW	25MG/VIAL¤	N20027 001	
		OCT 24, 1991	
	50MG/VIAL¤	N20027 002	
		OCT 24, 1991	

DIMENHYDRINATE

INJECTABLE; INJECTION

DIMENHYDRINATE			
/AP/ /LEMMON/	/50MG/ML/	/N83531/001/	
AP STERIS	50MG/ML	N83531 001	

LIQUID; ORAL

DIMENHYDRINATE		
∂ ALRA	12.5MG/4ML	N80715 001
/∂/BANMAX/	/12.5MG/4ML/	/N80715/001/

/TABLET; ORAL/

/DIMENHYDRINATE/			
/AA/ /CHELSEA/	/50MG/	/N85166/001/	
∂ CHELSEA	50MG	N85166 001	

TABLET; ORAL

DIMENHYDRINATE		
∂ HEATHER	50MG	N80841 001

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

DIPHENHYDRAMINE HCL			
∂ ALRA	25MG	N80519 004	
∂	50MG	N80519 003	
/∂/BANMAX/	/50MG/	/N80519/003/	
>DLT>/AA/ /BOLAR/	/25MG/	/N83797/001/	
>DLT>/AA/	/50MG/	/N83797/002/	
>ADD> ∂ BOLAR	25MG	N83797 001	
>ADD> ∂	50MG	N83797 002	

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

DIPHENHYDRAMINE HCL			
>ADD> ∂ ELKINS SINN	25MG	N85701 001	
>ADD> ∂	50MG	N85701 002	
>DLT> /∂/QUANTUM/PHARMICS/	/25MG/	/N85701/001/	
>DLT> /∂/	/50MG/	/N85701/002/	

ELIXIR; ORAL

DIPHENHYDRAMINE HCL			
/AA/ /KV/	/12.5MG/5ML/	/N85621/001/	
∂ KV	12.5MG/5ML	N85621 001	

INJECTABLE; INJECTION

DIPHENHYDRAMINE HCL			
/AP/ /ELKINS/SINN/	/50MG/ML/	/N83183/001/	
∂ ELKINS SINN	50MG/ML	N83183 001	
/AP/ /LEMMON/	/10MG/ML/	/N83533/001/	
AP STERIS	10MG/ML	N83533 001	

DIPYRIDAMOLE

TABLET; ORAL

DIPYRIDAMOLE			
AB GENEVA	25MG¤	N86944 002	
		APR 16, 1991	
AB LEDERLE	25MG¤	N88999 001	
		FEB 05, 1991	
AB	50MG¤	N89000 001	
		FEB 05, 1991	
AB	75MG¤	N89001 001	
		FEB 05, 1991	

DISOPYRAMIDE PHOSPHATE

CAPSULE; ORAL

DISOPYRAMIDE PHOSPHATE			
/AB/ /BOLAR/	/EQ 100MG BASE/	/N70240/001/	
		/FEB/02,/1986/	
/AB/	/EQ 150MG BASE/	/N70241/001/	
		/FEB/02,/1986/	
∂ BOLAR	EQ 100MG BASE	N70240 001	
		FEB 02, 1986	
∂	EQ 150MG BASE	N70241 001	
		FEB 02, 1986	

DISOPYRAMIDE PHOSPHATE

CAPSULE; ORAL

DISOPYRAMIDE PHOSPHATE

B*	CHELSEA	EQ 100MG BASE	N71020 001 DEC 01, 1986
B*		EQ 150MG BASE	N71021 001 DEC 01, 1986
/BX/		/EQ/100MG/BASE/	/N71020/001/ /DEC/01,/1986/
/BX/		/EQ/150MG/BASE/	/N71021/001/ /DEC/01,/1986/
/AB/	/MYLAN/	/EQ 100MG BASE/	/N70138/001/ /JUN/14,/1985/
/AB/		/EQ 150MG BASE/	/N70139/001/ /JUN/14,/1985/
	ə MYLAN	EQ 100MG BASE	N70138 001 JUN 14, 1985
	ə	EQ 150MG BASE	N70139 001 JUN 14, 1985

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOBUTREX

	LILLY	EQ 12.5MG BASE/ML /EQ/250MG/BASE/VIAL/	N17820 002 /N17820/002/

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOPAMINE HCL

AP	GENSIA	40MG/ML¤	N72999 001 OCT 23, 1991
AP		80MG/ML¤	N73000 001 OCT 23, 1991
/AP/	/SOLOPAK/	/40MG/ML/	/N70011/001/ /AUG/29,/1985/
	ə SOLOPAK	40MG/ML	N70011 001 AUG 29, 1985

DOXACURIUM CHLORIDE

INJECTABLE; INJECTION

NUROMAX

	BURROUGHS WELLCOME	EQ 1MG BASE/ML¤	N19946 001 MAR 07, 1991

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIN HCL

/AB/	/BARR/	/EQ 25MG BASE/	/N71502/001/ /FEB/18,/1988/
/AB/		/EQ 50MG BASE/	/N71653/001/ /FEB/18,/1988/
/AB/		/EQ 75MG BASE/	/N71654/001/ /FEB/18,/1988/
/AB/		/EQ 100MG BASE/	/N71521/001/ /FEB/18,/1988/
	ə BARR	EQ 25MG BASE	N71502 001 FEB 18, 1988
	ə	EQ 50MG BASE	N71653 001 FEB 18, 1988
	ə	EQ 75MG BASE	N71654 001 FEB 18, 1988
	ə	EQ 100MG BASE	N71521 001 FEB 18, 1988
/B*/	/CHELSEA/	/EQ/10MG/BASE/	/N70952/001/ /MAR/04,/1987/
/B*/		/EQ/25MG/BASE/	/N70953/001/ /MAY/15,/1986/
/B*/		/EQ/50MG/BASE/	/N70954/001/ /MAY/15,/1986/
/B*/		/EQ/75MG/BASE/	/N71763/001/ /FEB/09,/1988/
/B*/		/EQ/100MG/BASE/	/N70955/001/ /MAY/15,/1986/
/B*/		/EQ/150MG/BASE/	/N71764/001/ /FEB/09,/1988/
	ə CHELSEA	EQ 10MG BASE	N70952 001 MAR 04, 1987
	ə	EQ 25MG BASE	N70953 001 MAY 15, 1986
	ə	EQ 50MG BASE	N70954 001 MAY 15, 1986
	ə	EQ 75MG BASE	N71763 001 FEB 09, 1988
	ə	EQ 100MG BASE	N70955 001 MAY 15, 1986
	ə	EQ 150MG BASE	N71764 001 FEB 09, 1988
/AB/	/PUREPAC/	/EQ 75MG BASE/	/N72386/001/ /SEP/08,/1988/
/AB/		/EQ 150MG BASE/	/N72387/001/ /SEP/08,/1988/
	ə PUREPAC	EQ 75MG BASE	N72386 001 SEP 08, 1988
	ə	EQ 150MG BASE	N72387 001 SEP 08, 1988

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL
DOXEPIN HCL

AB	ROYCE	EQ 10MG BASE¤	N72985 001 MAR 29, 1991	> DLT >	
AB		EQ 25MG BASE¤	N72986 001 MAR 29, 1991	> DLT >	
AB		EQ 50MG BASE¤	N72987 001 MAR 29, 1991	> DLT >	

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
ADRIAMYCIN PFS

AP	ADRIA	2MG/ML	N50629 001 DEC 23, 1987	> ADD >	
AP		200MG/100ML	N50629 002 MAY 03, 1988	> ADD >	
AP		2MG/ML¤	N63165 001 JAN 30, 1991	> ADD >	
AP		200MG/100ML¤	N63165 002 JAN 30, 1991	> ADD >	
	/ADRIAMYCIN PFS/	/2MG/ML/	/N50629/002/ /MAY/03,/1988/		

DOXORUBICIN HCL

AP	CETUS BEN VENUE	2MG/ML	N62975 001 MAR 17, 1989		

DOXYCYCLINE HYCLATE

CAPSULE; ORAL
DOXYCYCLINE HYCLATE

/AB/	/SUPERPHARM/	/EQ 50MG BASE/	/N62469/001/ /OCT/31,/1984/		
/AB/		/EQ 100MG BASE/	/N62469/002/ /OCT/31,/1984/		
	∂ SUPERPHARM	EQ 50MG BASE	N62469 001 OCT 31, 1984		
	∂	EQ 100MG BASE	N62469 002 OCT 31, 1984		

DOXYCYCLINE HYCLATE

INJECTABLE; INJECTION
DOXYCYCLINE HYCLATE

/AP/	/QUAD/	/EQ 100MG BASE/VIAL/	/N62643/001/ /FEB/13,/1986/	> DLT >/AP/	
		/EQ 200MG BASE/VIAL/	/N62643/002/ /FEB/13,/1986/	> DLT >	
	∂ QUAD	EQ 100MG BASE/VIAL	N62643 001 FEB 13, 1986	> ADD >	
	∂	EQ 200MG BASE/VIAL	N62643 002 FEB 13, 1986	> ADD >	

TABLET; ORAL
DOXYCYCLINE HYCLATE

/AB/	/CHELSEA/	/EQ 100MG BASE/	/N62392/002/ /MAR/31,/1983/		
	∂ CHELSEA	EQ 100MG BASE	N62392 002 MAR 31, 1983		

DOXYLAMINE SUCCINATE

/TABLET;ORAL/
/DOXYLAMINE SUCCINATE/

/AA/	/COPLEY/	/25MG/	/N088966/001/ /OCT/06,/1985/		

DROPERIDOL

INJECTABLE; INJECTION
DROPERIDOL

/AP/	/ASTRA/	/2.5MG/ML/	/N72020/001/ /OCT/19,/1988/		
	∂ ASTRA	2.5MG/ML	N72020 001 OCT 19, 1988		
/AP/	/QUAD/	/2.5MG/ML/	/N71942/001/ /AUG/17,/1988/		
	∂ QUAD	2.5MG/ML	N71942 001 AUG 17, 1988		
AP	STERIS	2.5MG/ML¤	N73520 001 NOV 27, 1991		
AP		2.5MG/ML¤	N73521 001 NOV 27, 1991		
AP		2.5MG/ML¤	N73523 001 NOV 27, 1991		

EDETATE DISODIUM

INJECTABLE; INJECTION

	DISODIUM EDETATE			
/AP/	/LEMMON/	/150MG/ML/	/N84356/001/	
AP	STERIS	150MG/ML	N84356 001	

> ADD > ENOXACIN

> ADD > TABLET; ORAL

> ADD > PENETREX

> ADD >	PARKE DAVIS	200MG¤	N19616 004 DEC 31, 1991
> ADD >		400MG¤	N19616 005 DEC 31, 1991

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HCL W/ EPINEPHRINE

/3/	/LEMMON/	/0.01MG/ML;1%/	/N85463/001/
	ə STERIS	0.01MG/ML;1%	N85463 001

ERGOLOID MESYLATES

TABLET; ORAL

	ERGOLOID MESYLATES		
/AB/	/BOLAR/	/1MG/	/N86433/001/ /MAY/27,/1982/
	ə BOLAR	1MG	N86433 001 MAY 27, 1982
AB	MUTUAL PHARM	1MG¤	N81113 001 OCT 31, 1991

TABLET; SUBLINGUAL

	/DEAPRIL-ST/		
/AA/	/BRISTOL/MYERS/SQUIBB/	1MG/	/N85020/002/
	ə BRISTOL MYERS SQUIBB	1MG	N85020 002
	ERGOLOID MESYLATES		
/AA/	/BOLAR/	/0.5MG/	/N84930/001/
/AA/		/1MG/	/N85177/001/
	ə BOLAR	0.5MG	N84930 001
	ə	1MG	N85177 001
/AA/	/KV/	/0.5MG/	/N86265/001/
/AA/		/1MG/	/N86264/001/
	ə KV	0.5MG	N86265 001
	ə	1MG	N86264 001

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL

	ERYC SPRINKLES			
> DLT >/AB/	/FAULDING/	/125MG/	/N50593/001/ /JUL/22,/1985/	
> DLT >				
> ADD >	FAULDING	125MG	N50593 001 JUL 22, 1985	
> ADD >				
> DLT >	/ERYC 125/			
> DLT >/AB/	/PARKE/DAVIS/	/125MG/	/N62648/001/ /OCT/24,/1985/	
> DLT >				
> ADD >	ə PARKE DAVIS	125MG	N62648 001 OCT 24, 1985	
> ADD >				

GEL; TOPICAL

	E/GEL		
	/FULTON/	/2%/	/N63107/001/ /AUG/23,/1991/
	EMGEL		
AT	GLAXO	2%¤	N63107 001 AUG 23, 1991
	ERYGEL		
AT	HERBERT	2%	N50617 001 OCT 21, 1987

SOLUTION; TOPICAL

	ERYTHROMYCIN		
AT	CLAY PARK	2%¤	N63038 001 JAN 11, 1991
/AT/	/LILLY/	/2%/	/N50532/001/
	ə LILLY	2%	N50532 001

ERYTHROMYCIN ETHYLSUCCINATE

SUSPENSION; ORAL

	ERYTHROMYCIN ETHYLSUCCINATE		
/AB/	/NASKA/	/EQ 400MG BASE/5ML/	/N62674/001/ /MAR/10,/1987/
	ə NASKA	EQ 400MG BASE/5ML	N62674 001 MAR 10, 1987

ERYTHROMYCIN LACTOBIONATE

INJECTABLE; INJECTION
ERYTHROMYCIN LACTOBIONATE

>DLT >/AP/	/QUAD/	/EQ 500MG BASE/VIAL/	/N62660/001/ /NOV/24,/1986/
>DLT >			
>DLT >/AP/		/EQ 1GM BASE/VIAL/	/N62660/003/ /NOV/24,/1986/
>DLT >			
>ADD >	ə QUAD	EQ 500MG BASE/VIAL	N62660 001 NOV 24, 1986
>ADD >			
>ADD >	ə	EQ 1GM BASE/VIAL	N62660 003 NOV 24, 1986
>ADD >			

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION
BREVIBLOC

	/DUPONT/	/100MG/ML/	/N19386/003/ /DEC/31,/1986/
	ə DUPONT	100MG/ML	N19386 003 DEC 31, 1986

ESTRADIOL CYPIONATE

INJECTABLE; INJECTION
ESTRADIOL CYPIONATE

/AO/	/QUAD/	/5MG/ML/	/N89310/001/ /FEB/09,/1987/
	ə QUAD	5MG/ML	N89310 001 FEB 09, 1987

ESTROGENS, CONJUGATED

TABLET; ORAL
CONJUGATED ESTROGENS

/BP/	/CHELSEA/	/1.25MG/	/N85861/001/
/BP/		/2.5MG/	/N85826/001/
	/ə/	/0.625MG/	/N85860/001/
	/ə/CORD/	/0.3MG/	/N86670/001/
	/ə/	/0.625MG/	/N83761/001/
	/ə/	/1.25MG/	/N83763/001/
	/ə/	/2.5MG/	/N83762/001/
	/ə/DURAMED/	/0.3MG/	/N86492/001/
	/ə/	/0.625MG/	/N83272/001/
	/ə/	/1.25MG/	/N83294/001/
	/ə/	/2.5MG/	/N83295/001/
	/ə/HEATHER/	/0.625MG/	/N83356/001/
	/ə/	/1.25MG/	/N83360/001/
	/ə/	/2.5MG/	/N84650/001/

ESTROGENS, CONJUGATED

TABLET; ORAL
CONJUGATED ESTROGENS

	/ə/PRIVATE/FORM/	/0.625MG/	/N83354/003/
	/ə/	/1.25MG/	/N83592/001/
	/ə/	/2.5MG/	/N85908/001/
/BP/	/ZENITH/	/0.3MG/	/N88569/001/ /NOV/29,/1984/
/BP/		/0.625MG/	/N83373/001/
/BP/		/1.25MG/	/N83601/001/
/BP/		/2.5MG/	/N83602/001/
	ə ZENITH	0.3MG	N88569 001 NOV 29, 1984
	ə	0.625MG	N83373 001
	ə	1.25MG	N83601 001
	ə	2.5MG	N83602 001

ESTROGENS, CONJUGATED; MEPROBAMATE

TABLET; ORAL
/MILPREM-200/

/BS/	/WALLACE/	/0.45MG;200MG/	/N11045/002/
	ə WALLACE	0.45MG;200MG	N11045 002
	/MILPREM-400/		
/BS/	/WALLACE/	/0.45MG;400MG/	/N11045/001/
	ə WALLACE	0.45MG;400MG	N11045 001
	PMB 200		
/BS/	/WYETH/AYERST/	/0.45MG;200MG/	/N10971/005/
	WYETH AYERST	0.45MG;200MG	N10971 005
	PMB 400		
/BS/	/WYETH/AYERST/	/0.45MG;400MG/	/N10971/003/
	WYETH AYERST	0.45MG;400MG	N10971 003

ESTROGENS, ESTERIFIED

TABLET; ORAL
/AMNESTROGEN/

/BS/	/SQUIBB/	/0.625MG/	/N83266/002/
/BS/		/1.25MG/	/N83266/003/
/BS/		/2.5MG/	/N83266/004/
	ə SQUIBB	0.625MG	N83266 002
	ə	1.25MG	N83266 003
	ə	2.5MG	N83266 004
	/ESTERIFIED/ESTROGENS/		
/BS/	/PRIVATE/FORM/	/2.5MG/	/N85907/001/
	ə PRIVATE FORM	2.5MG	N85907 001

ESTROGENS, ESTERIFIED

TABLET; ORAL

/BS/	/EVEX/ /SYNTEX/	/0.625MG/	/N84215/001/	
/BS/		/1.25MG/	/N83376/002/	
	@ SYNTEX	0.625MG	N84215 001	
	@	1.25MG	N83376 002	
	/FEMOGEN/			
/BS/	/PRIVATE/FORM/	/0.625MG/	/N85076/001/	
	@ PRIVATE FORM	0.625MG	N85076 001	

ESTROPIPATE

TABLET; ORAL

	OGEN			
AB	ABBOTT	0.75MG	N83220 001	
AB		1.5MG	N83220 002	
	ORTHO-EST			
AB	JOHNSON RW	0.75MG¤	N89567 001 FEB 27, 1991	
AB		1.5MG¤	N89582 001 JUL 17, 1991	

ETHANOLAMINE OLEATE

INJECTABLE; INJECTION

	ETHAMOLIN			
>DLT>	/BLOCK/DRUG/	/50MG/ML/	/N19357/001/	
>DLT>			/DEC/22,/1988/	
>ADD>	REED AND CARNRICK	50MG/ML	N19357 001	
>ADD>			DEC 22, 1988	

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET; ORAL-21

	DEMULEN 1/35-21			
>ADD> AB	SEARLE	0.035MG;1MG	N18168 001	
	DEMULEN 1/50-21			
>ADD> AB	SEARLE	0.05MG;1MG	N16927 001	
>ADD>	ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL 1/35-21			
>ADD> AB	WATSON	0.035MG;1MG¤	N72720 001 DEC 30, 1991	
>ADD>	ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL 1/50-21			
>ADD> AB	WATSON	0.05MG;1MG¤	N72722 001 DEC 30, 1991	

TABLET; ORAL-28

	DEMULEN 1/35-28			
>ADD> AB	SEARLE	0.035MG;1MG	N18160 001	

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET; ORAL-28

	DEMULEN 1/50-28			
>ADD> AB	SEARLE	0.05MG;1MG	N16936 001	
>ADD>	ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL 1/35-28			
>ADD> AB	WATSON	0.035MG;1MG¤	N72721 001 DEC 30, 1991	
>ADD>	ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL 1/50-28			
>ADD> AB	WATSON	0.05MG;1MG¤	N72723 001 DEC 30, 1991	

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

	/NORETHINDRONE AND ETHINYL ESTRADIOL/			
/AB/	/WATSON/	/0.035MG;0.5MG AND 1MG/	/N71043/001/ /APR/01,/1988/	
	NORETHINDRONE AND ETHINYL ESTRADIOL (10/11)			
AB	WATSON	0.035MG;0.5MG AND 1MG	N71043 001 APR 01, 1988	
	NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)			
	WATSON	0.035MG;0.5MG AND 1MG¤	N71041 001 SEP 24, 1991	

TABLET; ORAL-28

	/NORETHINDRONE AND ETHINYL ESTRADIOL/			
/AB/	/WATSON/	/0.035MG;0.5MG AND 1MG/	/N71044/001/ /APR/01,/1988/	
	NORETHINDRONE AND ETHINYL ESTRADIOL (10/11)			
AB	WATSON	0.035MG;0.5MG AND 1MG	N71044 001 APR 01, 1988	
	NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)			
	WATSON	0.035MG;0.5MG AND 1MG¤	N71042 001 SEP 24, 1991	

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

/TABLET;/ORAL-28/

/NORLESTRIN/28/1/50/			
/PARKE/DAVIS/	/0.05MG;1MG/		/N16723/001/

TABLET; ORAL-28

NORLESTRIN 28 1/50			
@ PARKE DAVIS	0.05MG;1MG		N16723 001

ETODOLAC

CAPSULE; ORAL
LODINE
WYETH AYERST 200MG¤ N18922 002 JAN 31, 1991
300MG¤ N18922 003 JAN 31, 1991

FELODIPINE

TABLET, EXTENDED RELEASE; ORAL
PLENDIL
MSD 5MG¤ N19834 001 JUL 26, 1991
10MG¤ N19834 002 JUL 26, 1991

FENOPROFEN CALCIUM

CAPSULE; ORAL
FENOPROFEN CALCIUM
> DLT > /AB/ /AM THERAP/ /EQ 200MG BASE/ /N72307 001/ /AUG 22, 1988/
> DLT >
> DLT > /AB/ /EQ 300MG BASE/ /N72308 001/ /AUG 22, 1988/
> DLT >
> ADD > @ AM THERAP EQ 200MG BASE N72307 001 AUG 22, 1988
> ADD >
> ADD > @ EQ 300MG BASE N72308 001 AUG 22, 1988
> ADD >
AB DANBURY EQ 200MG BASE¤ N72981 001 AUG 19, 1991
AB EQ 300MG BASE¤ N72982 001 AUG 19, 1991
AB WARNER CHILCOTT EQ 200MG BASE¤ N72946 001 APR 30, 1991
AB EQ 300MG BASE¤ N72472 001 APR 30, 1991

TABLET; ORAL
FENOPROFEN CALCIUM
> DLT > /AB/ /AM THERAP/ /EQ 600MG BASE/ /N72309 001/ /JUN 16, 1988/
> DLT >
> ADD > @ AM THERAP EQ 600MG BASE N72309 001 JUN 16, 1988
> ADD >
/AB/ /PHARM BASICS/ /EQ 600MG BASE/ /N72362 001/ /JUN 16, 1988/
@ PHARM BASICS EQ 600MG BASE N72362 001 JUN 16, 1988

FENTANYL CITRATE

INJECTABLE; INJECTION
FENTANYL CITRATE
AP STERLING EQ 0.05MG BASE/ML¤ N72786 001 SEP 24, 1991

FIBRINOGEN, I-125

INJECTABLE; INJECTION
/IBRIN/
/AMERSHAM/ /154 UCI/VIAL/ /N17879 001/
@ AMERSHAM 154 UCI/VIAL N17879 001

FLOXURIDINE

INJECTABLE; INJECTION
/FLOXURIDINE/
/AP/ /QUAD/ /500MG/VIAL/ /N71055 001/ /AUG 24, 1987/
@ QUAD 500MG/VIAL N71055 001 AUG 24, 1987

FUDR
/AP/ /ROCHE/ /500MG/VIAL/ /N16929 001/
ROCHE 500MG/VIAL N16929 001

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION
FLUDARA
BERLEX 50MG/VIAL¤ N20038 001 APR 18, 1991

> ADD > FLUMAZENIL

> ADD > INJECTABLE; INJECTION
> ADD > MAZICON
> ADD > ROCHE 0.1MG/ML¤ N20073 001 DEC 20, 1991
> ADD >

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL
/FLUOCET/
/AT/ /NMC/ /0.01%/ /N88361 001/ /JAN 16, 1984/

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL
FLUOCINOLONE ACETONIDE
AT NMC 0.01% N88361 001 JAN 16, 1984

FLUOCINONIDE

CREAM; TOPICAL
FLUOCINONIDE
AB TARO 0.05% N19117 001 JUN 26, 1984
AB TICAN 0.05% N72494 001 JAN 19, 1989
/VASODERM/
/AB/ /TARO/ /0.05%/ /N19117/001/ /JUN/26,/1984/
/VASODERM'E/
/AB/ /TICAN/ /0.05%/ /N72494/001/ /JAN/19,/1989/

OINTMENT; TOPICAL
> ADD > FLUOCINONIDE
> ADD > AB LEMMON 0.05%¤ N73481 001 DEC 27, 1991
> ADD >
LIDEX
> ADD > AB SYNTEX 0.05% N16909 002

FLUOROURACIL

INJECTABLE; INJECTION
ADRUCIL
AP ADRIA 50MG/ML¤ N40023 001 OCT 18, 1991
AP 50MG/ML¤ N81222 001 JUN 28, 1991
AP 50MG/ML¤ N81225 001 AUG 28, 1991
FLUOROURACIL
> ADD > AP ABIC 50MG/ML N88929 001 MAR 04, 1986
> ADD >
> DLT >/AP/ /AKORN/ /50MG/ML/ /N88929/001/ /MAR/04,/1986/
> DLT >

FLUOROURACIL

INJECTABLE; INJECTION
FLUOROURACIL
/AP/ /QUAD/ /50MG/ML/ /N89368/001/ /FEB/03,/1987/
/AP/ /50MG/ML/ /N89455/001/ /FEB/03,/1987/
∂ QUAD 50MG/ML N89368 001 FEB 03, 1987
∂ 50MG/ML N89455 001 FEB 03, 1987
/AP/ /SOLOPAK/ /50MG/ML/ /N88766/001/ /DEC/28,/1984/
∂ SOLOPAK 50MG/ML N88766 001 DEC 28, 1984

FLUOXETINE HYDROCHLORIDE

SOLUTION; ORAL
PROZAC
LILLY EQ 20MG BASE/5ML¤ N20101 001 APR 24, 1991

FLUOXYMESTERONE

TABLET; ORAL
FLUOXYMESTERONE
/BP/ /BOLAR/ /2MG/ /N88266/001/ /DEC/06,/1983/
/BP/ /5MG/ /N88265/001/ /DEC/06,/1983/
/BP/ /10MG/ /N88309/001/ /DEC/06,/1983/
∂ BOLAR 2MG N88260 001 DEC 06, 1983
∂ 5MG N88265 001 DEC 06, 1983
∂ 10MG N88309 001 DEC 06, 1983
> DLT > /ORA-TESTRYL/
> DLT > /BP/ /SQUIBB/ /2MG/ /N11359/001/
> DLT > /BP/ /5MG/ /N11359/002/
> ADD > ∂ SQUIBB 2MG N11359 001
> ADD > ∂ 5MG N11359 002

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION
FLUPHENAZINE

/AO/	/QUAD/	/25MG/ML/	/N70762/001/	
			/FEB/20,/1986/	
	∂ QUAD	25MG/ML	N70762 001	
			FEB 20, 1986	

FLUPHENAZINE HYDROCHLORIDE

CONCENTRATE; ORAL
FLUPHENAZINE HCL

AA	COPLEY	5MG/ML¤	N73058 001
			AUG 30, 1991

INJECTABLE; INJECTION
FLUPHENAZINE HCL

/AP/	/QUAD/	/2.5MG/ML/	/N89800/001/
			/JUN/08,/1988/
	∂ QUAD	2.5MG/ML	N89800 001
			JUN 08, 1988

TABLET; ORAL
FLUPHENAZINE HCL

/AB/	/BOLAR/	/1MG/	/N88555/001/		
			/DEC/18,/1987/		
/AB/		/2.5MG/	/N88544/001/		
			/DEC/18,/1987/		
/AB/		/5MG/	/N88527/001/		
			/DEC/18,/1987/		
/AB/		/10MG/	/N88550/001/		
			/DEC/18,/1987/		
	∂ BOLAR	1MG	N88555 001		
			DEC 18, 1987		
	∂	2.5MG	N88544 001	>DLT>	
			DEC 18, 1987	>ADD>	
	∂	5MG	N88527 001		
			DEC 18, 1987		
	∂	10MG	N88550 001		
			DEC 18, 1987		

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL
FLURAZEPAM HCL

AB	GENEVA	15MG¤	N71716 001		
			JUL 31, 1991		
AB		30MG¤	N71717 001		
			JUL 31, 1991		

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL
FLURAZEPAM HCL

/AB/	/PHARM/BASICS/	/15MG/	/N70562/001/		
			/JUL/09,/1987/		
/AB/		/30MG/	/N70563/001/		
			/JUL/09,/1987/		
B*	PHARM BASICS	15MG	N70562 001		
			JUL 09, 1987		
B*		30MG	N70563 001		
			JUL 09, 1987		

FOSCARNET SODIUM

INJECTABLE; INJECTION
FOSCAVIR

	ASTRA	24MG/ML¤	N20068 001
			SEP 27, 1991

FOSINOPRIL SODIUM

TABLET; ORAL
MONOPRIL

	BRISTOL MYERS SQUIBB	10MG¤	N19915 002
			MAY 16, 1991
		20MG¤	N19915 003
			MAY 16, 1991

FURAZOLIDONE

SUSPENSION; ORAL
FUROXONE

	/NORWICH/EATON/	/50MG/15ML/	/N11323/002/	>DLT>	
	ROBERTS	50MG/15ML	N11323 002	>ADD>	

TABLET; ORAL
FUROXONE

	/NORWICH/EATON/	/100MG/	/N11270/002/	>DLT>	
	ROBERTS	100MG	N11270 002	>ADD>	

FUROSEMIDE

INJECTABLE; INJECTION
FUROSEMIDE

/AP/	/SOLOPAK/	/10MG/ML/	/N70023/001/	
			/FEB/05,/1986/	
	∂ SOLOPAK	10MG/ML	N70023 001	
			FEB 05, 1986	

FUROSEMIDE

INJECTABLE; INJECTION
FUROSEMIDE
AP STERLING 10MG/ML* N72080 001 AUG 13, 1991

SOLUTION; ORAL
FUROSEMIDE
AA PHARM BASICS 10MG/ML N70655 001 OCT 02, 1987

/MYROSEMIDE/
/AA/ /PHARM/BASICS/ /10MG/ML/ /N70655/001/ /OCT/02/1987/

GALLIUM NITRATE

INJECTABLE; INJECTION
GANITE
FUJISAWA 25MG/ML* N19961 002 JAN 17, 1991

GENTAMICIN SULFATE

INJECTABLE; INJECTION
GENTAMICIN SULFATE
AP GENSIA EQ 10MG BASE/ML* N63149 001 NOV 21, 1991
AP EQ 40MG BASE/ML* N63106 002 NOV 21, 1991

SOLUTION/DROPS; OPHTHALMIC
GENTAMICIN SULFATE
/AT/ /PACO/ /EQ 3MG BASE/ML/ /N62932/001/ /NOV/07/1988/
∂ PACO EQ 3MG BASE/ML N62932 001 NOV 07, 1988

GENTIAN VIOLET

/TAMPON;/VAGINAL/
/GENAPAX/
/KEY/PHARMS/ /5MG/ /N85017/001/
∂ KEY PHARMS 5MG N85017 001

GLUCAGON HYDROCHLORIDE

INJECTABLE; INJECTION
GLUCAGON
/AP/ /LILLY/ /EQ 1MG BASE/VIAL/ /N12122/002/
LILLY EQ 1MG BASE/VIAL N12122 002
/AP/ /QUAD/ /EQ 1MG BASE/VIAL/ /N71023/001/ /MAR/04/1987/
∂ QUAD EQ 1MG BASE/VIAL N71023 001 MAR 04, 1987

GLUTETHIMIDE

TABLET; ORAL
/DORIDEN/
/AA/ /RHONE/POULENC/RORER/ /250MG/ /N09519/002/
/AA/ /500MG/ /N09519/005/
∂ RHONE POULENC RORER 250MG N09519 002
∂ 500MG N09519 005
GLUTETHIMIDE
/AA/ /CHELSEA/ /500MG/ /N85763/001/
∂ CHELSEA 500MG N85763 001

GLYCOPYRROLATE

INJECTABLE; INJECTION
GLYCOPYRROLATE
AP GENSIA 0.2MG/ML* N81169 001 SEP 10, 1991
/AP/ /QUAD/ /0.2MG/ML/ /N89397/001/ /DEC/09/1986/
∂ QUAD 0.2MG/ML N89397 001 DEC 09, 1986

TABLET; ORAL
GLYCOPYRROLATE
/AA/ /BOLAR/ /1MG/ /N85562/001/
∂ BOLAR 1MG N85562 001

GONADOTROPIN, CHORIONIC

INJECTABLE; INJECTION
CHORIONIC GONADOTROPIN

/AP/	/QUAD/	/5,000 UNITS/VIAL/	/N89312/001/	/DEC/04,/1986/
/AP/		/5,000 UNITS/VIAL/	/N89313/001/	/DEC/04,/1986/
/AP/		/10,000 UNITS/VIAL/	/N89314/001/	/DEC/04,/1986/
/AP/		/10,000 UNITS/VIAL/	/N89315/001/	/DEC/04,/1986/
/AP/		/20,000 UNITS/VIAL/	/N89316/001/	/DEC/04,/1986/
	@ QUAD	5,000 UNITS/VIAL	N89312 001	DEC 04, 1986
	@	5,000 UNITS/VIAL	N89313 001	DEC 04, 1986
	@	10,000 UNITS/VIAL	N89314 001	DEC 04, 1986
	@	10,000 UNITS/VIAL	N89315 001	DEC 04, 1986
	@	20,000 UNITS/VIAL	N89316 001	DEC 04, 1986

GUANETHIDINE MONOSULFATE

TABLET; ORAL
/GUANETHIDINE MONOSULFATE/

/AB/	/BOLAR/	/EQ 10MG SULFATE/	/N86113/001/	/MAR/26,/1985/
/AB/		/EQ 25MG SULFATE/	/N86114/001/	/MAR/26,/1985/
	@ BOLAR	EQ 10MG SULFATE	N86113 001	MAR 26, 1985
	@	EQ 25MG SULFATE	N86114 001	MAR 26, 1985

ISMELIN

/AB/	/CIBA/	/EQ 10MG SULFATE/	/N12329/001/	
/AB/		/EQ 25MG SULFATE/	/N12329/002/	
	CIBA	EQ 10MG SULFATE	N12329 001	
		EQ 25MG SULFATE	N12329 002	

HALOBETASOL PROPIONATE

CREAM; TOPICAL
ULTRAVATE

/BRISTOL/MYERS/SQUIBB/0.05%/		/N19967/001/	/DEC/27,/1990/
WESTWOOD SQUIBB	0.05%	N19967 001	DEC 27, 1990

HALOBETASOL PROPIONATE

OINTMENT; TOPICAL
ULTRAVATE

/BRISTOL/MYERS/SQUIBB/0.05%/		/N19968/001/	/DEC/17,/1990/
WESTWOOD SQUIBB	0.05%	N19968 001	DEC 17, 1990

HALOPERIDOL

TABLET; ORAL
HALOPERIDOL

/AB/	/BOLAR/	/0.5MG/	/N71571/001/	/JUN/03,/1988/
/AB/		/1MG/	/N71572/001/	/JUN/03,/1988/
/AB/		/2MG/	/N71573/001/	/JUN/03,/1988/
/AB/		/5MG/	/N71374/001/	/JUN/03,/1988/
/AB/		/10MG/	/N71375/001/	/JUN/03,/1988/
/AB/		/20MG/	/N71376/001/	/JUN/03,/1988/
	@ BOLAR	0.5MG	N71571 001	JUN 03, 1988
	@	1MG	N71572 001	JUN 03, 1988
	@	2MG	N71573 001	JUN 03, 1988
	@	5MG	N71374 001	JUN 03, 1988
	@	10MG	N71375 001	JUN 03, 1988
	@	20MG	N71376 001	JUN 03, 1988
AB	DANBURY	10MG*	N72113 001	AUG 27, 1991
AB		20MG*	N72353 001	AUG 27, 1991

HALOPERIDOL

TABLET; ORAL

HALOPERIDOL

> DLT >	/AB/	/DURAMED/	/0.5MG/	/N71216/001/	/DEC/04,/1986/
> DLT >					
> DLT >	/AB/		/1MG/	/N71217/001/	/DEC/04,/1986/
> DLT >					
> DLT >	/AB/		/2MG/	/N71218/001/	/DEC/04,/1986/
> DLT >					
> DLT >	/AB/		/5MG/	/N71219/001/	/DEC/04,/1986/
> DLT >					
> DLT >	/AB/		/10MG/	/N71220/001/	/JUL/07,/1987/
> DLT >					
> DLT >	/AB/		/20MG/	/N71221/001/	/JUL/07,/1987/
> DLT >					
> ADD >		ə DURAMED	0.5MG	N71216 001	DEC 04, 1986
> ADD >					
> ADD >		ə	1MG	N71217 001	DEC 04, 1986
> ADD >					
> ADD >		ə	2MG	N71218 001	DEC 04, 1986
> ADD >					
> ADD >		ə	5MG	N71219 001	DEC 04, 1986
> ADD >					
> ADD >		ə	10MG	N71220 001	JUL 07, 1987
> ADD >					
> ADD >		ə	20MG	N71221 001	JUL 07, 1987
> ADD >					
> DLT >	/AB/	/PAR/	/20MG/	/N71328/001/	/JUL/20,/1987/
> DLT >					
> ADD >		ə PAR	20MG	N71328 001	JUL 20, 1987
> ADD >					
> ADD >	AB	SCHIAPPARELLI SEARLE	0.5MG	N70720 001	JUN 10, 1986
> ADD >					
> ADD >	AB		1MG	N70721 001	JUN 10, 1986
> ADD >					
> ADD >	AB		2MG	N70722 001	JUN 10, 1986
> ADD >					
> ADD >	AB		5MG	N70723 001	JUN 10, 1986
> ADD >					
> ADD >	AB		10MG	N70724 001	JUN 10, 1986
> ADD >					
> ADD >	AB		20MG	N70725 001	JUN 10, 1986
> ADD >					

HALOPERIDOL

TABLET; ORAL

HALOPERIDOL

> DLT >	/AB/	/SEARLE/	/0.5MG/	/N70726/001/	/JUN/10,/1986/
> DLT >					
> DLT >	/AB/		/1MG/	/N70721/001/	/JUN/10,/1986/
> DLT >					
> DLT >	/AB/		/2MG/	/N70722/001/	/JUN/10,/1986/
> DLT >					
> DLT >	/AB/		/5MG/	/N70723/001/	/JUN/10,/1986/
> DLT >					
> DLT >	/AB/		/10MG/	/N70724/001/	/JUN/10,/1986/
> DLT >					
> DLT >	/AB/		/20MG/	/N70725/001/	/JUN/10,/1986/
> DLT >					

HALOPERIDOL LACTATE

CONCENTRATE; ORAL

HALOPERIDOL

> ADD >	AA	SCHIAPPARELLI SEARLE	EQ 2MG BASE/ML	N70726 001 JUN 10, 1986
> ADD >				
> DLT >	/AA/	/SEARLE/	/EQ 2MG BASE/ML/	/N70726/001/ /JUN/10,/1986/
> DLT >				

INJECTABLE; INJECTION

HALOPERIDOL

	/AP/	/LEMMON/	/EQ 5MG BASE/ML/	/N70713/001/ /MAY/17,/1988/
	/AP/		/EQ 5MG BASE/ML/	/N70714/001/ /MAY/17,/1988/
	/AP/		/EQ 5MG BASE/ML/	/N70744/001/ /MAY/17,/1988/
	/AP/	/QUAD/	/EQ 5MG BASE/ML/	/N71082/001/ /JAN/02,/1987/
		ə QUAD	EQ 5MG BASE/ML	N71082 001 JAN 02, 1987
	/AP/	/SOLOPAK/	/EQ 5MG BASE/ML/	/N70802/001/ /DEC/14,/1987/
		ə SOLOPAK	EQ 5MG BASE/ML	N70802 001 DEC 14, 1987
	AP	STERIS	EQ 5MG BASE/ML	N70713 001 MAY 17, 1988
	AP		EQ 5MG BASE/ML	N70714 001 MAY 17, 1988
	AP		EQ 5MG BASE/ML	N70744 001 MAY 17, 1988

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN LOCK FLUSH

/AP/	/INTL/MEDICATION/	/10 UNITS/ML/	/N86357/001/	
	∂ INTL MEDICATION	10 UNITS/ML	N86357 001	
		/500/UNITS/ML/	/N86357/002/	
	∂	500 UNITS/ML	N86357 002	
/AP/	/SOLOPAK/	/100 UNITS/ML/	/N87959/001/ /APR/20,/1983/	
	∂ SOLOPAK	100 UNITS/ML	N87959 001 APR 20, 1983	

HEPARIN SODIUM

/AP/	/LYPHOMED/	/5,000 UNITS/ML/	/N17029/002/	
	∂ LYPHOMED	5,000 UNITS/ML	N17029 002	
	/HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5%/			
/AP/	/ABBOTT/	/10,000 UNITS/100ML/	/N18911/006/ /JAN/30,/1985/	
	∂ ABBOTT	10,000 UNITS/100ML	N18911 006 JAN 30, 1985	
	/HEPARIN SODIUM 25000 UNITS IN SODIUM CHLORIDE 0.9% IN/ /PLASTIC CONTAINER/			
/AP/	/MCGAW/	/5,000 UNITS/100ML/	/N19135/001/ /MAR/29,/1985/	
	∂ MCGAW	5,000 UNITS/100ML	N19135 001 MAR 29, 1985	

> ADD > HISTRELIN ACETATE

> ADD > INJECTABLE; INJECTION

> ADD > SUPPRELIN

> ADD >	JOHNSON RW	EQ 0.2MG BASE/ML*	N19836 001 DEC 24, 1991
> ADD >		EQ 0.5MG BASE/ML*	N19836 002 DEC 24, 1991
> ADD >		EQ 1MG BASE/ML*	N19836 003 DEC 24, 1991

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDRALAZINE HCL

/AP/	/SOLOPAK/	/20MG/ML/	/N88517/001/ /AUG/22,/1985/	
/AP/		/20MG/ML/	/N88518/001/ /APR/20,/1984/	
	∂ SOLOPAK	20MG/ML	N88517 001 AUG 22, 1985	
	∂	20MG/ML	N88518 001 APR 20, 1984	

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

HYDRALAZINE HCL

/AA/	/CHELSEA/	/25MG/	/N85532/002/ /MAY/24,/1982/	
/AA/		/50MG/	/N85533/002/ /MAY/25,/1982/	
	∂ CHELSEA	25MG	N85532 002 MAY 24, 1982	
	∂	50MG	N85533 002 MAY 25, 1982	

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE

/AB/	/BOLAR/	/25MG;25MG/	/N85457/001/ /MAR/04,/1982/	
/AB/		/50MG;50MG/	/N85446/001/ /MAR/04,/1982/	
/AB/		/100MG;50MG/	/N85440/001/ /MAR/04,/1982/	
	∂ BOLAR	25MG;25MG	N85457 001 MAR 04, 1982	
	∂	50MG;50MG	N85446 001 MAR 04, 1982	
	∂	100MG;50MG	N85440 001 MAR 04, 1982	

TABLET; ORAL

APRESOLINE-ESIDRIX

/AB/	/CIBA/	/25MG;15MG/	/N12026/002/	
	CIBA	25MG;15MG	N12026 002	
	/HYDROCHLOROTHIAZIDE/W/HYDRALAZINE/			
/BP/	/BOLAR/	/25MG;15MG/	/N85373/001/	
	∂ BOLAR	25MG;15MG	N85373 001	

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

/HYDROCHLOROTHIAZIDE/W/RESERPINE/AND/HYDRALAZINE/

/BP/	/BOLAR/	/25MG;15MG;0.1MG/	/N83770/001/	
	∂ BOLAR	25MG;15MG;0.1MG	N83770 001	

HYDROCHLOROTHIAZIDE

TABLET; ORAL

	HYDROCHLOROTHIAZIDE			
	∂ ALRA	25MG	N86369 001	
	∂	50MG	N83554 001	
/∂/	/BANMAX/	/25MG/	/N86369/001/	
/∂/		/50MG/	/N83554/001/	
/AB/	/BOLAR/	/25MG/	/N83458/001/	
/AB/		/50MG/	/N83456/001/	
/AB/		/100MG/	/N85099/001/	
	∂ BOLAR	25MG	N83458 001	
	∂	50MG	N83456 001	
	∂	100MG	N85099 001	
>ADD >	∂ ELKINS SINN	50MG	N85152 002	
>DLT >	/∂/QUANTUM/PHARMICS/	/50MG/	/N85152/002/	

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

	METHYLDOPA AND HYDROCHLOROTHIAZIDE			
/AB/	/BOLAR/	/15MG;250MG/	/N70365/001/	/MAR/19,/1986/
/AB/		/25MG;250MG/	/N70366/001/	/APR/16,/1986/
/AB/		/30MG;500MG/	/N70367/001/	/MAR/19,/1986/
/AB/		/50MG;500MG/	/N70368/001/	/APR/16,/1986/
	∂ BOLAR	15MG;250MG	N70365 001	MAR 19, 1986
	∂	25MG;250MG	N70366 001	APR 16, 1986
	∂	30MG;500MG	N70367 001	MAR 19, 1986
	∂	50MG;500MG	N70368 001	APR 16, 1986

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

>DLT >	/PROPRANOLOL HCL & HYDROCHLOROTHIAZIDE/			
>DLT >/AB/	/DURAMED/	/25MG;40MG/	/N71126/001/	/MAR/02,/1987/
>DLT >				
>DLT >/AB/		/25MG;80MG/	/N71127/001/	/MAR/02,/1987/
>DLT >				
>ADD >	∂ DURAMED	25MG;40MG	N71126 001	MAR 02, 1987
>ADD >				
>ADD >	∂	25MG;80MG	N71127 001	MAR 02, 1987
>ADD >				

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

	PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE			
>ADD > AB	DANBURY	25MG;40MG¤	N71498 001	DEC 18, 1991
>ADD >				
>ADD > AB		25MG;80MG¤	N71501 001	DEC 18, 1991
>ADD >				

HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

	HYDROCHLOROTHIAZIDE W/ RESERPINE			
/BP/	/BOLAR/	/25MG;0.125MG/	/N85317/001/	
/BP/		/50MG;0.125MG/	/N83666/001/	
	∂ BOLAR	25MG;0.125MG	N85317 001	
	∂	50MG;0.125MG	N83666 001	
	RESERPINE AND HYDROCHLOROTHIAZIDE			
/BP/	/CORD/	/50MG;0.125MG/	/N88200/001/	/JAN/31,/1984/
	∂ CORD	50MG;0.125MG	N88200 001	JAN 31, 1984

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL

	SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE			
/AB/	/SUPERPHARM/	/25MG;25MG/	/N89137/001/	/AUG/26,/1985/
	∂ SUPERPHARM	25MG;25MG	N89137 001	AUG 26, 1985
	SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE			
/AB/	/BOLAR/	/25MG;25MG/	/N85974/001/	
	∂ BOLAR	25MG;25MG	N85974 001	

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL

	DYAZIDE		
AB	SKF	25MG;50MG	N16042 002
	TRIAMTERENE AND HYDROCHLOROTHIAZIDE		
AB	GENEVA	25MG;50MG¤	N73191 001 JUL 31, 1991

TABLET; ORAL

	TRIAMTERENE AND HYDROCHLOROTHIAZIDE			
>DLT >/AB/	/AM THERAP/	/50MG;75MG/	/N72022/001/	/NOV/03,/1987/
>DLT >				
>ADD >	∂ AM THERAP	50MG;75MG	N72022 001	NOV 03, 1987
>ADD >				

HYDROCHLOROTHIAZIDE; TRIAMTERENE

TABLET; ORAL
TRIAMTERENE AND HYDROCHLOROTHIAZIDE

> DLT >	/B*/	/PAR/	/50MG;75MG/	/N72337/001/ /MAY/11,/1988/	
> DLT >					
> ADD >	B*	VITARINE	50MG;75MG	N71360 001 DEC 08, 1987	
> ADD >					
> DLT >		/2/	/50MG;75MG/	/N71360/001/ /DEC/08,/1987/	
> DLT >					

HYDROCORTISONE

CREAM; TOPICAL
ANUSOL HC

AT	PARKE DAVIS	2.5%	N88250 001 JUN 06, 1984

H-CORT

/AT/	/PHARMS/ASSOC/	/0.5%/	/N86823/001/
	∂ PHARMS ASSOC	0.5%	N86823 001

HC #1

/AT/	/MILES/	/0.5%/	/N80438/001/
	∂ MILES	0.5%	N80438 001

HC #4

/AT/	/MILES/	/1%/	/N80438/002/
	∂ MILES	1%	N80438 002

HYDROCORTISONE

AT	BAUSCH AND LOMB	1%	N87838 001 JUL 28, 1982
/AT/	/NASKA/	/1%/	/N89706/001/ /MAR/10,/1988/
	∂ NASKA	1%	N89706 001 MAR 10, 1988
/AT/	/PHARMAFAIR/	/1%/	/N87838/001/ /JUL/28,/1982/
/AT/	/WHITE/TOWNE/PAULSEN/	/1%/	/N80496/002/
	∂ WHITE TOWNE PAULSEN	1%	N80496 002

PENECORT

/AT/	/PARKE/DAVIS/	/2.5%/	/N88250/001/ /JUN/06,/1984/

SYNACORT

/AT/	/SYNTEX/	/0.5%/	/N87459/001/
	∂ SYNTEX	0.5%	N87459 001

LOTION; TOPICAL
HYDROCORTISONE

/AT/	/NASKA/	/1%/	/N89705/001/ /APR/25,/1988/
	∂ NASKA	1%	N89705 001 APR 25, 1988

HYDROCORTISONE

/LOTION;/TOPICAL/
/TEXACORT/

/AT/	/COOPERCARE/	/1%/	/N80425/001/

OINTMENT; TOPICAL
HYDROCORTISONE

/AT/	/NASKA/	/1%/	/N89704/001/ /MAR/10,/1988/
	∂ NASKA	1%	N89704 001 MAR 10, 1988

SOLUTION; TOPICAL
PENECORT

AT	HERBERT	1%	N88214 001 JUN 06, 1984

TEXACORT

AT	GENDERM	1%	N80425 001

TABLET; ORAL
HYDROCORTISONE

> ADD >	∂ ELKINS SINN	20MG	N80624 001
/BP/	/PUREPAC/	/20MG/	/N80395/001/
	∂ PUREPAC	20MG	N80395 001
> DLT >	/2/QUANTUM/PHARMICS/	/20MG/	/N80624/001/

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC
OTOCORT

/AT/	/LEMMON/	/1%;EQ 3.5MG BASE/ML;/ /10,000 UNITS/ML/	/N60736/002/
AT	STERIS	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N60730 002

SUSPENSION; OTIC
OTOCORT

/AT/	/LEMMON/	/1%;EQ 3.5MG BASE/ML;/ /10,000 UNITS/ML/	/N62521/001/ /JUL/11,/1985/
AT	STERIS	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N62521 001 JUL 11, 1985

HYDROCORTISONE ACETATE

CREAM; TOPICAL
HYDROCORTISONE ACETATE

AT	CENCI	1%	N80419 001 JAN 25, 1982

HYDROCORTISONE ACETATE

CREAM; TOPICAL

	HYDROCORTISONE ACETATE		
/AT/	/LIFE/LABS/	/1%/	/N86419/001/ /JAN/25,/1982/

INJECTABLE; INJECTION

	HYDROCORTISONE ACETATE		
/BP/	/LEMMON/	/25MG/ML/	/N83759/001/
/BP/		/50MG/ML/	/N83759/002/
BP	STERIS	25MG/ML	N83759 001
BP		50MG/ML	N83759 002

HYDROCORTISONE BUTYRATE

CREAM; TOPICAL

	/HYDROCORTISONE/BUTYRATE/		
	/a/GIST/	/0.1%/	/N18514/001/ /MAR/31,/1982/
	/LOCOID/		
	/OWEN/GALDERMA/	/0.1%/	/N18795/001/ /JAN/07,/1983/
	LOCOID		
	BROCADES PHARMA	0.1%	N18514 001 MAR 31, 1982
a	OWEN GALDERMA	0.1%	N18795 001 JAN 07, 1983

SOLUTION; TOPICAL

	HYDROCORTISONE BUTYRATE		
/AT/	/GIST/	/0.1%/	/N19116/001/ /FEB/25,/1987/
	/LOCOID/		
/AT/	/OWEN/GALDERMA/	/0.1%/	/N19819/001/ /SEP/15,/1988/
	LOCOID		
	BROCADES PHARMA	0.1%	N19116 001 FEB 25, 1987
a	OWEN GALDERMA	0.1%	N19819 001 SEP 15, 1988

HYDROCORTISONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

	/HYDROCORTISONE SODIUM PHOSPHATE/		
/AP/	/QUAD/	/EQ 50MG BASE/ML/	/N89581/001/ /MAY/28,/1987/
a	QUAD	EQ 50MG BASE/ML	N89581 001 MAY 28, 1987
	HYDROCORTONE		
/AP/	/MSD/	/EQ 50MG BASE/ML/	/N12052/001/
	MSD	EQ 50MG BASE/ML	N12052 001

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION

	HYDROCORTISONE SODIUM SUCCINATE		
/AP/	/LYPHOMED/	/EQ 100MG BASE/VIAL/	/N88667/001/ /JUN/08,/1984/
/AP/		/EQ 100MG BASE/VIAL/	/N88712/001/ /JUN/08,/1984/
/AP/		/EQ 250MG BASE/VIAL/	/N88668/001/ /JUN/08,/1984/
/AP/		/EQ 500MG BASE/VIAL/	/N88669/001/ /JUN/08,/1984/
/AP/		/EQ 1GM BASE/VIAL/	/N88670/001/ /JUN/08,/1984/
a	LYPHOMED	EQ 100MG BASE/VIAL	N88667 001 JUN 08, 1984
a		EQ 100MG BASE/VIAL	N88712 001 JUN 08, 1984
a		EQ 250MG BASE/VIAL	N88668 001 JUN 08, 1984
a		EQ 500MG BASE/VIAL	N88669 001 JUN 08, 1984
a		EQ 1GM BASE/VIAL	N88670 001 JUN 08, 1984

HYDROFLUMETHIAZIDE; RESERPINE

TABLET; ORAL

	HYDROFLUMETHIAZIDE AND RESERPINE		
B*	PHARM BASICS	50MG;0.125MG	N88195 001 OCT 26, 1983
/BP/		/50MG;0.125MG/	/N88195/001/ /OCT/26,/1983/

HYDROFLUMETHIAZIDE; RESERPINE

TABLET; ORAL
/HYDROFLUMETHIAZIDE/W/RESERPINE/

/BP/	/BOLAR/	/25MG;0.125MG/	/N88127/001/	/MAR/22,/1983/
/BP/		/50MG;0.125MG/	/N88110/001/	/MAR/22,/1983/
	ə BOLAR	25MG;0.125MG	N88127 001	MAR 22, 1983
	ə	50MG;0.125MG	N88110 001	MAR 22, 1983
	SALUTENSIN-DEMI			
/BP/	/BRISTOL/	/25MG;0.125MG/	/N12359/004/	
	BRISTOL	25MG;0.125MG	N12359 004	

HYDROXOCOBALAMIN

INJECTABLE; INJECTION
HYDROCOBALAMIN

/AP/	/LEMMON/	/1MG/ML/	/N85528/001/
AP	STERIS	1MG/ML	N85528 001

HYDROXYAMPHETAMINE HYDROBROMIDE

SOLUTION/DROPS; OPHTHALMIC
PAREDRINE

> ADD >	PHARMICS	1%	N00004 004
> DLT >	/SKF/	/1%/	/N00004/004/

HYDROXYPROGESTERONE CAPROATE

INJECTABLE; INJECTION
/DURA-LUTIN/

/AO/	/STERIS/	/125MG/ML/	/N17439/001/
/AO/		/250MG/ML/	/N17439/002/
	HYDROXYPROGESTERONE CAPROATE		
/AO/	/QUAD/	/125MG/ML/	/N89330/001/ /JAN/02,/1987/
/AO/		/250MG/ML/	/N89331/001/ /JAN/02,/1987/
	ə QUAD	125MG/ML	N89330 001 JAN 02, 1987
	ə	250MG/ML	N89331 001 JAN 02, 1987
AO	STERIS	125MG/ML	N17439 001
AO		250MG/ML	N17439 002

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION
HYDROXYZINE HCL

/AP/	/LEMMON/	/25MG/ML/	/N87274/001/
/AP/		/50MG/ML/	/N87274/002/
AP	STERIS	25MG/ML	N87274 001
AP		50MG/ML	N87274 002

TABLET; ORAL
HYDROXYZINE HCL

/AB/	/BARR/	/10MG/	/N88409/001/ /NOV/15,/1983/
/AB/		/25MG/	/N87857/001/ /APR/18,/1983/
/AB/		/50MG/	/N87860/001/ /APR/18,/1983/
/AB/		/100MG/	/N87862/001/ /APR/18,/1983/
	ə BARR	10MG	N88409 001 NOV 15, 1983
	ə	25MG	N87857 001 APR 18, 1983
	ə	50MG	N87860 001 APR 18, 1983
	ə	100MG	N87862 001 APR 18, 1983
/AB/	/PHARM/BASICS/	/10MG/	/N89121/001/ /MAR/20,/1986/
/AB/		/25MG/	/N89122/001/ /MAR/20,/1986/
/AB/		/50MG/	/N89123/001/ /MAR/20,/1986/
B*	PHARM BASICS	10MG	N89121 001 MAR 20, 1986
B*		25MG	N89122 001 MAR 20, 1986
B*		50MG	N89123 001 MAR 20, 1986

HYDROXYZINE PAMOATE

CAPSULE; ORAL
HYDROXYZINE PAMOATE

/AB/	/BOLAR/	/EQ 25MG HCL/	/N86698/001/
/AB/		/EQ 50MG HCL/	/N86695/001/
/AB/		/EQ 100MG HCL/	/N86697/001/
	ə BOLAR	EQ 25MG HCL	N86698 001
	ə	EQ 50MG HCL	N86695 001
	ə	EQ 100MG HCL	N86697 001
AB	DANBURY	EQ 25MG HCL*	N81165 001 JUL 31, 1991

HYDROXYZINE PAMOATE

CAPSULE; ORAL

HYDROXYZINE PAMOATE

>DLT >/AB/	/DURAMED/	/EQ 25MG HCL/	/N88593/001/		
>DLT >			/FEB/29,/1984/		
>DLT >/AB/		/EQ 50MG HCL/	/N88594/001/		
>DLT >			/FEB/29,/1984/		
>DLT >/AB/		/EQ 100MG HCL/	/N88595/001/		
>DLT >			/FEB/29,/1984/		
>ADD >	@ DURAMED	EQ 25MG HCL	N88593 001		
>ADD >			FEB 29, 1984		
>ADD >	@	EQ 50MG HCL	N88594 001		
>ADD >			FEB 29, 1984		
>ADD >	@	EQ 100MG HCL	N88595 001		
>ADD >			FEB 29, 1984		
AB	GENEVA	EQ 25MG HCL*	N81127 001		
			JUN 28, 1991		
AB		EQ 50MG HCL*	N81128 001		
			JUN 28, 1991		
AB		EQ 100MG HCL*	N81129 001		
			JUN 28, 1991		
>DLT >/AB/	/PAR/	/EQ 25MG HCL/	/N87656/001/		
>DLT >			/JUN/11,/1982/		
>DLT >/AB/		/EQ 25MG HCL/	/N89145/001/		
>DLT >			/MAR/17,/1986/		
>DLT >/AB/		/EQ 50MG HCL/	/N87657/001/		
>DLT >			/JUN/11,/1982/		
>DLT >/AB/		/EQ 50MG HCL/	/N89146/001/		
>DLT >			/MAR/17,/1986/		
>DLT >/AB/		/EQ 100MG HCL/	/N87658/001/		
>DLT >			/JUN/11,/1982/		
>ADD >	@ PAR	EQ 25MG HCL	N87656 001		
>ADD >			JUN 11, 1982		
>ADD >	@	EQ 25MG HCL	N89145 001		
>ADD >			MAR 17, 1986		
>ADD >	@	EQ 50MG HCL	N87657 001		
>ADD >			JUN 11, 1982		
>ADD >	@	EQ 50MG HCL	N89146 001		
>ADD >			MAR 17, 1986		
>ADD >	@	EQ 100MG HCL	N87658 001		
>ADD >			JUN 11, 1982		

HYDROXYZINE PAMOATE

CAPSULE; ORAL

HYDROXYZINE PAMOATE

/AB/	/SUPERPHARM/	/EQ 25MG HCL/	/N89031/001/
			/JAN/02,/1987/
/AB/		/EQ 50MG HCL/	/N89032/001/
			/JAN/02,/1987/
/AB/		/EQ 100MG HCL/	/N89033/001/
			/JAN/02,/1987/
@ SUPERPHARM		EQ 25MG HCL	N89031 001
			JAN 02, 1987
@		EQ 50MG HCL	N89032 001
			JAN 02, 1987
@		EQ 100MG HCL	N89033 001
			JAN 02, 1987
/AB/	/VANGARD/	/EQ 25MG HCL/	/N88392/001/
			/SEP/19,/1983/
@ VANGARD		EQ 25MG HCL	N88392 001
			SEP 19, 1983

IBUPROFEN

SUSPENSION; ORAL

RUFEN

BX	BOOTS	100MG/5ML	N19784 001
			DEC 18, 1989

TABLET; ORAL

IBUPROFEN

/B*/	/CHELSEA/	/400MG/	/N70038/001/
			/SEP/06,/1985/
/B*/		/600MG/	/N70041/001/
			/SEP/06,/1985/
/B*/		/800MG/	/N71911/001/
			/OCT/13,/1987/
@ CHELSEA		400MG	N70038 001
			SEP 06, 1985
@		600MG	N70041 001
			SEP 06, 1985
@		800MG	N71911 001
			OCT 13, 1987
/BX/	/SUPERPHARM/	/400MG/	/N70708/001/
			/APR/25,/1986/

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL

IMIPRAMINE HCL

/AB/	/BOLAR/	/10MG/	/N85220/001/	
/AB/		/25MG/	/N84252/002/	
/AB/		/50MG/	/N85221/001/	
	ə BOLAR	10MG	N85220 001	
	ə	25MG	N84252 002	
	ə	50MG	N85221 001	
	PRAMINE			
	ə ALRA	10MG	N83827 001	
	ə	25MG	N83827 002	
	ə	50MG	N83827 003	
	/ə/BANMAX/	/10MG/	/N83827/001/	
	/ə/	/25MG/	/N83827/002/	
	/ə/	/50MG/	/N83827/003/	

INDOMETHACIN

CAPSULE; ORAL

INDOMETHACIN

/AB/	/BOLAR/	/25MG/	/N70784/001/ AUG 20, 1986	
/AB/		/50MG/	/N70785/001/ AUG 20, 1986	
	ə BOLAR	25MG	N70784 001 AUG 20, 1986	
	ə	50MG	N70785 001 AUG 20, 1986	
AB	DANBURY	25MG¤	N72996 001 JUL 31, 1991	
AB		50MG¤	N72997 001 JUL 31, 1991	
>DLT>/AB/	/DURAMED/	/25MG/	/N70326/001/ OCT 18, 1985	
>DLT>				
>DLT>/AB/		/50MG/	/N70327/001/ OCT 18, 1985	
>DLT>				
>ADD>	ə DURAMED	25MG	N70326 001 OCT 18, 1985	
>ADD>				
>ADD>	ə	50MG	N70327 001 OCT 18, 1985	
>ADD>				
/AB/	/ROXANE/	/25MG/	/N70353/001/ JUN 18, 1985	
/AB/		/50MG/	/N70354/001/ JUN 18, 1985	
	ə ROXANE	25MG	N70353 001 JUN 18, 1985	
	ə	50MG	N70354 001 JUN 18, 1985	

INDOMETHACIN

CAPSULE; ORAL

INDOMETHACIN

/AB/	/SUPERPHARM/	/25MG/	/N70487/001/ OCT 10, 1986	
/AB/		/50MG/	/N70488/001/ OCT 10, 1986	
	ə SUPERPHARM	25MG	N70487 001 OCT 10, 1986	
	ə	50MG	N70488 001 OCT 10, 1986	

CAPSULE, EXTENDED RELEASE; ORAL

INDOMETHACIN

>ADD>	B* VITARINE	75MG	N71531 001 JUL 21, 1987	
>ADD>				
>DLT>	/ə/	/75MG/	/N71531/001/ JUL 21, 1987	
>DLT>				

IOPAMIDOL

INJECTABLE; INJECTION

ISOVUE-M 200

SQUIBB	41%	N18735 001 DEC 31, 1985	

ISOVUE-200

/SQUIBB/	/41%/	/N18735/001/ DEC 31, 1985	
SQUIBB	41%	N18735 006 JUL 07, 1987	

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION

ISOETHARINE HCL

/AN/	/ARMOUR/	/0.125%¤/	/N89615/001/ JUN 13, 1991	
/AN/		/0.167%¤/	/N89616/001/ JUN 13, 1991	
/AN/		/0.2%¤/	/N89617/001/ JUN 13, 1991	
/AN/		/0.25%¤/	/N89618/001/ JUN 13, 1991	
		/0.062½%¤/	/N89614/001/ JUN 13, 1991	

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION
ISOETHARINE HCL

AN ASTRA	0.125%	N89615 001 JUN 13, 1991	
AN	0.167%	N89616 001 JUN 13, 1991	
AN	0.2%	N89617 001 JUN 13, 1991	
AN	0.25%	N89618 001 JUN 13, 1991	
	0.062%	N89614 001 JUN 13, 1991	

ISOETHARINE MESYLATE

AEROSOL, METERED; INHALATION
BRONKOMETER

/BN/ /STERLING/	/0.34MG/BASE/INH/	/N12339/001/	
BN STERLING	0.34MG/INH	N12339 007	

ISONIAZID

INJECTABLE; INJECTION
ISONIAZID

/AP/ /QUAD/	/100MG/ML/	/N89816/001/ OCT/28,/1988/	
ə QUAD	100MG/ML	N89816 001 OCT 28, 1988	

HYDRAZID

/AP/ /SQUIBB/	/100MG/ML/	/N08662/001/	
SQUIBB	100MG/ML	N08662 001	

SYRUP; ORAL
RINIFON

/AA/ /ROCHE/	/50MG/5ML/	/N08420/001/	
ə ROCHE	50MG/5ML	N08420 001	

TABLET; ORAL
ISONIAZID

/AA/ /BOLAR/	/100MG/	/N80401/001/	
/AA/	/300MG/	/N83178/001/	
ə BOLAR	100MG	N80401 001	
ə	300MG	N83178 001	
AA ZENITH	300MG	N83610 001	

>ADD > ISOSORBIDE MONONITRATE

>ADD > TABLET; ORAL
>ADD > ISMO
>ADD > WYETH | 20MG | N19091 001 DEC 30, 1991
>ADD >

KANAMYCIN SULFATE

INJECTABLE; INJECTION
KANAMYCIN SULFATE

/AP/ /INTL/MEDICATION/	/EQ 500MG BASE/2ML/	/N62466/001/ SEP/30,/1983/	
/AP/	/EQ 1GM BASE/3ML/	/N62466/002/ SEP/30,/1983/	
ə INTL MEDICATION	EQ 500MG BASE/2ML	N62466 001 SEP 30, 1983	
ə	EQ 1GM BASE/3ML	N62466 002 SEP 30, 1983	

>DLT >/AP/ /QUAD/ /EQ 75MG BASE/2ML/ /N62642/001/ FEB/03,/1986/
>DLT >
>DLT >/AP/ /EQ 500MG BASE/2ML/ /N62642/002/ FEB/03,/1986/
>DLT >
>DLT >/AP/ /EQ 1GM BASE/3ML/ /N62642/003/ FEB/03,/1986/
>DLT >

>ADD > ə QUAD	EQ 75MG BASE/2ML	N62642 001 FEB 03, 1986	
>ADD > ə	EQ 500MG BASE/2ML	N62642 002 FEB 03, 1986	
>ADD > ə	EQ 1GM BASE/3ML	N62642 003 FEB 03, 1986	

KETAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
KETALAR

/AP/ /PARKE/DAVIS/	/EQ 10MG BASE/ML/	/N16812/001/	
/AP/	/EQ 50MG BASE/ML/	/N16812/002/	
/AP/	/EQ 100MG BASE/ML/	/N16812/003/	
PARKE DAVIS	EQ 10MG BASE/ML	N16812 001	
	EQ 50MG BASE/ML	N16812 002	
	EQ 100MG BASE/ML	N16812 003	

KETAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

KETAMINE HCL

/AP/	/QUAD/	/EQ 10MG BASE/ML/	/N71949/001/	/APR/11,/1988/
/AP/		/EQ 50MG BASE/ML/	/N71950/001/	/APR/11,/1988/
/AP/		/EQ 100MG BASE/ML/	/N71951/001/	/APR/11,/1988/
	∂ QUAD	EQ 10MG BASE/ML	N71949 001	APR 11, 1988
	∂	EQ 50MG BASE/ML	N71950 001	APR 11, 1988
	∂	EQ 100MG BASE/ML	N71951 001	APR 11, 1988

KETOCONAZOLE

/SUSPENSION;/ORAL/

/NIZORAL/

/JANSSEN/ /100MG/5ML/ /N70767/001/ /NOV/07,/1986/

∂ JANSSEN	100MG/5ML	N70767 001 NOV 07, 1986

KETOROLAC TROMETHAMINE

TABLET; ORAL

TORADOL

> ADD > SYNTEX	10MG	N19645 001 DEC 20, 1991

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION

LEUCOVORIN CALCIUM

> ADD > AP	ABIC	EQ 3MG BASE/ML	N89352 001	JUN 01, 1988
> ADD > AP		EQ 50MG BASE/VIAL	N89353 001	JUN 01, 1988
> DLT >/AP/	/AKORN/	/EQ 5MG BASE/ML/	/N89352/001/	/JUN/01,/1988/
> DLT >/AP/		/EQ 50MG BASE/VIAL/	/N89353/001/	/JUN/01,/1988/

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION

LEUCOVORIN CALCIUM

/AP/	/QUAD/	/EQ 5MG BASE/ML/	/N89503/001/	/OCT/05,/1987/
/AP/		/EQ 5MG BASE/ML/	/N89504/001/	/DEC/22,/1987/
/AP/		/EQ 50MG BASE/VIAL/	/N89496/001/	/MAR/05,/1987/
/AP/		/EQ 100MG BASE/VIAL/	/N89636/001/	/DEC/24,/1987/
	∂ QUAD	EQ 5MG BASE/ML	N89503 001	OCT 05, 1987
	∂	EQ 5MG BASE/ML	N89504 001	DEC 22, 1987
	∂	EQ 50MG BASE/VIAL	N89496 001	MAR 05, 1987
	∂	EQ 100MG BASE/VIAL	N89636 001	DEC 24, 1987

WELLCOVORIN

/AP/	/BURROUGHS/WELLCOME/	/EQ 5MG BASE/ML/	/N87439/001/	/OCT/19,/1982/
	BURROUGHS WELLCOME	EQ 5MG BASE/ML	N87439 001	OCT 19, 1982

TABLET; ORAL

LEUCOVORIN CALCIUM

> DLT >/AB/	/PAR/	/EQ 5MG BASE/	/N71600/001/	/OCT/14,/1987/
> DLT >/AB/		/EQ 25MG BASE/	/N71598/001/	/OCT/14,/1987/
> ADD >	∂ PAR	EQ 5MG BASE	N71600 001	OCT 14, 1987
> ADD >	∂	EQ 25MG BASE	N71598 001	OCT 14, 1987

LEVODOPA

CAPSULE; ORAL

DOPAR

> DLT > /BD/	/NORWICH/EATON/	/100MG/	/N16913/003/	
> DLT > /BD/		/250MG/	/N16913/001/	
> DLT > /BD/		/500MG/	/N16913/002/	
> ADD >	NORWICH EATON	100MG	N16913 003	
> ADD >		250MG	N16913 001	
> ADD >		500MG	N16913 002	

LEVODOPA

CAPSULE; ORAL

>DLT>	/LARODOPA/				
>DLT> /BD/	/ROCHE/	/100MG/	/N16912/002/		
>DLT> /BD/		/250MG/	/N16912/001/		
>DLT> /BD/		/500MG/	/N16912/006/		
>ADD>	ə ROCHE	100MG	N16912 002		
>ADD>	ə	250MG	N16912 001		
>ADD>	ə	500MG	N16912 006		

LEVONORGESTREL

IMPLANT; IMPLANTATION

/LEVONORGESTREL/SYSTEM/			
/WYETH/AYERST/	/36MG/IMPLANT/	/N20088/001/	
		/DEC/10,/1990	
NORPLANT SYSTEM			
WYETH AYERST	36MG/IMPLANT	N20088 001	
		DEC 10, 1990	

>ADD> LEVORPHANOL TARTRATE

>ADD> INJECTABLE; INJECTION
>ADD> LEVO-DROMORAN
>ADD> ROCHE 2MG/ML¤ N08719 001
>ADD> DEC 19, 1991

>ADD> TABLET; ORAL
>ADD> LEVO-DROMORAN
>ADD> ROCHE 2MG¤ N08720 001
>ADD> DEC 19, 1991

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HCL				
/AP/ /CUTTER/	/1%/	/N86414/001/		
/AP/	/2%/	/N86414/002/		
ə CUTTER	1%	N86414 001		
ə	2%	N86414 002		
/AP/ /ELKINS/SINN/	/0.5%/	/N85131/001/		
/AP/	/4%/	/N84626/001/		
ə ELKINS SINN	0.5%	N85131 001		
ə	4%	N84626 001		
/ə/LEMMON/	/1%/	/N83627/001/		
/ə/	/2%/	/N83627/002/		
ə STERIS	1%	N83627 001		
ə	2%	N83627 002		

LIDOCAINE HYDROCHLORIDE

SOLUTION; TOPICAL

LIDOCAINE HCL				
/AT/ /PACO/	/4%/	/N89688/001/		
		/JUN/30,/1989/		
ə PACO	4%	N89688 001		
		JUN 30, 1989		

LINCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

LINCOMYCIN HCL				
>DLT> /AP/ /QUAD/	/EQ 300MG BASE/ML/	/N62784/001/		
>DLT>		/MAR/14,/1988/		
>ADD> ə QUAD	EQ 300MG BASE/ML	N62784 001		
>ADD>		MAR 14, 1988		
AP STERIS	EQ 300MG BASE/ML¤	N63180 001		
		APR 16, 1991		

LINDANE

LOTION; TOPICAL

GAMENE				
>DLT> /ə/BARNES/HIND/	/1%/	/N84989/001/		
>ADD> ə SOLA BARNES HIND	1%	N84989 001		

SHAMPOO; TOPICAL

GAMENE				
>DLT> /ə/BARNES/HIND/	/1%/	/N84988/001/		
>ADD> ə SOLA BARNES HIND	1%	N84988 001		

LIOTHYRONINE SODIUM

INJECTABLE; INJECTION

>ADD>	TRIOSTAT			
>ADD>	SMITHKLINE BEECHAM	EQ 0.01MG BASE/ML¤	N20105 001	
>ADD>			DEC 31, 1991	

TABLET; ORAL

CYTOMEL				
/AB/ /SKF/	/EQ 0.025MG BASE/	/N10379/002/		
SKF	EQ 0.025MG BASE	N10379 002		
/LIOTHYRONINE SODIUM/				
/AB/ /BOLAR/	/EQ 0.025MG BASE/	/N85755/001/		
		/JAN/25,/1982/		
ə BOLAR	EQ 0.025MG BASE	N85755 001		
		JAN 25, 1982		

LITHIUM CARBONATE

CAPSULE; ORAL
LITHIUM CARBONATE

/AB/	/BOLAR/	/300MG/	/N70407/001/	/MAR/19,/1987/
	∂ BOLAR	300MG	N70407 001	MAR 19, 1987
/AB/	/PHARM/BASICS/	/300MG/	/N72542/001/	/FEB/01,/1989/
B*	PHARM BASICS	300MG	N72542 001	FEB 01, 1989

LOPERAMIDE HYDROCHLORIDE

CAPSULE; ORAL
IMODIUM

AB	JANSSEN	2MG	N17694 001	
>DLT>		/2MG/	/N17690/001/	
>ADD>	∂	2MG	N17690 001	

LOPERAMIDE HCL

AB	MYLAN	2MG¤	N72741 001	SEP 18, 1991
AB	NOVOPHARM	2MG¤	N73122 001	AUG 30, 1991
AB	ROXANE	2MG¤	N73080 001	NOV 27, 1991

>ADD> LORACARBEF

>ADD> CAPSULE; ORAL
>ADD> LORABID
>ADD> LILLY 200MG¤ N50668 001 DEC 31, 1991
>ADD>

>ADD> POWDER FOR RECONSTITUTION; ORAL
>ADD> LORABID
>ADD> LILLY 100MG/5ML¤ N50667 001 DEC 31, 1991
>ADD>
>ADD> LORABID
>ADD> LILLY 200MG/5ML¤ N50667 002 DEC 31, 1991
>ADD>

LORAZEPAM

CONCENTRATE; ORAL
LORAZEPAM INTENSOL
ROXANE 2MG/ML¤ N72755 001 JUN 28, 1991

LORAZEPAM

TABLET; ORAL
LORAZEPAM

/BX/	/AM THERAP/	/0.5MG/	/N70727/001/	/MAR/07,/1986/
/BX/		/1MG/	/N70728/001/	/MAR/07,/1986/
/BX/		/2MG/	/N70729/001/	/MAR/07,/1986/
	∂ AM THERAP	0.5MG	N70727 001	MAR 07, 1986
	∂	1MG	N70728 001	MAR 07, 1986
	∂	2MG	N70729 001	MAR 07, 1986
AB	MUTUAL PHARM	0.5MG¤	N72553 001	MAR 29, 1991
AB		1MG¤	N72554 001	MAR 29, 1991
AB		2MG¤	N72555 001	MAR 29, 1991
/AB/	/PHARM/BASICS/	/1MG/	/N70539/001/	/DEC/22,/1986/
/AB/		/2MG/	/N70540/001/	/DEC/22,/1986/
B*	PHARM BASICS	1MG	N70539 001	DEC 22, 1986
B*		2MG	N70540 001	DEC 22, 1986
AB	ROYCE	0.5MG¤	N72926 001	OCT 31, 1991
AB		1MG¤	N72927 001	OCT 31, 1991
AB		2MG¤	N72928 001	OCT 31, 1991

LOVASTATIN

TABLET; ORAL
MEVACOR
MSD 10MG¤ N19643 002 MAR 28, 1991

MANNITOL

INJECTABLE; INJECTION
MANNITOL 10%

/AP/	/CUTTER/	/10GM/100ML/	/N16472/002/	
	∂ CUTTER	10GM/100ML	N16472 002	

MANNITOL

INJECTABLE; INJECTION

MANNITOL 15%

/AP/	/CUTTER/	/15GM/100ML/	/N16472/005/
	ə CUTTER	15GM/100ML	N16472 005

MANNITOL 20%

/AP/	/CUTTER/	/20GM/100ML/	/N16472/004/
	ə CUTTER	20GM/100ML	N16472 004

MAPROTILINE HYDROCHLORIDE

TABLET; ORAL

MAPROTILINE HCL

> DLT >/AB/	/AM/THERAP/	/25MG/	/N72129/001/
> DLT >			/JAN/14,/1988/
> DLT >/AB/		/50MG/	/N72130/001/
> DLT >			/JAN/14,/1988/
> DLT >/AB/		/75MG/	/N72131/001/
> DLT >			/JAN/14,/1988/
> ADD >	ə AM THERAP	25MG	N72129 001
> ADD >			JAN 14, 1988
> ADD >	ə	50MG	N72130 001
> ADD >			JAN 14, 1988
> ADD >	ə	75MG	N72131 001
> ADD >			JAN 14, 1988
/AB/	/BOLAR/	/25MG/	/N71943/001/
			/DEC/30,/1987/
/AB/		/50MG/	/N71944/001/
			/DEC/30,/1987/
/AB/		/75MG/	/N71945/001/
			/DEC/30,/1987/
	ə BOLAR	25MG	N71943 001
			DEC 30, 1987
	ə	50MG	N71944 001
			DEC 30, 1987
	ə	75MG	N71945 001
			DEC 30, 1987

MECLOFENAMATE SODIUM

CAPSULE; ORAL

MECLOFENAMATE SODIUM

> DLT >/AB/	/AM/THERAP/	/EQ 50MG BASE/	/N71362/001/
> DLT >			/FEB/10,/1987/
> DLT >/AB/		/EQ 100MG BASE/	/N71363/001/
> DLT >			/FEB/10,/1987/
> ADD >	ə AM THERAP	EQ 50MG BASE	N71362 001
> ADD >			FEB 10, 1987
> ADD >	ə	EQ 100MG BASE	N71363 001
> ADD >			FEB 10, 1987

MECLOFENAMATE SODIUM

CAPSULE; ORAL

MECLOFENAMATE SODIUM

> DLT >/AB/	/CHELSEA/	/EQ 50MG BASE/	/N71640/001/
> DLT >			/AUG/11,/1987/
> DLT >/AB/		/EQ 100MG BASE/	/N71641/001/
> DLT >			/AUG/11,/1987/
> ADD >	ə CHELSEA	EQ 50MG BASE	N71640 001
> ADD >			AUG 11, 1987
> ADD >	ə	EQ 100MG BASE	N71641 001
> ADD >			AUG 11, 1987
> DLT >/AB/	/PAR/	/EQ 50MG BASE/	/N72077/001/
> DLT >			/MAR/10,/1988/
> DLT >/AB/		/EQ 100MG BASE/	/N72078/001/
> DLT >			/MAR/10,/1988/
> ADD >	ə PAR	EQ 50MG BASE	N72077 001
> ADD >			MAR 10, 1988
> ADD >	ə	EQ 100MG BASE	N72078 001
> ADD >			MAR 10, 1988
/AB/	/PHARM/BASICS/	/EQ 50MG BASE/	/N71007/001/
			/MAR/25,/1988/
/AB/		/EQ 100MG BASE/	/N71008/001/
			/MAR/25,/1988/
B*	PHARM BASICS	EQ 50MG BASE	N71007 001
			MAR 25, 1988
B*		EQ 100MG BASE	N71008 001
			MAR 25, 1988

MEGESTROL ACETATE

TABLET; ORAL

MEGESTROL ACETATE

B*	PHARM BASICS	20MG	N70646 001
			OCT 02, 1987
B*		40MG	N70647 001
			OCT 02, 1987
/BX/		/20MG/	/N70646/001/
			/OCT/02,/1987/
/BX/		/40MG/	/N70647/001/
			/OCT/02,/1987/

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

MEPERIDINE HCL

/AP/	/ELKINS/SINN/	/25MG/ML/	/N88279/001/ /JUN/15,/1984/
/AP/		/50MG/ML/	/N88280/001/ /JUN/15,/1984/
/AP/		/75MG/ML/	/N88281/001/ /JUN/15,/1984/
/AP/		/100MG/ML/	/N88282/001/ /JUN/15,/1984/
	∂ ELKINS SINN	25MG/ML	N88279 001 JUN 15, 1984
	∂	50MG/ML	N88280 001 JUN 15, 1984
	∂	75MG/ML	N88281 001 JUN 15, 1984
	∂	100MG/ML	N88282 001 JUN 15, 1984

MEPROBAMATE

TABLET; ORAL

BAMATE

	∂ ALRA	200MG	N80380 001
	∂	400MG	N80380 002
	/∂/BANMAX/	/200MG/	/N80380/001/
	/∂/	/400MG/	/N80380/002/

MEPROBAMATE

>DLT >/AA/	/SOLVAY/	/400MG/	/N84369/002/

TRANMEP

>DLT >/AA/	/SOLVAY/	/400MG/	/N84369/001/
>ADD >	∂ SOLVAY	400MG	N84369 001

MESTRANOL; NORETHYNODREL

/TABLET;/ORAL-21/

/ENOVID-E/21/

	/SEARLE/	/0.1MG;2.5MG/	/N10976/001/
	∂ SEARLE	0.1MG;2.5MG	N10976 001

METAPROTERENOL SULFATE

SYRUP; ORAL

METAPROTERENOL SULFATE

AA	COPLEY	10MG/5ML¤	N73034 001 AUG 30, 1991

METAPROTERENOL SULFATE

TABLET; ORAL

METAPROTERENOL SULFATE

/AB/	/AM/THERAP/	/10MG/	/N72054/001/ /JUN/23,/1988/
/AB/		/20MG/	/N72055/001/ /JUN/23,/1988/
	∂ AM THERAP	10MG	N72054 001 JUN 23, 1988
	∂	20MG	N72055 001 JUN 23, 1988
AB	DANBURY	10MG¤	N73013 001 JAN 31, 1991
AB		20MG¤	N72795 001 JAN 31, 1991
/AB/	/PHARM/BASICS/	/10MG/	/N71013/001/ /JAN/25,/1988/
/AB/		/20MG/	/N71014/001/ /JAN/25,/1988/
B*	PHARM BASICS	10MG	N71013 001 JAN 25, 1988
B*		20MG	N71014 001 JAN 25, 1988

METARAMINOL BITARTRATE

INJECTABLE; INJECTION

METARAMINOL BITARTRATE

/AP/	/BRISTOL/	/EQ 10MG BASE/ML/	/N80431/001/
AP	LYPHOMED	EQ 10MG BASE/ML	N80431 001

METHADONE HYDROCHLORIDE

/TABLET;/EFFERVESCENT;/ORAL/

/WESTADONE/

/VITARINE/	/2.5MG/	/N17108/001/
	/5MG/	/N17108/002/
	/10MG/	/N17108/003/
	/40MG/	/N17108/004/
∂ VITARINE	2.5MG	N17108 001
∂	5MG	N17108 002
∂	10MG	N17108 003
∂	40MG	N17108 004

METHANTHELINE BROMIDE

TABLET; ORAL

BANTHINE

AA	SCHIAPPARELLI SEARLE	50MG N07390 001

METHANTHELINE BROMIDE

TABLET; ORAL
BANTHINE
/AA/ /SEARLE/ /50MG/ /N071396/001/

METHOCARBAMOL

INJECTABLE; INJECTION
METHOCARBAMOL
> ADD > AP MARSAM 100MG/ML* N89849 001 DEC 27, 1991
> ADD >

TABLET; OTHER
METHOCARBAMOL
> DLT >/AA/ /AM THERAP/ /500MG/ /N89417/001/ /FEB/11,/1987/
> DLT >
> DLT >/AA/ /750MG/ /N89418/001/ /FEB/11,/1987/
> DLT >
> ADD > ∂ AM THERAP 500MG N89417 001 FEB 11, 1987
> ADD >
> ADD > ∂ 750MG N89418 001 FEB 11, 1987
> ADD >
/AA/ /BOLAR/ /500MG/ /N83605/001/
/AA/ /750MG/ /N83605/002/
∂ BOLAR 500MG N83605 001
∂ 750MG N83605 002

METHOTREXATE SODIUM

INJECTABLE; INJECTION
ABITREXATE
> ADD > AP ABIC EQ 25MG BASE/ML N89161 001 MAR 10, 1987
> ADD >
> ADD > AP EQ 50MG BASE/VIAL N89354 001 JUL 17, 1987
> ADD >
> ADD > AP EQ 100MG BASE/VIAL N89355 001 JUL 17, 1987
> ADD >
> ADD > AP EQ 250MG BASE/VIAL N89356 001 JUL 17, 1987
> ADD >
> DLT >/AP/ /AKORN/ /EQ 25MG BASE/ML/ /N89161/001/ /MAR/10,/1987/
> DLT >
> DLT >/AP/ /EQ 50MG BASE/VIAL/ /N89354/001/ /JUL/17,/1987/
> DLT >
> DLT >/AP/ /EQ 100MG BASE/VIAL/ /N89355/001/ /JUL/17,/1987/
> DLT >
> DLT >/AP/ /EQ 250MG BASE/VIAL/ /N89356/001/ /JUL/17,/1987/
> DLT >
FOLEX PFS
AP ADRIA EQ 25MG BASE/ML* N81242 001 AUG 23, 1991

METHOTREXATE SODIUM

INJECTABLE; INJECTION
METHOTREXATE
/AP/ /LEDERLE/ /EQ 2.5MG BASE/ML/ /N11719/004/
LEDERLE EQ 2.5MG BASE/ML N11719 004
METHOTREXATE SODIUM
/AP/ /LYPHOMED/ /EQ 2.5MG BASE/ML/ /N89323/001/ /JUN/13,/1986/
/AP/ /EQ 25MG BASE/ML/ /N89322/001/ /JUN/13,/1986/
∂ LYPHOMED EQ 2.5MG BASE/ML N89323 001 JUN 13, 1986
∂ EQ 25MG BASE/ML N89322 001 JUN 13, 1986
/AP/ /QUAD/ /EQ 25MG BASE/ML/ /N89308/001/ /JUL/10,/1986/
/AP/ /EQ 25MG BASE/ML/ /N89309/001/ /JUL/10,/1986/
/AP/ /EQ 20MG BASE/VIAL/ /N89293/001/ /JUL/10,/1986/
/AP/ /EQ 50MG BASE/VIAL/ /N89294/001/ /JUL/10,/1986/
/AP/ /EQ 100MG BASE/VIAL/ /N89295/001/ /JUL/10,/1986/
/AP/ /EQ 250MG BASE/VIAL/ /N89296/001/ /JUL/10,/1986/
∂ QUAD EQ 25MG BASE/ML N89308 001 JUL 10, 1986
∂ EQ 25MG BASE/ML N89309 001 JUL 10, 1986
∂ EQ 20MG BASE/VIAL N89293 001 JUL 10, 1986
∂ EQ 50MG BASE/VIAL N89294 001 JUL 10, 1986
∂ EQ 100MG BASE/VIAL N89295 001 JUL 10, 1986
∂ EQ 250MG BASE/VIAL N89296 001 JUL 10, 1986

METHYCLOTHIAZIDE

TABLET; ORAL
METHYCLOTHIAZIDE
/AA/ /BOLAR/ /2.5MG/ /N85487/001/ /MAR/11,/1982/
/AA/ /5MG/ /N85476/001/ /MAR/11,/1982/
∂ BOLAR 2.5MG N85487 001 MAR 11, 1982
∂ 5MG N85476 001 MAR 11, 1982

METHYCLOTHIAZIDE

TABLET; ORAL

METHYCLOTHIAZIDE

/AB/	/PHARM/BASICS/	/5MG/	/N88745/001/	/MAR/21,/1985/
B*	PHARM BASICS	5MG	N88745 001	MAR 21, 1985

METHYLDOPA

TABLET; ORAL

METHYLDOPA

/AB/	/BOLAR/	/125MG/	/N70245/001/	/FEB/25,/1986/
/AB/		/250MG/	/N70246/001/	/FEB/25,/1986/
/AB/		/500MG/	/N70247/001/	/FEB/25,/1986/
	∂ BOLAR	125MG	N70245 001	FEB 25, 1986
	∂	250MG	N70246 001	FEB 25, 1986
	∂	500MG	N70247 001	FEB 25, 1986
>DLT >/AB/	/CHELSEA/	/125MG/	/N70260/001/	/JUN/24,/1985/
>DLT >/AB/		/250MG/	/N70261/001/	/JUN/24,/1985/
>DLT >/AB/		/500MG/	/N70262/001/	/JUN/24,/1985/
>ADD >	∂ CHELSEA	125MG	N70260 001	JUN 24, 1985
>ADD >	∂	250MG	N70261 001	JUN 24, 1985
>ADD >	∂	500MG	N70262 001	JUN 24, 1985
>DLT >/AB/	/DURAMED/	/250MG/	/N71006/001/	/DEC/16,/1986/
>DLT >/AB/		/500MG/	/N71009/001/	/DEC/16,/1986/
>ADD >	∂ DURAMED	250MG	N71006 001	DEC 16, 1986
>ADD >	∂	500MG	N71009 001	DEC 16, 1986

METHYLDOPA

TABLET; ORAL

METHYLDOPA

/AB/	/ROXANE/	/125MG/	/N70192/001/	/APR/25,/1986/
/AB/		/250MG/	/N70193/001/	/APR/25,/1986/
/AB/		/500MG/	/N70194/001/	/APR/25,/1986/
	∂ ROXANE	125MG	N70192 001	APR 25, 1986
	∂	250MG	N70193 001	APR 25, 1986
	∂	500MG	N70194 001	APR 25, 1986

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION

METHYLDOPATE HCL

AP	GENSIA	50MG/ML*	N72974 001	NOV 22, 1991
/AP/	/QUAD/	/50MG/ML/	/N71024/001/	/SEP/18,/1986/
	∂ QUAD	50MG/ML	N71024 001	SEP 18, 1986

METHYLPHENIDATE HYDROCHLORIDE

TABLET; ORAL

METHYLPHENIDATE HCL

>DLT >/AA/	/MD/PHARM/	/5MG/	/N86429/001/	
>DLT >/AA/		/10MG/	/N85799/001/	
>DLT >/AA/		/20MG/	/N86428/001/	
>ADD > AB	MD PHARM	5MG	N86429 001	
>ADD > AB		10MG	N85799 001	
>ADD > AB		20MG	N86428 001	

RITALIN

>DLT >/AA/	/CIBA/	/5MG/	/N10187/003/	
>DLT >/AA/		/10MG/	/N10187/006/	
>DLT >/AA/		/20MG/	/N10187/010/	
>ADD > AB	CIBA	5MG	N10187 003	
>ADD > AB		10MG	N10187 006	
>ADD > AB		20MG	N10187 010	

METHYLPREDNISOLONE ACETATE

INJECTABLE; INJECTION
METHYLPREDNISOLONE ACETATE

/ⓐ/	/LEMMON/	/20MG/ML/	/N87248/001/
/ⓐ/		/40MG/ML/	/N85374/001/
/ⓐ/		/80MG/ML/	/N86507/001/
ⓐ	STERIS	20MG/ML	N87248 001
ⓐ		40MG/ML	N85374 001
ⓐ		80MG/ML	N86507 001

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION
A-METHAPRED

AP	ABBOTT	EQ 40MG BASE/VIAL*	N89573 001 FEB 22, 1991
AP		EQ 125MG BASE/VIAL*	N89574 001 FEB 22, 1991
AP		EQ 500MG BASE/VIAL*	N89575 001 FEB 22, 1991
AP		EQ 1GM BASE/VIAL*	N89576 001 FEB 22, 1991

METHYLPREDNISOLONE SODIUM SUCCINATE

/AP/	/LYPHOMED/	/EQ 40MG BASE/VIAL/	/N88676/001/ /JUN/08,/1984/
/AP/		/EQ 125MG BASE/VIAL/	/N88677/001/ /JUN/08,/1984/
/AP/		/EQ 500MG BASE/VIAL/	/N88678/001/ /JUN/08,/1984/
/AP/		/EQ 500MG BASE/VIAL/	/N89186/001/ /MAR/28,/1986/
/AP/		/EQ 1GM BASE/VIAL/	/N88679/001/ /JUN/08,/1984/
/AP/		/EQ 1GM BASE/VIAL/	/N89188/001/ /MAR/28,/1986/
ⓐ	LYPHOMED	EQ 40MG BASE/VIAL	N88676 001 JUN 08, 1984
ⓐ		EQ 125MG BASE/VIAL	N88677 001 JUN 08, 1984
ⓐ		EQ 500MG BASE/VIAL	N88678 001 JUN 08, 1984
ⓐ		EQ 500MG BASE/VIAL	N89186 001 MAR 28, 1986
ⓐ		EQ 1GM BASE/VIAL	N88679 001 JUN 08, 1984
ⓐ		EQ 1GM BASE/VIAL	N89188 001 MAR 28, 1986

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION
METHYLPREDNISOLONE SODIUM SUCCINATE

/AP/	/QUAD/	/EQ 40MG BASE/VIAL/	/N89264/001/ /JAN/22,/1986/
/AP/		/EQ 125MG BASE/VIAL/	/N89265/001/ /JAN/22,/1986/
/AP/		/EQ 500MG BASE/VIAL/	/N89266/001/ /JAN/22,/1986/
/AP/		/EQ 1GM BASE/VIAL/	/N89267/001/ /JAN/22,/1986/
ⓐ	QUAD	EQ 40MG BASE/VIAL	N89264 001 JAN 22, 1986
ⓐ		EQ 125MG BASE/VIAL	N89265 001 JAN 22, 1986
ⓐ		EQ 500MG BASE/VIAL	N89266 001 JAN 22, 1986
ⓐ		EQ 1GM BASE/VIAL	N89267 001 JAN 22, 1986

METHYLTESTOSTERONE

TABLET; BUCCAL/SUBLINGUAL
/METANDREN/

/AB/	/CIBA/	/5MG/	/N03240/004/
/AB/		/10MG/	/N03240/005/
ⓐ	CIBA	5MG	N03240 004
ⓐ		10MG	N03240 005

METHYLTESTOSTERONE

/BP/	/PHARM BASICS/	/10MG/	/N80271/001/
ⓐ	PHARM BASICS	10MG	N80271 001

TABLET; ORAL
/METANDREN/

/AB/	/CIBA/	/10MG/	/N03240/001/
/AB/		/25MG/	/N03240/003/
ⓐ	CIBA	10MG	N03240 001
ⓐ		25MG	N03240 003

METHYPRYLON

TABLET; ORAL
NOLUDAR
/ROCHE/ /50MG/ /N09660/002/
ⓐ ROCHE 50MG N09660 002

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

METOCLOPRAMIDE HCL

AP	ABBOTT	EQ 10MG BASE/2ML*	N73117 001 JAN 17, 1991
AP		EQ 10MG BASE/2ML*	N73118 001 JAN 17, 1991
AP	GENSIA	EQ 10MG BASE/2ML*	N73135 001 NOV 27, 1991
/AP/	/QUAD/	/EQ 10MG BASE/2ML/	/N70671/001/ /MAY/27,/1986/
∂	QUAD	EQ 10MG BASE/2ML	N70671 001 MAY 27, 1986
/AP/	/SOLOPAK/	/EQ 10MG BASE/2ML/	/N70622/001/ /MAR/02,/1987/
∂	SOLOPAK	EQ 10MG BASE/2ML	N70622 001 MAR 02, 1987

SYRUP; ORAL

METOCLOPRAMIDE HCL

/AA/	/PACO/	/EQ 5MG BASE/5ML/	/N71665/001/ /DEC/05,/1988/
∂	PACO	EQ 5MG BASE/5ML	N71665 001 DEC 05, 1988
AA	PHARMS ASSOC	EQ 5MG BASE/5ML*	N72744 001 MAY 28, 1991

TABLET; ORAL

METOCLOPRAMIDE HCL

/AB/	/BARR/	/EQ 10MG BASE/	/N70660/001/ /FEB/10,/1987/
∂	BARR	EQ 10MG BASE	N70660 001 FEB 10, 1987
/AB/	/BOLAR/	/EQ 10MG BASE/	/N70363/001/ /MAR/02,/1987/
∂	BOLAR	EQ 10MG BASE	N70363 001 MAR 02, 1987
>DLT >/AB/	/CHELSEA/	/EQ 10MG BASE/	/N70453/001/ /JUN/06,/1986/
>DLT > >ADD > >ADD >	∂ CHELSEA	EQ 10MG BASE	N70453 001 JUN 06, 1986
AB	LEDERLE	EQ 10MG BASE*	N72639 001 MAY 09, 1991
/AB/	/MARTEC/	/EQ 10MG BASE/	/N70598/001/ /FEB/02,/1987/
/AB/	/PHARM/BASICS/	/EQ 10MG BASE/	/N70339/001/ /JUL/29,/1985/
B*	PHARM BASICS	EQ 10MG BASE	N70339 001 JUL 29, 1985
AB	SCHERING	EQ 10MG BASE	N70598 001 FEB 02, 1987

METOCURINE IODIDE

INJECTABLE; INJECTION

METOCURINE IODIDE

/AP/	/QUAD/	/2MG/ML/	/N89443/001/ /JUN/01,/1988/
∂	QUAD	2MG/ML	N89443 001 JUN 01, 1988

METUBINE IODIDE

/AP/	/LILLY/	/2MG/ML/	/N06632/003/
	LILLY	2MG/ML	N06632 003

METRONIDAZOLE

INJECTABLE; INJECTION

FLAGYL I.V. RTU IN PLASTIC CONTAINER

>ADD > AP	SCHIAPPARELLI SEARLE	500MG/100ML	N18353 002
>ADD > AP		500MG/100ML	N18657 001
>DLT >/AP/	/SEARLE/	/500MG/100ML/	/N18353/002/
>DLT >/AP/		/500MG/100ML/	/N18657/001/

METRONIDAZOLE

/AP/	/INTL/MEDICATION/	/500MG/100ML/	/N70004/001/ /MAY/08,/1985/
∂	INTL MEDICATION	500MG/100ML	N70004 001 MAY 08, 1985
AP	STERIS	500MG/100ML	N70042 001 DEC 20, 1984

METRYL IV

/AP/	/STERIS/	/500MG/100ML/	/N70042/001/ /DEC/20,/1984/

TABLET; ORAL

METRONIDAZOLE

>DLT >/AB/	/CHELSEA/	/250MG/	/N18599/001/ /SEP/17,/1982/
>DLT > >DLT >/AB/		/500MG/	/N18599/002/ /FEB/13,/1984/
>DLT > >ADD > >ADD >	∂ CHELSEA	250MG	N18599 001 SEP 17, 1982
>ADD > >ADD >	∂	500MG	N18599 002 FEB 13, 1984
/AB/	/SUPERPHARM/	/250MG/	/N70008/001/ /DEC/11,/1984/
/AB/		/500MG/	/N70009/001/ /DEC/11,/1984/
∂	SUPERPHARM	250MG	N70008 001 DEC 11, 1984
∂		500MG	N70009 001 DEC 11, 1984

METRONIDAZOLE HYDROCHLORIDE

INJECTABLE; INJECTION
FLAGYL I.V.

> ADD >	AP	SCHIAPPARELLI SEARLE	EQ 500MG BASE/VIAL		N18353 001
> DLT >	/AP/	/SEARLE/	/EQ 500MG BASE/VIAL/		/N18353/001/

MICONAZOLE NITRATE

CREAM; VAGINAL
MONISTAT 7

> ADD >		JOHNSON RW	2%	N17450 001

SUPPOSITORY; VAGINAL
MONISTAT 7

> ADD >		JOHNSON RW	100MG	N18520 001
> ADD >				MAR 15, 1982

MILRINONE LACTATE

/INJECTABLE;/INJECTION/
/MILRINONE/LACTATE/

		/STERLING/	/EQ/1MG/BASE/ML/	/N19436/001/ /DEC/31,/1987/
		∂ STERLING	EQ 1MG BASE/ML	N19436 001 DEC 31, 1987

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL
MINOCYCLINE HCL

> ADD >	AB	DANBURY	EQ 50MG BASE¤	N63181 001
> ADD >				DEC 30, 1991
> ADD >	AB		EQ 100MG BASE¤	N63065 001
> ADD >				DEC 30, 1991

MINOXIDIL

TABLET; ORAL
MINOXIDIL

/AB/		/PHARM/BASICS/	/2.5MG/	/N71537/001/ /DEC/16,/1988/
	B¤	PHARM BASICS	2.5MG	N71537 001 DEC 16, 1988

MORPHINE SULFATE

INJECTABLE; INJECTION
INFUMORPH

		ELKINS SINN	10MG/ML¤	N18565 003 JUL 19, 1991
			25MG/ML¤	N18565 004 JUL 19, 1991

MORPHINE SULFATE

AP		STERIS	0.5MG/ML¤	N73373 001 SEP 30, 1991
AP			0.5MG/ML¤	N73375 001 SEP 30, 1991
AP			1MG/ML¤	N73374 001 SEP 30, 1991
AP			1MG/ML¤	N73376 001 SEP 30, 1991

TABLET, EXTENDED RELEASE; ORAL
MS CONTIN

BC		PURDUE FREDERICK	30MG	N19516 001 MAY 29, 1987
BC			60MG	N19516 002 APR 08, 1988
BC			100MG	N19516 004 JAN 16, 1990

ORAMORPH SR

BC		ROXANE LABS	30MG¤	N19977 001 AUG 15, 1991
BC			60MG¤	N19977 002 AUG 15, 1991
BC			100MG¤	N19977 003 AUG 15, 1991

> ADD > NABUMETONE

TABLET; ORAL
RELAFEN

> ADD >		SMITHKLINE BEECHAM	500MG¤	N19583 001 DEC 24, 1991
> ADD >			750MG¤	N19583 002 DEC 24, 1991

NAFARELIN ACETATE

SPRAY, METERED; NASAL
SYNAREL

> DLT >		/SYNTEX/	/EQ/2MG/BASE/ML/	/N19886/001/ /FEB/13,/1990/
> ADD >		SYNTEX	EQ 0.2MG BASE/INH	N19886 001 FEB 13, 1990

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

NALBUPHINE

/AP/	/QUAD/	/10MG/ML/	/N70692/001/ /MAR/25,/1986/
/AP/		/20MG/ML/	/N70693/001/ /MAR/25,/1986/
	∂ QUAD	10MG/ML	N70692 001 MAR 25, 1986
	∂	20MG/ML	N70693 001 MAR 25, 1986

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE

/AP/	/ELKINS/SINN/	/0.4MG/ML/	/N70496/001/ /OCT/22,/1985/
	∂ ELKINS SINN	0.4MG/ML	N70496 001 OCT 22, 1985

NALOXONE HCL

/AP/	/LYPHOMED/	/1MG/ML/	/N71604/001/ /DEC/16,/1988/
	∂ LYPHOMED	1MG/ML	N71604 001 DEC 16, 1988
/AP/	/QUAD/	/0.02MG/ML/	/N70678/001/ /DEC/18,/1986/
/AP/		/0.4MG/ML/	/N70679/001/ /DEC/18,/1986/
/AP/		/1MG/ML/	/N70680/001/ /DEC/18,/1986/
	∂ QUAD	0.02MG/ML	N70678 001 DEC 18, 1986
	∂	0.4MG/ML	N70679 001 DEC 18, 1986
	∂	1MG/ML	N70680 001 DEC 18, 1986

NANDROLONE DECANOATE

INJECTABLE; INJECTION

NANDROLONE DECANOATE

/AA/	/LEMMON/	/50MG/ML/	/N87598/001/ /OCT/06,/1983/
/AO/		/50MG/ML/	/N88554/001/ /FEB/10,/1986/
/AO/		/100MG/ML/	/N87599/001/ /OCT/06,/1983/

NANDROLONE DECANOATE

INJECTABLE; INJECTION

NANDROLONE DECANOATE

/AO/	/QUAD/	/50MG/ML/	/N89248/001/ /JUN/25,/1986/
/AO/		/100MG/ML/	/N89249/001/ /JUN/25,/1986/
/AO/		/200MG/ML/	/N89250/001/ /JUN/25,/1986/
	∂ QUAD	50MG/ML	N89248 001 JUN 25, 1986
	∂	100MG/ML	N89249 001 JUN 25, 1986
	∂	200MG/ML	N89250 001 JUN 25, 1986
AO	STERIS	50MG/ML	N87598 001 OCT 06, 1983
AO		50MG/ML	N88554 001 FEB 10, 1986
AO		100MG/ML	N87599 001 OCT 06, 1983

NANDROLONE PHENPROPIONATE

INJECTABLE; INJECTION

NANDROLONE PHENPROPIONATE

/AO/	/QUAD/	/25MG/ML/	/N89297/001/ /OCT/01,/1986/
/AO/		/50MG/ML/	/N89298/001/ /OCT/01,/1986/
	∂ QUAD	25MG/ML	N89297 001 OCT 01, 1986
	∂	50MG/ML	N89298 001 OCT 01, 1986

NEOMYCIN SULFATE

TABLET; ORAL

NEOMYCIN SULFATE

/AA/	/ROXANE/	/EQ 350MG BASE/	/N62173/001/
	∂ ROXANE	EQ 350MG BASE	N62173 001

NIACIN

TABLET; ORAL

NIACIN

>DLT>/AA/	/BOLAR/	/500MG/	/N83136/001/
>ADD>	∂ BOLAR	500MG	N83136 001

NIACIN

TABLET; ORAL

NIACIN

/AA/	/WEST/WARD/	/500MG/	/N83718/001/	
	∂ WEST WARD	500MG	N83718 001	

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL

HABITROL

BC	CIBA GEIGY	7MG/24HR¤	N20076 001	NOV 27, 1991
BC		14MG/24HR¤	N20076 002	NOV 27, 1991
BC		21MG/24HR¤	N20076 003	NOV 27, 1991

NICODERM

BC	MARION MERRELL DOW	7MG/24HR¤	N20165 001	NOV 07, 1991
BC		14MG/24HR¤	N20165 002	NOV 07, 1991
BC		21MG/24HR¤	N20165 003	NOV 07, 1991

NIFEDIPINE

CAPSULE; ORAL

NIFEDIPINE

AB	CHASE	20MG¤	N73421 001	JUN 19, 1991
AB	SCHERER	10MG¤	N73250 001	OCT 08, 1991

NITROFURANTOIN

TABLET; ORAL

NITROFURANTOIN

>ADD>	∂ ELKINS SINN	50MG	N80003 001	
>ADD>	∂	100MG	N80003 002	
>DLT>	/∂/QUANTUM/PHARMICS/	/50MG/	/N80003/001/	
>DLT>	/∂/	/100MG/	/N80003/002/	

>ADD> NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

>ADD> CAPSULE, EXTENDED RELEASE; ORAL

>ADD> MACROBID

>ADD>	NORWICH EATON	75MG;25MG¤	N20064 001	DEC 24, 1991

NITROFURAZONE

CREAM; TOPICAL

FURACIN

	/NORWICH/EATON/	/0.2%/	/N83789/001/	
	ROBERTS	0.2%	N83789 001	

DRESSING; TOPICAL

>DLT> /ACTIN-N/

>DLT> /AT/	/CHESEBROUGH/PONDS/	/0.2%/	/N17343/001/	
>ADD>	∂ SHERWOOD	0.2%	N17343 001	

POWDER; TOPICAL

FURACIN

	/NORWICH/EATON/	/0.2%/	/N83791/001/	
	ROBERTS	0.2%	N83791 001	

NITROGLYCERIN

INJECTABLE; INJECTION

NITRO-BID

/AP/	/MARION/MERRELL/DOW/	/10MG/ML/	/N71159/001/	/FEB/28,/1990/
	MARION MERRELL DOW	10MG/ML	N71159 001	FEB 28, 1990

NITROGLYCERIN

/AP/	/LYPHOMED/	/5MG/ML/	/N71203/001/	/MAY/08,/1987/
	∂ LYPHOMED	5MG/ML	N71203 001	MAY 08, 1987
/AP/	/QUAD/	/5MG/ML/	/N71094/001/	/JUL/31,/1987/
/AP/		/10MG/ML/	/N71095/001/	/JUL/31,/1987/
	∂ QUAD	5MG/ML	N71094 001	JUL 31, 1987
	∂	10MG/ML	N71095 001	JUL 31, 1987
/AP/	/SOLOPAK/	/5MG/ML/	/N70634/001/	/JUN/19,/1986/
	∂ SOLOPAK	5MG/ML	N70634 001	JUN 19, 1986

NITROL

/AP/	/KREMERS/URBAN/	/0.8MG/ML/	/N18774/001/	/JAN/19,/1983/
	∂ RORER	0.8MG/ML	N18774 001	JAN 19, 1983

NITROSTAT

/AP/	/PARKE/DAVIS/	/0.8MG/ML/	/N18588/001/	
	PARKE DAVIS	0.8MG/ML	N18588 001	

NORFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

CHIBROXIN				
MSD	0.3%	N19757 001		
		JUN 17, 1991		

NYSTATIN

CREAM; TOPICAL

~~CANDEX~~				
~~AT~~ ~~MILES~~	~~100,000 UNITS/GM~~	~~N61810 001~~		
@ MILES	100,000 UNITS/GM	N61810 001		

SUSPENSION; ORAL

NYSTATIN				
>ADD> AA ROXANE	100,000 UNITS/ML%	N62832 001		
>ADD>		DEC 27, 1991		

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

ZOFRAN				
GLAXO	EQ 2MG BASE/ML%	N20007 001		
		JAN 04, 1991		

ORPHENADRINE CITRATE

TABLET, EXTENDED RELEASE; ORAL

NORFLEX				
~~AB~~ ~~3M~~	~~100MG~~	~~N12157 001~~		
3M	100MG	N12157 001		
~~ORPHENADRINE CITRATE~~				
~~AB~~ ~~BOLAR~~	~~100MG~~	~~N84303 001~~		
@ BOLAR	100MG	N84303 001		

OXACILLIN SODIUM

INJECTABLE; INJECTION

OXACILLIN SODIUM				
>ADD> AP APOTHECON	EQ 250MG BASE/VIAL	N61490 001		
>ADD> AP	EQ 500MG BASE/VIAL	N61490 002		
>ADD> AP	EQ 1GM BASE/VIAL	N61490 003		
>ADD> AP	EQ 1GM BASE/VIAL	N62737 001		
>ADD>		DEC 23, 1986		
>ADD> AP	EQ 2GM BASE/VIAL	N62737 002		
>ADD>		DEC 23, 1986		
>ADD> AP	EQ 10GM BASE/VIAL%	N61490 006		
>ADD>		MAY 09, 1991		
>ADD>	@ EQ 250MG BASE/VIAL	N50195 001		
>ADD>	@ EQ 500MG BASE/VIAL	N50195 002		
>ADD>	@ EQ 1GM BASE/VIAL	N50195 003		
>ADD>	@ EQ 2GM BASE/VIAL	N50195 004		
>ADD>	@ EQ 4GM BASE/VIAL	N50195 005		
>ADD>	~~AP~~ ~~ELKINS/SINN~~	~~EQ 250MG BASE/VIAL~~	~~N62711 001~~	
			~~FEB 03, 1989~~	
	~~AP~~	~~EQ 500MG BASE/VIAL~~	~~N62711 002~~	
			~~FEB 03, 1989~~	
	~~AP~~	~~EQ 1GM BASE/VIAL~~	~~N62711 003~~	
			~~FEB 03, 1989~~	
	~~AP~~	~~EQ 2GM BASE/VIAL~~	~~N62711 004~~	
			~~FEB 03, 1989~~	
	~~AP~~	~~EQ 4GM BASE/VIAL~~	~~N62711 005~~	
			~~FEB 03, 1989~~	
	~~AP~~	~~EQ 10GM BASE/VIAL~~	~~N62711 006~~	
			~~FEB 03, 1989~~	
	@ ELKINS SINN	EQ 250MG BASE/VIAL	N62711 001	
			FEB 03, 1989	
	@	EQ 500MG BASE/VIAL	N62711 002	
			FEB 03, 1989	
	@	EQ 1GM BASE/VIAL	N62711 003	
			FEB 03, 1989	
	@	EQ 2GM BASE/VIAL	N62711 004	
			FEB 03, 1989	
	@	EQ 4GM BASE/VIAL	N62711 005	
			FEB 03, 1989	
	@	EQ 10GM BASE/VIAL	N62711 006	
			FEB 03, 1989	

OXACILLIN SODIUM

INJECTABLE; INJECTION

>_DLT_>	/PROSTAPHLIN/						
>_DLT_>/AP/	/BRISTOL/	/EQ 250MG BASE/VIAL/	/N50195/001/				
>_DLT_>/AP/		/EQ 250MG BASE/VIAL/	/N61490/001/				
>_DLT_>/AP/		/EQ 500MG BASE/VIAL/	/N50195/002/				
>_DLT_>/AP/		/EQ 500MG BASE/VIAL/	/N61490/002/				
>_DLT_>/AP/		/EQ 1GM BASE/VIAL/	/N50195/003/				
>_DLT_>/AP/		/EQ 1GM BASE/VIAL/	/N61490/003/				
>_DLT_>/AP/		/EQ 1GM BASE/VIAL/	/N62737/001/				
>_DLT_>			/DEC/23,/1986/				
>_DLT_>/AP/		/EQ 2GM BASE/VIAL/	/N50195/004/				
>_DLT_>/AP/		/EQ 2GM BASE/VIAL/	/N62737/002/				
>_DLT_>			/DEC/23,/1986/				
>_DLT_>/AP/		/EQ 4GM BASE/VIAL/	/N50195/005/				

OXANDROLONE

/TABLET;/ORAL/

/ANAVAR/			
/3/SEARLE/	/2.5MG/	/N13718/001/	

TABLET; ORAL

OXANDRIN		
GYNEX	2.5MG	N13718 001

OXAZEPAM

CAPSULE; ORAL

		OXAZEPAM					
>_DLT_>/AB/	/AM/THERAP/	/10MG/	/N71955/001/				
>_DLT_>			/MAR/03,/1988/				
>_DLT_>/AB/		/15MG/	/N71956/001/				
>_DLT_>			/MAR/03,/1988/				
>_DLT_>/AB/		/30MG/	/N71957/001/				
>_DLT_>			/MAR/03,/1988/				
>_ADD_>	∂ AM THERAP	10MG	N71955 001				
>_ADD_>			MAR 03, 1988				
>_ADD_>	∂	15MG	N71956 001				
>_ADD_>			MAR 03, 1988				
>_ADD_>	∂	30MG	N71957 001				
>_ADD_>			MAR 03, 1988				

OXAZEPAM

CAPSULE; ORAL

		OXAZEPAM					
B*	CHELSEA	10MG	N71661 001				
			MAR 02, 1988				
B*		15MG	N71662 001				
			MAR 02, 1988				
B*		30MG	N71663 001				
			MAR 02, 1988				
/BX/		/10MG/	/N71661/001/				
			/MAR/02,/1988/				
/BX/		/15MG/	/N71662/001/				
			/MAR/02,/1988/				
/BX/		/30MG/	/N71663/001/				
			/MAR/02,/1988/				

OXTRIPHYLLINE

TABLET, DELAYED RELEASE; ORAL

		CHOLEDYL					
/AB/	/PARKE/DAVIS/	/100MG/	/N09268/003/				
/AB/		/200MG/	/N09268/007/				
	PARKE DAVIS	200MG	N09268 007				
		100MG	N09268 003				
	/OXTRIPHYLLINE/						
/AB/	/BOLAR/	/100MG/	/N87866/001/				
			/AUG/25,/1983/				
/AB/		/200MG/	/N87835/001/				
			/AUG/25,/1983/				
	∂ BOLAR	100MG	N87866 001				
			AUG 25, 1983				
	∂	200MG	N87835 001				
			AUG 25, 1983				

OXYBUTYNIN CHLORIDE

TABLET; ORAL

		OXYBUTYNIN CHLORIDE					
/AB/	/BOLAR/	/5MG/	/N72485/001/				
			/APR/19,/1989/				
	∂ BOLAR	5MG	N72485 001				
			APR 19, 1989				
>_DLT_>/AB/	/PHARM/BASICS/	/5MG/	/N70746/001/				
>_DLT_>			/MAR/10,/1988/				
>_ADD_>	B* PHARM BASICS	5MG	N70746 001				
>_ADD_>			MAR 10, 1988				

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION
AREDIA
CIBA GEIGY 30MG/VIAL* N20036 001
OCT 31, 1991

PANCURONIUM BROMIDE

INJECTABLE; INJECTION
PANCURONIUM BROMIDE
/AP/ /QUAD/ /1MG/ML/ /N72209/001/
/JUN/03,/1988/
/AP/ /2MG/ML/ /N72208/001/
/JUN/03,/1988/
∂ QUAD 1MG/ML N72209 001
JUN 03, 1988
∂ 2MG/ML N72208 001
JUN 03, 1988

PENTOBARBITAL SODIUM

CAPSULE; ORAL
SODIUM PENTOBARBITAL
/AA/ /CHELSEA/ /100MG/ /N85791/001/
∂ CHELSEA 100MG N85791 001
>ADD> ∂ ELKINS SINN 100MG N83368 001
>DLT> /∂/QUANTUN/PHARMICS/ /100MG/ /N83368/001/
/AA/ /WYETH/AYERST/ /100MG/ /N83239/001/
∂ WYETH AYERST 100MG N83239 001

PENTOSTATIN

INJECTABLE; INJECTION
NIPENT
PARKE DAVIS 10MG/VIAL* N20122 001
OCT 11, 1991

PERPHENAZINE

TABLET; ORAL
PERPHENAZINE
B* CHELSEA 8MG N89700 001
DEC 23, 1987
/BX/ /8MG/ /N89700/001/
/DEC/23,/1987/

PHENDIMETRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL
PHENDIMETRAZINE TARTRATE
BC VITARINE 105MG N18074 001
/∂/ /105MG/ /N18074/001/
/SPRX-105/
/BC/ /SOLVAY/ /105MG/ /N88024/001/
/DEC/22,/1982/
∂ SOLVAY 105MG N88024 001
DEC 22, 1982

TABLET; ORAL
>ADD> BONTRIL PDM
>ADD> AA CARNRICK 35MG N85272 001
>DLT> /PHENDIMETRAZINE TARTRATE/
>DLT> /AA/ /CORD/ /35MG/ /N85272/001/
/AA/ /35MG/ /N86365/001/
PHENDIMETRAZINE TARTRATE
∂ CORD 35MG N86365 001
AA MIKART 35MG* N89452 001
OCT 30, 1991

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL
PHENTERMINE HCL
>DLT> /AA/ /DURAMED/ /30MG/ /N88948/001/
>DLT> /APR/25,/1986/
>ADD> ∂ DURAMED 30MG N88948 001
>ADD> APR 25, 1986

PHENYTOIN SODIUM

INJECTABLE; INJECTION
PHENYTOIN SODIUM
/AP/ /SOLOPAK/ /50MG/ML/ /N88521/001/
/DEC/18,/1984/
∂ SOLOPAK 50MG/ML N88521 001
DEC 18, 1984

PINACIDIL

CAPSULE, EXTENDED RELEASE; ORAL
PINDAC
LEO 12.5MG N19456 001
DEC 28, 1989
25MG N19456 002
DEC 28, 1989

PINACIDIL

CAPSULE, EXTENDED RELEASE; ORAL
PINDAC
/LILLY/ /12.5MG/ /N19456/001/ /DEC/28,/1989/
/25MG/ /N19456/002/ /DEC/28,/1989/

PIPECURONIUM BROMIDE

INJECTABLE; INJECTION
ARDUAN
>DLT > /ORGANON/ /1MG/ML/ /N19638/001/ /JUN/26,/1990/
>ADD > ORGANON 10MG/VIAL N19638 001 JUN 26, 1990

PIPERAZINE CITRATE

SYRUP; ORAL
PIPERAZINE CITRATE
/AA/ /BARRE/ /EQ 500MG BASE/5ML/ /N80774/001/
∂ BARRE EQ 500MG BASE/5ML N80774 001

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

POWDER FOR RECONSTITUTION; ORAL
NULYTELY
BRAINTREE 420GM/BOT;1.48GM/BOT;5.72GM/BOT; 11.2GM/BOT¤ N19797 001 APR 22, 1991

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS

POWDER FOR RECONSTITUTION; ORAL
COLYTE
/AA/ /REED/AND/CARNRICK/ /227.1GM/PACKET;2.82GM/PACKET;/ /6.36GM/PACKET;5.53GM/PACKET;/ /21.5GM/PACKET/ /N18983/004/ /OCT/26,/1984/
AA REED AND CARNRICK 227.1GM/BOT;2.82GM/BOT;6.36GM/BOT; 5.53GM/BOT;21.5GM/BOT¤ N18983 010 JAN 31, 1989
∂ 227.1GM/PACKET;2.82GM/PACKET; 6.36GM/PACKET;5.53GM/PACKET; 21.5GM/PACKET N18983 004 OCT 26, 1984
COLYTE-FLAVORED
AA REED AND CARNRICK 227.1GM/BOT;2.82GM/BOT;6.36GM/BOT; 5.53GM/BOT;21.5GM/BOT¤ N18983 008 NOV 14, 1991
AA 240GM/BOT;2.98GM/BOT;6.72GM/BOT; 5.84GM/BOT;22.72GM/BOT¤ N18983 009 NOV 14, 1991
GLYCOPREP
AA GOLDLINE 236GM/BOT;2.97GM/BOT;6.74GM/BOT; 5.86GM/BOT;22.74GM/BOT N72319 001 DEC 23, 1988
/AA/ /SUPERPHARM/ /236GM/BOT;2.97GM/BOT;6.74GM/BOT;/ /5.86GM/BOT;22.74GM/BOT/ /N72319/001/ /DEC/23,/1988/

POTASSIUM CHLORIDE

INJECTABLE; INJECTION
POTASSIUM CHLORIDE
>DLT >/AP/ /ABBOTT/ /1MEQ/ML/ /N80205/003/
>DLT >/AP/ /1MEQ/ML/ /N83345/003/
>ADD > ∂ ABBOTT 1MEQ/ML N80205 003
>ADD > ∂ 1MEQ/ML N83345 003
>DLT > /2.4MEQ/ML/ /N80205/004/
>ADD > ∂ 2.4MEQ/ML N80205 004
>DLT > /3.2MEQ/ML/ /N80205/005/
>ADD > ∂ 3.2MEQ/ML N80205 005
/AP/ /CUTTER/ /1MEQ/ML/ /N80195/002/
/AP/ /2MEQ/ML/ /N80195/001/
/AP/ /3MEQ/ML/ /N80195/003/
∂ CUTTER 1MEQ/ML N80195 002
∂ 2MEQ/ML N80195 001
∂ 3MEQ/ML N80195 003
/AP/ /ELKINS/SINN/ /2MEQ/ML/ /N80203/001/
∂ ELKINS SINN 2MEQ/ML N80203 001

POTASSIUM CHLORIDE

INJECTABLE; INJECTION
POTASSIUM CHLORIDE

/AP/	/LEMMON/	/2MEQ/ML/	/N86208/001/		
/AP/		/3MEQ/ML/	/N86210/001/		
/AP/	/LILLY/	/2MEQ/ML/	/N07865/002/		
	∂ LILLY	2MEQ/ML	N07865 002		
AP	STERIS	2MEQ/ML	N86208 001		
AP		3MEQ/ML	N86210 001		

PRALIDOXIME CHLORIDE

INJECTABLE; INJECTION
PRALIDOXIME CHLORIDE

/AP/	/QUAD/	/1GM/VIAL/	/N72224/001/ /NOV/23,/1988/
	∂ QUAD	1GM/VIAL	N72224 001 NOV 23, 1988

PROTOPAM CHLORIDE

/AP/	/WYETH/AYERST/	/1GM/VIAL/	/N14134/001/
	WYETH AYERST	1GM/VIAL	N14134 001

PRAVASTATIN SODIUM

TABLET; ORAL
PRAVACHOL

	BRISTOL MYERS SQUIBB	10MG¤	N19898 002 OCT 31, 1991
		20MG¤	N19898 003 OCT 31, 1991

PRAZEPAM

CAPSULE; ORAL
PRAZEPAM

/AB/	/PHARM/BASICS/	/5MG/	/N70427/001/ /NOV/06,/1987/
/AB/		/10MG/	/N70428/001/ /NOV/06,/1987/
B*	PHARM BASICS	5MG	N70427 001 NOV 06, 1987
B*		10MG	N70428 001 NOV 06, 1987

PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL
PRAZOSIN HCL

>DLT>	/AB/	/AM/THERAP/	/EQ 1MG BASE/	/N72782/001/ /APR/11,/1989/	
>DLT>	/AB/		/EQ 2MG BASE/	/N72783/001/ /APR/11,/1989/	
>DLT>	/AB/		/EQ 5MG BASE/	/N72784/001/ /APR/11,/1989/	
>ADD>		∂ AM THERAP	EQ 1MG BASE	N72782 001 APR 11, 1989	
>ADD>		∂	EQ 2MG BASE	N72783 001 APR 11, 1989	
>ADD>		∂	EQ 5MG BASE	N72784 001 APR 11, 1989	

PREDNICARBATE

OINTMENT; TOPICAL
DERMATOP

	HOECHST ROUSSEL	0.1%	N19568 001 SEP 23, 1991

PREDNISOLONE

TABLET; ORAL
PREDNISOLONE

>ADD>		∂ ELKINS SINN	5MG	N80625 001	
>DLT>	/∂/QUANTUM/PHARMICS/	/5MG/	/N80625/001/		

PREDNISOLONE ACETATE

INJECTABLE; INJECTION
PREDNISOLONE ACETATE

/BP/	/CENTRAL/PHARMS/	/25MG/ML/	/N84717/001/
	∂ CENTRAL PHARMS	25MG/ML	N84717 001
/BP/	/LEMMON/	/25MG/ML/	/N83654/001/
/BP/		/50MG/ML/	/N85781/001/
BP	STERIS	25MG/ML	N83654 001
BP		50MG/ML	N85781 001

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION/DROPS; OPHTHALMIC

PREDNISOLONE SODIUM PHOSPHATE

>DLT >/AT/	/BARNES/HIND/	/EQ 0.11% PHOSPHATE/	/N84171/001/	
>DLT >	/∂/	/EQ/0.9%/PHOSPHATE/	/N84168/001/	
>DLT >	/∂/	/EQ/0.9%/PHOSPHATE/	/N84169/001/	
>DLT >	/∂/	/EQ/0.9%/PHOSPHATE/	/N84172/001/	
>ADD >	∂ SOLA BARNES HIND	EQ 0.11% PHOSPHATE	N84171 001	
>ADD >	∂	EQ 0.9% PHOSPHATE	N84168 001	
>ADD >	∂	EQ 0.9% PHOSPHATE	N84169 001	
>ADD >	∂	EQ 0.9% PHOSPHATE	N84172 001	
AT	STERIS	EQ 0.11% PHOSPHATE¤	N81043 001	OCT 24, 1991
AT		EQ 0.9% PHOSPHATE¤	N81044 001	OCT 24, 1991

PREDNISONE

TABLET; ORAL

/DELTA-DOME/

/BX/	/MILES/	/5MG/	/N80293/001/	
	∂ MILES	5MG	N80293 001	

PREDNICEN-M

AB	CENTRAL PHARMS	5MG	N84655 001	
/BX/		/5MG/	/N84655/001/	

PREDNISONE

/BX/	/AM/THERAP/	/5MG/	/N89387/001/	/NOV/06,/1986/
/BX/		/10MG/	/N89388/001/	/NOV/06,/1986/
/BX/		/20MG/	/N89389/001/	/NOV/06,/1986/
	∂ AM THERAP	5MG	N89387 001	NOV 06, 1986
	∂	10MG	N89388 001	NOV 06, 1986
	∂	20MG	N89389 001	NOV 06, 1986
/BX/	/BARR/	/50MG/	/N86596/001/	
	∂ BARR	50MG	N86596 001	

PREDNISONE

TABLET; ORAL

PREDNISONE

>DLT >/AB/	/DURAMED/	/5MG/	/N88394/001/	/OCT/04,/1983/
>DLT >				
>DLT >/AB/		/10MG/	/N88395/001/	/OCT/04,/1983/
>DLT >				
>DLT >/AB/		/20MG/	/N88396/001/	/OCT/04,/1983/
>DLT >				
>ADD >	∂ DURAMED	5MG	N88394 001	OCT 04, 1983
>ADD >				
>ADD >	∂	10MG	N88395 001	OCT 04, 1983
>ADD >				
>ADD >	∂	20MG	N88396 001	OCT 04, 1983
>ADD >				
>ADD >	∂ ELKINS SINN	5MG	N80491 001	
>ADD >	∂	20MG	N85811 001	
>DLT >	/∂/QUANTUM/PHARMICS/	/5MG/	/N80491/001/	
>DLT >	/∂/	/20MG/	/N85811/001/	
AB	ROXANE	1MG	N87800 001	APR 22, 1982
AB		2.5MG	N87801 001	APR 22, 1982
AB		10MG	N84122 001	
AB		20MG	N87342 001	
AB		50MG	N84283 001	
/BX/		/20MG/	/N17109/001/	
	/∂/	/1MG	/N87800/001/	/APR/22,/1982/
	/∂/	/2.5MG	/N87801/001/	/APR/22,/1982/
	/∂/	/10MG	/N84122/001/	
	∂ QUANTUM PHARMICS	20MG	N17109 001	
	/∂/	/20MG	/N87342/001/	
	/∂/	/50MG	/N84283/001/	

PRIMIDONE

TABLET; ORAL

PRIMIDONE

/AB/	/BOLAR/	/250MG/	/N85052/001/
	∂ BOLAR	250MG	N85052 001

PROCAINAMIDE HYDROCHLORIDE

CAPSULE; ORAL

PROCAINAMIDE HCL

AB	BOLAR	250MG	N83795	001
AB		500MG	N84357	001
	∂ BOLAR	250MG	N83795	001
	∂	500MG	N84357	001

INJECTABLE; INJECTION

PROCAINAMIDE HCL

AP	QUAD	100MG/ML	N89256	001 MAY 30, 1986
AP		500MG/ML	N89257	001 MAY 30, 1986
AP	WARNER/CHILCOTT	100MG/ML	N89528	001 MAY 03, 1988
AP		500MG/ML	N89529	001 MAY 03, 1988
	∂ QUAD	100MG/ML	N89256	001 MAY 30, 1986
	∂	500MG/ML	N89257	001 MAY 30, 1986
	∂ WARNER CHILCOTT	100MG/ML	N89528	001 MAY 03, 1988
	∂	500MG/ML	N89529	001 MAY 03, 1988

TABLET, EXTENDED RELEASE; ORAL

PROCAINAMIDE HCL

AB	BOLAR	1GM	N89520	001 JAN 15, 1987
	∂ BOLAR	1GM	N89520	001 JAN 15, 1987

PROCAN SR

AB	PARKE/DAVIS	1GM	N88489	001 JAN 16, 1985
	PARKE DAVIS	1GM	N88489	001 JAN 16, 1985

PROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROCAINE HCL

AP	CUTTER	1%	N80415	001
AP		2%	N80415	002
AP	LEMMON	1%	N83535	001
AP		2%	N83535	002
AP	STERIS	1%	N83535	001
AP		2%	N83535	002
	∂ CUTTER	1%	N80415	001
	∂	2%	N80415	002
	∂ LEMMON	1%	N83535	001
	∂	2%	N83535	002

PROCHLORPERAZINE EDISYLATE

CONCENTRATE; ORAL

PROCHLORPERAZINE EDISYLATE

AB	PHARM BASICS	EQ 10MG BASE/ML	N88598	001 OCT 25, 1984
	∂ PHARM BASICS	EQ 10MG BASE/ML	N88598	001 OCT 25, 1984

INJECTABLE; INJECTION

PROCHLORPERAZINE EDISYLATE

AP	QUAD	EQ 5MG BASE/ML	N89637	001 FEB 01, 1988
AP		EQ 5MG BASE/ML	N89638	001 FEB 01, 1988
	∂ QUAD	EQ 5MG BASE/ML	N89637	001 FEB 01, 1988
	∂	EQ 5MG BASE/ML	N89638	001 FEB 01, 1988

SYRUP; ORAL

COMPAZINE

AA	SKF	EQ 5MG BASE/5ML	N11188	001
	SKF	EQ 5MG BASE/5ML	N11188	001

PROCHLORPERAZINE EDISYLATE

AA	PHARM BASICS	EQ 5MG BASE/5ML	N88597	001 OCT 25, 1984
	∂ PHARM BASICS	EQ 5MG BASE/5ML	N88597	001 OCT 25, 1984

PROCHLORPERAZINE MALEATE

TABLET; ORAL

PROCHLORPERAZINE

AB	BOLAR	EQ 5MG BASE	N85580	001
AB		EQ 10MG BASE	N85178	001
AB		EQ 25MG BASE	N85579	001
	∂ BOLAR	EQ 5MG BASE	N85580	001
	∂	EQ 10MG BASE	N85178	001
	∂	EQ 25MG BASE	N85579	001

PROCHLORPERAZINE MALEATE

TABLET; ORAL

PROCHLORPERAZINE MALEATE

/AB/	/DURAMED/	/EQ 5MG BASE/	/N89484/001/	/JAN/20,/1987/
/AB/		/EQ 10MG BASE/	/N89485/001/	/JAN/20,/1987/
/AB/		/EQ 25MG BASE/	/N89486/001/	/JAN/20,/1987/
B*	DURAMED	EQ 5MG BASE	N89484 001	JAN 20, 1987
B*		EQ 10MG BASE	N89485 001	JAN 20, 1987
B*		EQ 25MG BASE	N89486 001	JAN 20, 1987

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROMETHAZINE HCL

/AP/	/LEMMON/	/25MG/ML/	/N83532/001/	
/AP/		/50MG/ML/	/N83532/002/	
AP	STERIS	25MG/ML	N83532 001	
AP		50MG/ML	N83532 002	

SUPPOSITORY; RECTAL

/PROMETHAZINE/HCL/

/BR/	/G/AND/W/	/50MG/	/N87165/001/	/AUG/14,/1987/
BR	PROMETHEGAN G AND W	50MG	N87165 001	AUG 14, 1987

PROPANTHELINE BROMIDE

TABLET; ORAL

PRO-BANTHINE

> ADD >	AA	SCHIAPPARELLI SEARLE	7.5MG		N08732 003
> ADD >	AA		15MG		N08732 002
> DLT >/	AA/	/SEARLE/	/7.5MG/	/N08732/003/	
> DLT >/	AA/		/15MG/	/N08732/002/	

PROPARACAINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

> DLT >		/PROPARACAINE HCL/		
> DLT >/	AT/	/BARNES/HIND/	/0.5%/	/N84144/001/
> DLT >/	AT/		/0.5%/	/N84151/001/
> ADD >		∂ SOLA BARNES HIND	0.5%	N84144 001
> ADD >		∂	0.5%	N84151 001

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

PROPOXYPHENE HCL

	∂ ALRA	65MG	N83184 001
/∂/	/BANMAX/	/65MG/	/N83184/001/

PROPRANOLOL HYDROCHLORIDE

INJECTABLE; INJECTION

PROPRANOLOL HCL

/AP/	/SOLOPAK/	/1MG/ML/	/N70135/001/	/APR/15,/1986/
	∂ SOLOPAK	1MG/ML	N70135 001	APR 15, 1986

SOLUTION; ORAL

PROPRANOLOL HCL

/AA/	/PHARM/BASICS/	/20MG/5ML/	/N71984/001/	/MAR/03,/1989/
/AA/		/40MG/5ML/	/N71985/001/	/MAR/03,/1989/
	∂ PHARM BASICS	20MG/5ML	N71984 001	MAR 03, 1989
	∂	40MG/5ML	N71985 001	MAR 03, 1989
/AA/	/ROXANE/	/20MG/5ML/	/N70979/001/	/MAY/15,/1987/
/AA/		/40MG/5ML/	/N70690/001/	/MAY/15,/1987/
	ROXANE	20MG/5ML	N70979 001	MAY 15, 1987
		40MG/5ML	N70690 001	MAY 15, 1987

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL
PROPRANOLOL HCL

/AB/	/BOLAR/	/10MG/	/N70378/001/	/MAR/19,/1987/	
/AB/		/20MG/	/N70379/001/	/MAR/19,/1987/	
/AB/		/40MG/	/N70380/001/	/MAR/19,/1987/	
/AB/		/60MG/	/N70381/001/	/MAR/19,/1987/	
/AB/		/80MG/	/N70382/001/	/MAR/19,/1987/	
	∂ BOLAR	10MG	N70378 001	MAR 19, 1987	
	∂	20MG	N70379 001	MAR 19, 1987	
	∂	40MG	N70380 001	MAR 19, 1987	
	∂	60MG	N70381 001	MAR 19, 1987	
	∂	80MG	N70382 001	MAR 19, 1987	
>DLT >/AB/	/CHELSEA/	/10MG/	/N70140/001/	/JUL/30,/1985/	
>DLT >					
>DLT >/AB/		/20MG/	/N70141/001/	/JUL/30,/1985/	
>DLT >					
>DLT >/AB/		/40MG/	/N70142/001/	/JUL/30,/1985/	
>DLT >					
>DLT >/AB/		/60MG/	/N70143/001/	/JAN/15,/1987/	
>DLT >					
>DLT >/AB/		/80MG/	/N70144/001/	/JUL/30,/1985/	
>DLT >					
>ADD >	∂ CHELSEA	10MG	N70140 001	JUL 30, 1985	
>ADD >					
>ADD >	∂	20MG	N70141 001	JUL 30, 1985	
>ADD >					
>ADD >	∂	40MG	N70142 001	JUL 30, 1985	
>ADD >					
>ADD >	∂	60MG	N70143 001	JAN 15, 1987	
>ADD >					
>ADD >	∂	80MG	N70144 001	JUL 30, 1985	
>ADD >					

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL
PROPRANOLOL HCL

>DLT >/AB/	/DURAMED/	/10MG/	/N70306/001/	/SEP/09,/1985/	
>DLT >					
>DLT >/AB/		/20MG/	/N70307/001/	/SEP/09,/1985/	
>DLT >					
>DLT >/AB/		/40MG/	/N71327/001/	/OCT/01,/1986/	
>DLT >					
>DLT > /B*/		/40MG/	/N70308/001/	/SEP/09,/1985/	
>DLT >					
>DLT > /B*/		/60MG/	/N70309/001/	/OCT/01,/1986/	
>DLT >					
>DLT > /B*/		/80MG/	/N70310/001/	/SEP/09,/1985/	
>DLT >					
>ADD >	∂ DURAMED	10MG	N70306 001	SEP 09, 1985	
>ADD >					
>ADD >	∂	20MG	N70307 001	SEP 09, 1985	
>ADD >					
>ADD >	∂	40MG	N70308 001	SEP 09, 1985	
>ADD >					
>ADD >	∂	60MG	N70309 001	OCT 01, 1986	
>ADD >					
>ADD >	∂	80MG	N70310 001	SEP 09, 1985	
>ADD >					
>ADD >	∂	90MG	N71327 001	OCT 01, 1986	
/AB/	/MARTEC/	/10MG/	/N70120/001/	/AUG/06,/1985/	
/AB/		/20MG/	/N70121/001/	/AUG/06,/1985/	
/AB/		/40MG/	/N70122/001/	/AUG/06,/1985/	
/AB/		/60MG/	/N70123/001/	/OCT/29,/1986/	
/AB/		/80MG/	/N70124/001/	/AUG/06,/1985/	
AB	SCHERING	10MG	N70120 001	AUG 06, 1985	
AB		20MG	N70121 001	AUG 06, 1985	
AB		40MG	N70122 001	AUG 06, 1985	
AB		60MG	N70123 001	OCT 29, 1986	
AB		80MG	N70124 001	AUG 06, 1985	

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL
PROPRANOLOL HCL

AB	SUPERPHARM	40MG	N71517 001 JUN 08, 1988
AB		80MG	N71518 001 JUN 08, 1988
	∂ SUPERPHARM	40MG	
	∂	80MG	

PROTAMINE SULFATE

INJECTABLE; INJECTION
PROTAMINE SULFATE

QUAD	50MG/VIAL	N89307 001 MAY 30, 1986
∂ QUAD	50MG/VIAL	

PSEUDOEPHEDRINE HYDROCHLORIDE; TERFENADINE

TABLET, EXTENDED RELEASE; ORAL
SELDANE-D

MERRELL DOW	120MG;60MG¤	N19664 001 AUG 19, 1991

PYRIDOSTIGMINE BROMIDE

TABLET; ORAL
PYRIDOSTIGMINE BROMIDE

KALI DUPHAR	30MG	N89572 001 NOV 27, 1990
PUREPAC	30MG	N89572 001 NOV 27, 1990

PYRIDOXINE HYDROCHLORIDE

INJECTABLE; INJECTION
PYRIDOXINE HCL

AP	LEMMON	100MG/ML	N83760 001
AP	STERIS	100MG/ML	

PYRILAMINE MALEATE

TABLET; ORAL
PYRILAMINE MALEATE

AA	CHELSEA	25MG	N85231 001
AA	RICHLYN	25MG	N80808 001
	∂ CHELSEA	25MG	
	RICHLYN	25MG	

QUAZEPAM

TABLET; ORAL
DORAL

BAKER CUMMINS	7.5MG	N18708 003 FEB 26, 1987
	15MG	N18708 001 DEC 27, 1985
DORMALIN		
BAKER/CUMMINS	7.5MG	N18708 003 FEB 26, 1987
	15MG	N18708 001 DEC 27, 1985

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL
ACCUPRIL

PARKE DAVIS	EQ 5MG BASE¤	N19885 001 NOV 19, 1991
	EQ 10MG BASE¤	N19885 002 NOV 19, 1991
	EQ 20MG BASE¤	N19885 003 NOV 19, 1991
	EQ 40MG BASE¤	N19885 004 NOV 19, 1991

QUINESTROL

TABLET; ORAL
ESTROVIS

PARKE DAVIS	0.1MG	N16768 002

QUINIDINE GLUCONATE

TABLET; ORAL
QUINACT

BERLEX	200MG	N85978 001
	400MG	N86099 001

QUINIDINE GLUCONATE

/TABLET;/ORAL/
/QUINACT/
ə BERLEX 266MG N85978 001
ə 400MG N86099 001

TABLET, EXTENDED RELEASE; ORAL
/QUINATIME/
/AB/ /BOLAR/ /324MG/ /N87448/001/
ə BOLAR 324MG N87448 001
QUINIDINE GLUCONATE
/AB/ /ROXANE/ /324MG/ /N88431/001/
/JAN/06,/1984/
ə ROXANE 324MG N88431 001
JAN 06, 1984

QUINIDINE SULFATE

TABLET; ORAL
QUINIDINE SULFATE
/AB/ /VANGARD/ /200MG/ /N87909/001/
/JUL/13,/1982/
ə VANGARD 200MG N87909 001 > ADD >
JUL 13, 1982 > ADD >
QUIHORA > DLT >
/AB/ /KEY/PHARMS/ /200MG/ /N83576/001/ > DLT >
ə KEY PHARMS 200MG N83576 001

RAMIPRIL

CAPSULE; ORAL
ALTACE
HOECHST ROUSSEL 1.25MG¤ N19901 001
JAN 28, 1991
2.5MG¤ N19901 002
JAN 28, 1991
5MG¤ N19901 003
JAN 28, 1991
10MG¤ N19901 004
JAN 28, 1991

RANITIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
ZANTAC IN PLASTIC CONTAINER
/GLAXO/ /EQ/50MG/BASE/100ML/ /N19593/001/
/DEC/17,/1986/
ə GLAXO EQ 50MG BASE/100ML N19593 001
DEC 17, 1986
EQ 1MG BASE/ML¤ N19593 002
SEP 27, 1991

RAUWOLFIA SERPENTINA

TABLET; ORAL
RAUWOLFIA SERPENTINA
BP DANBURY 50MG N80907 001
/ə/ /50MG/ /N80907/001/

RESERPINE

TABLET; ORAL
RESERPINE
ə ELKINS SINN 0.1MG N83145 001
ə 0.25MG N83145 002
/ə/QUANTUM/PHARMICS/ /0.1MG/ /N83145/001/
/ə/ /0.25MG/ /N83145/002/
/BP/ /WHITE/TOWNE/PAULSEN/ /0.1MG/ /N80723/001/
/BP/ /0.25MG/ /N80723/002/
ə WHITE TOWNE PAULSEN 0.1MG N80723 001
ə 0.25MG N80723 002
/1MG/ /N80723/003/
ə 1MG N80723 003

RITODRINE HYDROCHLORIDE

INJECTABLE; INJECTION
RITODRINE HCL
AP ABBOTT 10MG/ML¤ N71618 001
FEB 28, 1991
AP 15MG/ML¤ N71619 001
FEB 28, 1991
/AP/ /QUAD/ /15MG/ML/ /N70701/001/
/OCT/06,/1986/
ə QUAD 15MG/ML N70701 001
OCT 06, 1986
RITODRINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER
ABBOTT 30MG/100ML¤ N71438 001
JAN 22, 1991

SECOBARBITAL SODIUM

CAPSULE; ORAL
SECOBARBITAL SODIUM
/AA/ /WYETH/AYERST/ /100MG/ /N86390/001/
∂ WYETH AYERST 100MG N86390 001

SELENIUM SULFIDE

LOTION/SHAMPOO; TOPICAL
SELENIUM SULFIDE
AT CLAY PARK 2.5%‡ N89996 001
JAN 10, 1991

> ADD > SERTRALINE HYDROCHLORIDE

> ADD > TABLET; ORAL
> ADD > ZOLOFT
> ADD > PFIZER EQ 50MG BASE‡ N19839 001
> ADD > DEC 30, 1991
> ADD > EQ 100MG BASE‡ N19839 002
> ADD > DEC 30, 1991
> ADD > ∂ EQ 150MG BASE‡ N19839 003
> ADD > DEC 30, 1991
> ADD > ∂ EQ 200MG BASE‡ N19839 004
> ADD > DEC 30, 1991

> ADD > SIMVASTATIN

> ADD > TABLET; ORAL
> ADD > ZOCOR
> ADD > MSD 5MG‡ N19766 001
> ADD > DEC 23, 1991
> ADD > 10MG‡ N19766 002
> ADD > DEC 23, 1991
> ADD > 20MG‡ N19766 003
> ADD > DEC 23, 1991
> ADD > 40MG‡ N19766 004
> ADD > DEC 23, 1991

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION
SODIUM NITROPRUSSIDE
/AP/ /LYPHOMED/ /50MG/VIAL/ /N70031/001/
/JAN/17,/1985/
∂ LYPHOMED 50MG/VIAL N70031 001
JAN 17, 1985

SPIRONOLACTONE

TABLET; ORAL
SPIRONOLACTONE
/AB/ /BOLAR/ /25MG/ /N86898/002/
/MAR/02,/1982/
∂ BOLAR 25MG N86898 002
MAR 02, 1982

SUCCIMER

CAPSULE; ORAL
CHEMET
MCNEIL 100MG‡ N19998 002
JAN 30, 1991

SUCRALFATE

TABLET; ORAL
CARAFATE
> ADD > BLUE RIDGE 1GM N18333 001
> DLT > /MARION/MERRELL/DOW/ /1GM/ /N18333/001/

SULFABENZAMIDE; SULFACETAMIDE; SULFATHIAZOLE

> ADD > CREAM; VAGINAL
> ADD > SULTRIN
> ADD > JOHNSON RW 3.7%;2.86%;3.42% N05794 001

SULFABENZAMIDE; SULFACETAMIDE; SULFATHIAZOLE; UREA

CREAM; VAGINAL
> DLT > /SULTRIN/
> DLT > /AT/ /JOHNSON/RW/ /3.7%;2.86%;3.42%;6.64%/ /N05794/001/

SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC

		SODIUM SULFACETAMIDE		
> DLT >	/AT/	/BARNES/HIND/	/10%/	/N84143/001/
> DLT >	/AT/		/10%/	/N84145/001/
> DLT >	/AT/		/30%/	/N84146/001/
> DLT >	/AT/		/30%/	/N84147/001/
> ADD >		∂ SOLA BARNES HIND	10%	N84143 001
> ADD >		∂	10%	N84145 001
> ADD >		∂	30%	N84146 001
> ADD >		∂	30%	N84147 001

SULFAMETHOXAZOLE

TABLET; ORAL

		SULFAMETHOXAZOLE		
/AB/	/BOLAR/	/500MG/		/N85053/001/
	∂ BOLAR	500MG		N85053 001

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION

		COTRIM		
/AP/	/STERIS/	/80MG/ML;16MG/ML		/N71556/001/ /DEC/17,/1987/
		SULFAMETHOPRIM		
/AP/	/QUAD/	/80MG/ML;16MG/ML/		/N71341/001/ /AUG/07,/1987/
	∂ QUAD	80MG/ML;16MG/ML		N71341 001 AUG 07, 1987

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION

	SULFAMETHOXAZOLE AND TRIMETHOPRIM		
AP	GENSIA	80MG/ML;16MG/ML¤	N73303 001 OCT 31, 1991
AP	STERIS	80MG/ML;16MG/ML	N71556 001 DEC 17, 1987

SUSPENSION; ORAL

	COTRIM PEDIATRIC		
AB	LEMMON	200MG/5ML;40MG/5ML	N70028 001 OCT 29, 1985
	SULFAMETHOXAZOLE AND TRIMETHOPRIM		
/AB/	/PLANTEX/	/200MG/5ML;40MG/5ML/	/N70028/001/ /OCT/29,/1985/

TABLET; ORAL

	SULFAMETHOXAZOLE AND TRIMETHOPRIM		
/AB/	/PHARM/BASICS/	/400MG;80MG/	/N70203/001/ /NOV/08,/1985/
/AB/		/800MG;160MG/	/N70204/001/ /NOV/08,/1985/
B*	PHARM BASICS	400MG;80MG	N70203 001 NOV 08, 1985
B*		800MG;160MG	N70204 001 NOV 08, 1985
AB	ROXANE	400MG;80MG¤	N72768 001 AUG 30, 1991
	SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH		
AB	ROXANE LABS	800MG;160MG¤	N72769 001 AUG 30, 1991

SULFANILAMIDE

CREAM; VAGINAL

	SULFANILAMIDE		
AT	LEMMON	15%	N88718 001 SEP 19, 1985
	VAGITROL		
/AT/	/LEMMON/	/15%/	/N88718/001/ /SEP/19,/1985/

SULFASALAZINE

TABLET; ORAL

		SULFASALAZINE		
> DLT >	/AB/	/BOLAR/	/500MG/	/N84964/001/
> ADD >		∂ BOLAR	500MG	N84964 001

SULFASALAZINE

TABLET, DELAYED RELEASE; ORAL
AZULFIDINE EN-TABS
KABI 500MG N07073 002 APR 06, 1983
/AB/ /PHARMACIA/ /500MG/ /N07073/002/ /APR/06,/1983/
/SULFASALAZINE/
/BE/ /BOLAR/ /500MG/ /N88052/001/ /MAY/24,/1983/
∂ BOLAR 500MG N88052 001 MAY 24, 1983

SULFISOXAZOLE

TABLET; ORAL
SOXAZOLE
∂ ALRA 500MG N80366 001
/∂/BANMAX/ /500MG/ /N80366/001/

SULINDAC

TABLET; ORAL
SULINDAC
AB GENEVA 150MG* N72712 001 AUG 30, 1991
AB 200MG* N72713 001 AUG 30, 1991
AB LEDERLE 150MG* N73261 001 SEP 06, 1991
AB 200MG* N73262 001 SEP 06, 1991
AB MUTUAL PHARM 150MG* N72050 001 APR 17, 1991
AB 200MG* N72051 001 APR 17, 1991
AB WARNER CHILCOTT 150MG* N72710 001 MAR 25, 1991
AB 200MG* N72711 001 MAR 25, 1991

TECHNETIUM TC-99M RED BLOOD CELL KIT

INJECTABLE; INJECTION
ULTRATAG
MALLINCKRODT N/A* N19981 001 JUN 10, 1991

TEMAZEPAM

CAPSULE; ORAL
RESTORIL
SANDOZ 7.5MG* N18163 003 OCT 25, 1991
TEMAZEPAM
/AB/ /BOLAR/ /15MG/ /N70383/001/ /MAR/23,/1987/
/AB/ /30MG/ /N70384/001/ /MAR/23,/1987/
∂ BOLAR 15MG N70383 001 MAR 23, 1987
∂ 30MG N70384 001 MAR 23, 1987
>DLT >/AB/ /DURAMED/ /15MG/ /N71708/001/ /SEP/29,/1988/
>DLT >/AB/ /30MG/ /N71709/001/ /SEP/29,/1988/
>DLT >
>DLT >
>ADD >
>ADD >
>ADD >
>ADD >
∂ DURAMED 15MG N71708 001 SEP 29, 1988
∂ 30MG N71709 001 SEP 29, 1988
/AB/ /PHARM/BASICS/ /15MG/ /N70489/001/ /JUL/07,/1986/
/AB/ /30MG/ /N70490/001/ /JUL/07,/1986/
B* PHARM BASICS 15MG N70489 001 JUL 07, 1986
B* 30MG N70490 001 JUL 07, 1986

TERCONAZOLE

CREAM; VAGINAL
TERAZOL 3
JOHNSON RW 0.8%* N19964 001 FEB 21, 1991

TESTOSTERONE CYPIONATE

INJECTABLE; INJECTION
TESTOSTERONE CYPIONATE
/AO/ /LEMMON/ /100MG/ML/ /N64461/001/
/AO/ /200MG/ML/ /N64461/002/

TESTOSTERONE CYPIONATE

INJECTABLE; INJECTION

TESTOSTERONE CYPIONATE

/AO/	/QUAD/	/100MG/ML/	/N89326/001/	
			/OCT/28,/1988/	
/AO/		/200MG/ML/	/N89327/001/	
			/OCT/28,/1988/	
	∂ QUAD	100MG/ML	N89326 001	
			OCT 28, 1988	
	∂	200MG/ML	N89327 001	
			OCT 28, 1988	
AO	STERIS	100MG/ML	N84401 001	
AO		200MG/ML	N84401 002	

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION

>DLT>	/DELATESTRYL/			
>DLT>/AO/	/SQUIBB/	/200MG/ML/	/N09165/001/	
>ADD>	∂ SQUIBB	200MG/ML	N09165 001	

TESTOSTERONE ENANTHATE

/AO/	/LEMMON/	/100MG/ML/	/N83667/001/	
/AO/		/200MG/ML/	/N83667/002/	
/AO/	/QUAD/	/100MG/ML/	/N89324/001/	
			/SEP/16,/1986/	
/AO/		/200MG/ML/	/N89325/001/	
			/SEP/16,/1986/	
	∂ QUAD	100MG/ML	N89324 001	
			SEP 16, 1986	
	∂	200MG/ML	N89325 001	
			SEP 16, 1986	
AO	STERIS	100MG/ML	N83667 001	
AO		200MG/ML	N83667 002	

TESTOSTERONE PROPIONATE

INJECTABLE; INJECTION

TESTOSTERONE PROPIONATE

/AO/	/LEMMON/	/25MG/ML/	/N85490/001/	
/AO/		/50MG/ML/	/N85490/002/	
/AO/		/100MG/ML/	/N83595/003/	
/AO/	/QUAD/	/100MG/ML/	/N89283/001/	
			/NOV/03,/1986/	
	∂ QUAD	100MG/ML	N89283 001	
			NOV 03, 1986	
AO	STERIS	25MG/ML	N85490 001	
AO		50MG/ML	N85490 002	
AO		100MG/ML	N83595 003	

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

TETRACYCLINE HCL

	∂ ELKINS SINN	250MG		N60059 001	
>ADD>	/∂/QUANTUM/PHARMICS/	/250MG/		/N60059/001/	
>DLT>					
>ADD> AB	VITARINE	250MG		N61471 001	
>DLT>	/∂/	/250MG/		/N61471/001/	

POWDER FOR RECONSTITUTION; TOPICAL

TOPICYCLINE

>DLT>	/P/AND/G/	/2.2MG/ML/		/N50493/001/
>ADD>	ROBERTS	2.2MG/ML		N50493 001

THEOPHYLLINE

CAPSULE; ORAL

/SOMOPHYLLIN-T/

/BX/	/FISONS/	/100MG/		/N87155/001/
				/FEB/25,/1985/
/BX/		/200MG/		/N87155/002/
				/FEB/25,/1985/
/BX/		/250MG/		/N87155/003/
				/FEB/25,/1985/
	∂ FISONS	100MG		N87155 001
				FEB 25, 1985
	∂	200MG		N87155 002
				FEB 25, 1985
	∂	250MG		N87155 003
				FEB 25, 1985

THEOPHYLLINE

/BX/	/SCHERER/	/100MG/		/N84731/002/
				/NOV/07,/1986/
/BX/		/200MG/		/N84731/001/
				/NOV/07,/1986/
/BX/		/250MG/		/N84731/003/
				/NOV/07,/1986/
	∂ SCHERER	100MG		N84731 002
				NOV 07, 1986
	∂	200MG		N84731 001
				NOV 07, 1986
	∂	250MG		N84731 003
				NOV 07, 1986

CAPSULE, EXTENDED RELEASE; ORAL

/THEOPHYL-SR/

/BC/	/JOHNSON/RW/	/125MG/		/N86480/001/
				/FEB/08,/1985/
	∂ JOHNSON RW	125MG		N86480 001
				FEB 08, 1985

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL

THEOPHYLLINE

/BC/	/CENTRAL/PHARMS/	/125MG/	/N86654/001/	/FEB/12,/1985/
/BC/		/250MG/	/N86689/001/	/FEB/12,/1985/
	∂ CENTRAL PHARMS	125MG	N88654 001	FEB 12, 1985
	∂	250MG	N88689 001	FEB 12, 1985

THEOPHYLLINE-SR

/BC/	/SCHERER/	/300MG/	/N86255/001/	/JUN/12,/1986/
	∂ SCHERER	300MG	N88255 001	JUN 12, 1986

TABLET; ORAL

THEOCLEAR-100

/BD/	/CENTRAL/PHARMS/	/100MG/	/N85353/002/	
	∂ CENTRAL PHARMS	100MG	N85353 002	

THEOCLEAR-200

/BD/	/CENTRAL/PHARMS/	/200MG/	/N85353/001/	
	∂ CENTRAL PHARMS	200MG	N85353 001	

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

THIAMINE HCL

/AP/	/LEMMON/	/100MG/ML/	/N83534/001/	
/AP/		/200MG/ML/	/N83534/002/	
/AP/	/LYPHOMED/	/100MG/ML/	/N80509/001/	
	∂ LYPHOMED	100MG/ML	N80509 001	
AP	STERIS	100MG/ML	N83534 001	
AP		200MG/ML	N83534 002	

THIORIDAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

THIORIDAZINE HCL

> DLT > /AA/	/BARRE/	/30MG/ML/	/N87766/001/	/APR/26,/1983/
> DLT >				
> ADD >	∂ BARRE	30MG/ML	N87766 001	APR 26, 1983
> ADD >				

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL

THIORIDAZINE HCL

/AB/	/BOLAR/	/10MG/	/N88412/001/	/SEP/12,/1983/
/AB/		/15MG/	/N88345/001/	/JUL/28,/1983/
/AB/		/25MG/	/N88296/001/	/JUL/28,/1983/
/AB/		/50MG/	/N88323/001/	/JUL/28,/1983/
/AB/		/100MG/	/N88284/001/	/AUG/25,/1983/
/AB/		/150MG/	/N88410/001/	/MAR/05,/1984/
/AB/		/200MG/	/N88381/001/	/MAR/14,/1984/
	∂ BOLAR	10MG	N88412 001	SEP 12, 1983
	∂	15MG	N88345 001	JUL 28, 1983
	∂	25MG	N88296 001	JUL 28, 1983
	∂	50MG	N88323 001	JUL 28, 1983
	∂	100MG	N88284 001	AUG 25, 1983
	∂	150MG	N88410 001	MAR 05, 1984
	∂	200MG	N88381 001	MAR 14, 1984

/AB/	/ROXANE/	/10MG/	/N88663/001/	/MAR/15,/1984/
/AB/		/25MG/	/N88664/001/	/MAR/15,/1984/
/AB/		/50MG/	/N88665/001/	/MAR/15,/1984/
/AB/		/100MG/	/N89048/001/	/FEB/26,/1985/
	∂ ROXANE	10MG	N88663 001	MAR 15, 1984
	∂	25MG	N88664 001	MAR 15, 1984
	∂	50MG	N88665 001	MAR 15, 1984
	∂	100MG	N89048 001	FEB 26, 1985

THIOTHIXENE

CAPSULE; ORAL
THIOTHIXENE

/AB/	/AM THERAP/	/1MG/	/N71884/001/ /AUG/12,/1987/		
/AB/		/2MG/	/N71885/001/ /AUG/12,/1987/		
>DLT >/AB/		/5MG/	/N71886/001/ /AUG/12,/1987/		
>DLT > /AB/		/10MG/	/N71887/001/ /AUG/12,/1987/		
>DLT >/AB/		/20MG/	/N72200/001/ /DEC/17,/1987/		
>DLT >	∂ AM THERAP	1MG	N71884 001 AUG 12, 1987		
	∂	2MG	N71885 001 AUG 12, 1987		
>ADD >	∂	5MG	N71886 001 AUG 12, 1987		
>ADD >	∂	10MG	N71887 001 AUG 12, 1987		
>ADD >	∂	20MG	N72200 001 DEC 17, 1987		
>ADD > >DLT >/AB/	/CHELSEA/	/2MG/	/N71626/001/ /JUN/25,/1987/		
>DLT > >DLT >/AB/		/5MG/	/N71627/001/ /JUN/25,/1987/		
>DLT > >DLT >/AB/		/10MG/	/N71628/001/ /JUN/25,/1987/		
>DLT > >ADD >	∂ CHELSEA	2MG	N71626 001 JUN 25, 1987		
>ADD > >ADD >	∂	5MG	N71627 001 JUN 25, 1987		
>ADD > >ADD >	∂	10MG	N71628 001 JUN 25, 1987		
>ADD >					

THIOTHIXENE HYDROCHLORIDE

CONCENTRATE; ORAL
THIOTHIXENE HCL

/AA/	/PACO/	/EQ 5MG BASE/ML/	/N71939/001/ /DEC/16,/1988/		
		/EQ/1MG/BASE/ML/	/N71917/001/ /SEP/20,/1989/		
	∂ PACO	EQ 5MG BASE/ML	N71939 001 DEC 16, 1988		
	∂	EQ 1MG BASE/ML	N71917 001 SEP 20, 1989		

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL
TICLID

	SYNTEX	250MG¤	N19979 002 OCT 31, 1991

TIMOLOL MALEATE

TABLET; ORAL
TIMOLOL MALEATE

/AB/	/BOLAR/	/5MG/	/N72269/001/ /MAR/14,/1989/	
/AB/		/10MG/	/N72270/001/ /MAR/14,/1989/	
/AB/		/20MG/	/N72271/001/ /MAR/14,/1989/	
	∂ BOLAR	5MG	N72269 001 MAR 14, 1989	
	∂	10MG	N72270 001 MAR 14, 1989	
	∂	20MG	N72271 001 MAR 14, 1989	
AB	DANBURY	5MG¤	N72917 001 JUL 31, 1991	
AB		10MG¤	N72918 001 JUL 31, 1991	
AB		20MG¤	N72919 001 JUL 31, 1991	
/AB/	/PHARM/BASICS/	/5MG/	/N72001/001/ /JAN/10,/1989/	
/AB/		/10MG/	/N72002/001/ /JAN/10,/1989/	
/AB/		/20MG/	/N72003/001/ /JAN/10,/1989/	
B*	PHARM BASICS	5MG	N72001 001 JAN 10, 1989	
B*		10MG	N72002 001 JAN 10, 1989	
B*		20MG	N72003 001 JAN 10, 1989	

TIOCONAZOLE

OINTMENT; VAGINAL

>DLT >	/VAGISTAT/		
>DLT >	/∂/FUJISAWA/	/6.5%/	/N19355/001/ /DEC/30,/1986/
>DLT >			
>ADD >	VAGISTAT-1		
>ADD >	BRISTOL MYERS	6.5%	N19355 001 DEC 30, 1986
>ADD >			

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION
TOBRAMYCIN SULFATE

AP	ABBOTT	EQ 10MG BASE/ML¤	N63080 001 APR 30, 1991
AP		EQ 10MG BASE/ML¤	N63112 001 APR 30, 1991
AP		EQ 40MG BASE/ML¤	N63111 001 APR 30, 1991
AP		EQ 40MG BASE/ML¤	N63161 001 MAY 29, 1991
AP	ELKINS SINN	EQ 10MG BASE/ML¤	N63128 001 NOV 27, 1991
AP		EQ 40MG BASE/ML¤	N63127 001 NOV 27, 1991
AP	LEDERLE	EQ 10MG BASE/ML¤	N63113 001 APR 26, 1991
AP		EQ 40MG BASE/ML¤	N63117 001 APR 26, 1991
AP		EQ 40MG BASE/ML¤	N63118 001 JUL 29, 1991

TOLAZAMIDE

TABLET; ORAL
TOLAZAMIDE

/AB/	/BOLAR/	/100MG/	/N70242/001/ /AUG/01,/1986/
/AB/		/250MG/	/N70243/001/ /AUG/01,/1986/
/AB/		/500MG/	/N70244/001/ /AUG/01,/1986/
∂	BOLAR	100MG	N70242 001 AUG 01, 1986
∂		250MG	N70243 001 AUG 01, 1986
∂		500MG	N70244 001 AUG 01, 1986
>DLT> /B*/	/CHELSEA/	/100MG/	/N70285/001/ /JAN/09,/1986/
>DLT> /B*/		/250MG/	/N70286/001/ /JAN/09,/1986/
>DLT> /B*/		/500MG/	/N70287/001/ /JAN/09,/1986/

TOLAZAMIDE

TABLET; ORAL
TOLAZAMIDE

>DLT>/AB/	/DURAMED/	/100MG/	/N70165/001/ /JAN/10,/1986/
>DLT>/AB/		/250MG/	/N70166/001/ /JAN/10,/1986/
>DLT>/AB/		/500MG/	/N70167/001/ /JAN/10,/1986/
>ADD>	∂ DURAMED	100MG	N70165 001 JAN 10, 1986
>ADD>	∂	250MG	N70166 001 JAN 10, 1986
>ADD>	∂	500MG	N70167 001 JAN 10, 1986
/AB/	/PHARM/BASICS/	/100MG/	/N71355/001/ /JAN/11,/1988/
/AB/		/250MG/	/N70168/001/ /APR/02,/1986/
/AB/		/500MG/	/N70169/001/ /APR/02,/1986/
B*	PHARM BASICS	100MG	N71355 001 JAN 11, 1988
B*		250MG	N70168 001 APR 02, 1986
B*		500MG	N70169 001 APR 02, 1986

TOLBUTAMIDE

TABLET; ORAL
TOLBUTAMIDE

∂	ALRA	500MG	N86141 001
/∂/	/BANMAX/	/500MG/	/N86141/001/
/AB/	/BOLAR/	/250MG/	/N89110/001/ /MAY/29,/1987/
/AB/		/500MG/	/N89111/001/ /MAY/29,/1987/
∂	BOLAR	250MG	N89110 001 MAY 29, 1987
∂		500MG	N89111 001 MAY 29, 1987

TOLMETIN SODIUM

CAPSULE; ORAL
TOLECTIN DS

AB	JOHNSON RW	EQ 400MG BASE	N18084 001

TOLMETIN SODIUM

CAPSULE; ORAL

	TOLMETIN SODIUM			
AB	MUTUAL PHARM	EQ 400MG BASE*	N73311 001	NOV 27, 1991
AB	NOVOPHARM	EQ 400MG BASE*	N73290 001	NOV 27, 1991

TABLET; ORAL

	TOLECTIN			
AB	JOHNSON RW	EQ 200MG BASE	N17628 001	
	TOLMETIN SODIUM			
AB	MUTUAL PHARM	EQ 200MG BASE*	N73310 001	NOV 27, 1991

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

		TRAZODONE HCL			
> DLT >	/AB/	/AM THERAP/	/50MG/	/N71139/001/	/OCT 29, 1986/
> DLT >					
> DLT >	/AB/		/100MG/	/N71140/001/	/OCT 29, 1986/
> DLT >					
> ADD >		ə AM THERAP	50MG	N71139 001	OCT 29, 1986
> ADD >					
> ADD >		ə	100MG	N71140 001	OCT 29, 1986
> ADD >					
	/AB/	/BOLAR/	/50MG/	/N71112/001/	/NOV 17, 1986/
	/AB/		/100MG/	/N71113/001/	/NOV 17, 1986/
		ə BOLAR	50MG	N71112 001	NOV 17, 1986
		ə	100MG	N71113 001	NOV 17, 1986
> DLT >	/B*/	/CHELSEA/	/50MG/	/N70568/001/	/OCT 10, 1986/
> DLT >					
> DLT >	/B*/		/100MG/	/N70569/001/	/OCT 10, 1986/
> DLT >					
	AB	MYLAN	50MG*	N71405 001	FEB 27, 1991
	AB		100MG*	N71406 001	FEB 27, 1991
	/AB/	/PHARM BASICS/	/50MG/	/N70491/001/	/APR 29, 1987/
	/AB/		/100MG/	/N70492/001/	/APR 29, 1987/
	B*	PHARM BASICS	50MG	N70491 001	APR 29, 1987
	B*		100MG	N70492 001	APR 29, 1987

TRETINOIN

GEL; TOPICAL

	RETIN-A			
/AT/	/JOHNSON RW/	/0.01%/	/N17579/003/	

TRIAMCINOLONE ACETONIDE

AEROSOL, METERED; NASAL

	NASACORT			
	RHONE POULENC RORER	55UGM/INH*	N19798 001	JUL 11, 1991

CREAM; TOPICAL

	KENAC			
/AT/	/NMC/	/0.025%/	/N87797/001/	/JUN 07, 1982/
/AT/		/0.1%/	/N87798/001/	/JUN 04, 1982/
	TRIAMCINOLONE ACETONIDE			
AT	G AND W	0.025%*	N89797 001	MAY 31, 1991
AT		0.1%*	N89798 001	MAY 31, 1991
AT	NMC	0.025%	N87797 001	JUN 07, 1982
AT		0.1%	N87798 001	JUN 04, 1982
/AT/	/PHARM BASICS/	/0.025%/	/N88094/001/	/SEP 01, 1983/
/AT/		/0.1%/	/N88095/001/	/SEP 01, 1983/
/AT/		/0.5%/	/N88096/001/	/SEP 01, 1983/
	ə PHARM BASICS	0.025%	N88094 001	SEP 01, 1983
	ə	0.1%	N88095 001	SEP 01, 1983
	ə	0.5%	N88096 001	SEP 01, 1983

/GEL;TOPICAL/

	ARISTOGEL			
	/LEDERLE/	/0.1%/	/N83380/001/	
	ə LEDERLE	0.1%	N83380 001	

OINTMENT; TOPICAL

	ARISTOCORT A			
/AT/	/LEDERLE/	/0.5%/	/N88781/001/	/OCT 05, 1984/
	ə LEDERLE	0.5%	N88781 001	OCT 05, 1984

TRIAMCINOLONE ACETONIDE

OINTMENT; TOPICAL

	KENAC			
/AT/	/NMC/	/0.1%/	/N87799/001/	/JUN/07,/1982/
	TRIAMCINOLONE ACETONIDE			
AT	NMC	0.1%	N87799 001	JUN 07, 1982
/AT/	/PHARM/BASICS/	/0.025%/	/N88090/001/	/SEP/01,/1983/
/AT/		/0.1%/	/N88091/001/	/SEP/01,/1983/
/AT/		/0.5%/	/N88092/001/	/SEP/01,/1983/
	∂ PHARM BASICS	0.025%	N88090 001	SEP 01, 1983
	∂	0.1%	N88091 001	SEP 01, 1983
	∂	0.5%	N88092 001	SEP 01, 1983

TRIAMCINOLONE DIACETATE

INJECTABLE; INJECTION

	TRIAMCINOLONE DIACETATE			
/BP/	/LEMMON/	/40MG/ML/	/N85529/001/	
BP	STERIS	40MG/ML	N85529 001	

TRICHLORMETHIAZIDE

TABLET; ORAL

	TRICHLORMETHIAZIDE			
/BP/	/BOLAR/	/4MG/	/N83462/001/	
	∂ BOLAR	4MG	N83462 001	

TRIFLUOPERAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

	STELAZINE			
/AP/	/SKF/	/EQ 2MG BASE/ML/	/N11552/005/	
	SKF	EQ 2MG BASE/ML	N11552 005	
	TRIFLUOPERAZINE HCL			
/AP/	/QUAD/	/EQ 2MG BASE/ML/	/N89893/001/	/OCT/17,/1988/
	∂ QUAD	EQ 2MG BASE/ML	N89893 001	OCT 17, 1988

TRIFLUOPERAZINE HYDROCHLORIDE

TABLET; ORAL

	TRIFLUOPERAZINE HCL					
/AB/	/BOLAR/	/EQ 1MG BASE/	/N85975/001/		/JUN/23,/1988/	
/AB/		/EQ 2MG BASE/	/N85976/001/		/JUN/23,/1988/	
/AB/		/EQ 5MG BASE/	/N85973/001/		/JUN/23,/1988/	
/AB/		/EQ 10MG BASE/	/N88710/001/		/JUN/23,/1988/	
	∂ BOLAR	EQ 1MG BASE	N85975 001		JUN 23, 1988	
	∂	EQ 2MG BASE	N85976 001		JUN 23, 1988	
	∂	EQ 5MG BASE	N85973 001		JUN 23, 1988	
	∂	EQ 10MG BASE	N88710 001		JUN 23, 1988	
>DLT>	/B*/	/DURAMED/	/EQ/1MG/BASE/	/N88967/001/	/APR/23,/1985/	
>DLT>	/B*/		/EQ/2MG/BASE/	/N88968/001/	/APR/23,/1985/	
>DLT>	/B*/		/EQ/5MG/BASE/	/N88969/001/	/APR/23,/1985/	
>DLT>	/B*/		/EQ/10MG/BASE/	/N88970/001/	/APR/23,/1985/	
>ADD>		∂ DURAMED	EQ 1MG BASE	N88967 001	APR 23, 1985	
>ADD>		∂	EQ 2MG BASE	N88968 001	APR 23, 1985	
>ADD>		∂	EQ 5MG BASE	N88969 001	APR 23, 1985	
>ADD>		∂	EQ 10MG BASE	N88970 001	APR 23, 1985	

TRIHEXYPHENIDYL HYDROCHLORIDE

TABLET; ORAL

	TRIHEXYPHENIDYL HCL			
/AA/	/BOLAR/	/2MG/	/N85117/001/	
/AA/		/5MG/	/N85105/001/	
	∂ BOLAR	2MG	N85117 001	
	∂	5MG	N85105 001	

TRIMEPRAZINE TARTRATE

SYRUP; ORAL

TEMARIL

/AA/	/HERBERT/	/EQ 2.5MG BASE/5ML/	/N11316/003/	
	HERBERT	EQ 2.5MG BASE/5ML	N11316 003	

TRIMEPRAZINE TARTRATE

/AA/	/PHARM BASICS/	/EQ 2.5MG BASE/5ML/	/N88285/001/ /APR 11, 1985/	
	∂ PHARM BASICS	EQ 2.5MG BASE/5ML	N88285 001 APR 11, 1985	

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

TRIMETHOBENZAMIDE HCL

/AP/	/SOLOPAK/	/100MG/ML/	/N89043/001/ /APR 04, 1986/	
	∂ SOLOPAK	100MG/ML	N89043 001 APR 04, 1986	

TRIMIPRAMINE MALEATE

CAPSULE; ORAL

TRIMIPRAMINE MALEATE

/AA/	/PHARM BASICS/	/EQ 25MG BASE/	/N71283/001/ /DEC 08, 1987/	
/AA/		/EQ 50MG BASE/	/N71284/001/ /DEC 08, 1987/	
/AA/		/EQ 100MG BASE/	/N71285/001/ /DEC 08, 1987/	
B*	PHARM BASICS	EQ 25MG BASE	N71283 001 DEC 08, 1987	
B*		EQ 50MG BASE	N71284 001 DEC 08, 1987	
B*		EQ 100MG BASE	N71285 001 DEC 08, 1987	

TRIPROLIDINE HYDROCHLORIDE

TABLET; ORAL

TRIPROLIDINE HCL

/AA/	/DANBURY/	/2.5MG/	/N85094/001/	
	DANBURY	2.5MG	N85094 001	
/AA/	/VITARINE/	/2.5MG/	/N85610/001/	
	∂ VITARINE	2.5MG	N85610 001	

TRISULFAPYRIMIDINES

SUSPENSION; ORAL

/SULFOSE/

/AB/	/WYETH AYERST/	/500MG/5ML/	/N80013/002/	
	∂ WYETH AYERST	500MG/5ML	N80013 002	

TABLET; ORAL

/SULFOSE/

/AB/	/WYETH AYERST/	/500MG/	/N80013/001/	
	∂ WYETH AYERST	500MG	N80013 001	

VALPROATE SODIUM

>DLT> /SYRUP; ORAL/

>DLT> /DEPAKENE/

>DLT> /AA/	/ABBOTT/	/EQ 250MG BASE/5ML/	/N18082/001/	
>DLT>	/MYPROIC ACID/			
>DLT> /AA/	/PHARM BASICS/	/EQ 250MG BASE/5ML/	/N70868/001/ /JUL 01, 1986/	

>DLT>

VALPROIC ACID

CAPSULE; ORAL

VALPROIC ACID

AB	SCHERER	250MG¤	N73229 001 OCT 29, 1991	

>ADD> SYRUP; ORAL

>ADD> DEPAKENE

>ADD> AA	ABBOTT	250MG/5ML	N18082 001	

>ADD> MYPROIC ACID

>ADD> AA	PHARM BASICS	250MG/5ML	N70868 001 JUL 01, 1986	

>ADD>

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

VANCOMYCIN HCL

>DLT> /AP/	/QUAD/	/EQ 500MG BASE/VIAL/	/N62845/001/ /JUL 15, 1988/	
>DLT> /AP/		/EQ 1GM BASE/VIAL/	/N62845/002/ /JUL 15, 1988/	
>ADD>	∂ QUAD	EQ 500MG BASE/VIAL	N62845 001 JUL 15, 1988	
>ADD>	∂	EQ 1GM BASE/VIAL	N62845 002 JUL 15, 1988	

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION

/CALAN/

/AP/	/SEARLE/	/2.5MG/ML/	/N18925/001/	/MAR/30,/1984/
	∂ SEARLE	2.5MG/ML	N18925 001	MAR 30, 1984

VERAPAMIL HCL

/AP/	/QUAD/	/2.5MG/ML/	/N70672/001/	/MAR/07,/1986/
	∂ QUAD	2.5MG/ML	N70672 001	MAR 07, 1986
/AP/	/SOLOPAK/	/2.5MG/ML/	/N70697/001/	/JUL/31,/1987/
	∂ SOLOPAK	2.5MG/ML	N70697 001	JUL 31, 1987

TABLET; ORAL

VERAPAMIL HCL

>DLT >/AB/	/CHELSEA/	/40MG/	/N72799/001/	/APR/28,/1989/	
>DLT > B*	CHELSEA	80MG	N70421 001	SEP 17, 1986	
B*		120MG	N70422 001	SEP 17, 1986	
/BX/		/80MG/	/N70421/001/	/SEP/17,/1986/	
/BX/		/120MG/	/N70422/001/	/SEP/17,/1986/	
>ADD > >ADD >	∂	40MG	N72799 001	APR 28, 1989	

TABLET, EXTENDED RELEASE; ORAL

ISOPTIN SR

KNOLL	120MG	N19152 003	MAR 06, 1991

VINBLASTINE SULFATE

INJECTABLE; INJECTION

VINBLASTINE SULFATE

/AP/	/LYPHOMED/	/1MG/ML/	/N89515/001/	/APR/29,/1987/
	LYPHOMED	1MG/ML	N89515 001	APR 29, 1987

VINBLASTINE SULFATE

INJECTABLE; INJECTION

VINBLASTINE SULFATE

/AP/	/QUAD/	/1MG/ML/	/N89311/001/	/MAR/23,/1987/
/AP/		/10MG/VIAL/	/N89365/001/	/AUG/07,/1986/
	∂ QUAD	1MG/ML	N89311 001	MAR 23, 1987
	∂	10MG/VIAL	N89365 001	AUG 07, 1986

VINCRISTINE SULFATE

INJECTABLE; INJECTION

VINCRISTINE SULFATE

>ADD > >ADD >	AP ABIC	1MG/ML	N70873 001	FEB 19, 1987
>DLT >/AP/ >DLT >	/AKORN/	/1MG/ML/	/N70873/001/	/FEB/19,/1987/
/AP/	/BULL/	/1MG/VIAL/	/N71559/001/	/APR/11,/1988/
/AP/		/2MG/VIAL/	/N71560/001/	/APR/11,/1988/
	BULL	1MG/VIAL	N71559 001	APR 11, 1988
		2MG/VIAL	N71560 001	APR 11, 1988
/AP/	/QUAD/	/1MG/ML/	/N70777/001/	/APR/29,/1986/
/AP/		/1MG/ML/	/N70778/001/	/MAY/01,/1986/
/AP/		/1MG/VIAL/	/N71222/001/	/MAR/07,/1988/
/AP/		/2MG/VIAL/	/N71223/001/	/MAR/07,/1988/
/AP/		/5MG/VIAL/	/N71937/001/	/MAR/07,/1988/
	∂ QUAD	1MG/ML	N70777 001	APR 29, 1986
	∂	1MG/ML	N70778 001	MAY 01, 1986
	∂	1MG/VIAL	N71222 001	MAR 07, 1988
	∂	2MG/VIAL	N71223 001	MAR 07, 1988
	∂	5MG/VIAL	N71937 001	MAR 07, 1988

VITAMIN A

> DLT > /INJECTABLE;INJECTION/
> DLT > /AQUASOL A/
> DLT > /ARMOUR/ /50,000 IU/ML/ /N06823/001/

VITAMIN A PALMITATE

CAPSULE; ORAL
/VI-DOM-A/
/AA/ /MILES/ /EQ 50,000 UNITS BASE/ /N80972/001/
∂ MILES EQ 50,000 UNITS BASE N80972 001

INJECTABLE; INJECTION
> ADD > AP AQUASOL A
> ADD > ARMOUR PHARM EQ 50,000 UNITS BASE/ML N06823 001

VITAMIN A PALMITATE
> ADD > AP BEL MAR LABS EQ 50,000 UNITS BASE/ML N80819 001
> DLT > /BEL/MAR/LABS/ /EQ/50,000/UNITS/BASE/ML/ /N80819/001/

WARFARIN SODIUM

TABLET; ORAL
WARFARIN SODIUM
/BX/ /BOLAR/ /2MG/ /N86123/001/ /AUG/17,/1982/
/BX/ /2.5MG/ /N86120/001/ /AUG/17,/1982/
/BX/ /5MG/ /N86119/001/ /AUG/17,/1982/
/BX/ /7.5MG/ /N86118/001/ /AUG/17,/1982/
/BX/ /10MG/ /N86122/001/ /AUG/17,/1982/

∂ BOLAR 2MG N86123 001 AUG 17, 1982
∂ 2.5MG N86120 001 AUG 17, 1982
∂ 5MG N86119 001 AUG 17, 1982
∂ 7.5MG N86118 001 AUG 17, 1982
∂ 10MG N86122 001 AUG 17, 1982

> DLT >/AA/ /PHARM/BASICS/ /2MG/ /N88719/001/ /JUN/27,/1985/
> DLT >
> DLT >/AA/ /2.5MG/ /N88720/001/ /AUG/06,/1985/
> DLT >
> DLT >/AA/ /5MG/ /N88721/001/ /JUL/02,/1985/
> DLT >
> ADD > B* PHARM BASICS 2MG N88719 001 JUN 27, 1985
> ADD >
> ADD > B* 2.5MG N88720 001 AUG 06, 1985
> ADD >
> ADD > B* 5MG N88721 001 JUL 02, 1985
> ADD >

XENON, XE-133

GAS; INHALATION
> DLT > /XENON XE 133-V,S,S,/
> DLT >/AA/ /MEDI/PHYSICS/ /10MCI/VIAL/ /N17687/001/
> ADD > ∂ MEDI PHYSICS 10MCI/VIAL N17687 001

XYLOSE

POWDER; ORAL
XYLO-PFAH
AA ADRIA 25GM/BOT /25GM/BOT/ N17605 001 /N17605/001/

XYLOSE
AA LYNE 25GM/BOT N18856 001 MAR 26, 1987
/3/ /25GM/BOT/ /N18856/001/ /MAR/26,/1987/

ACETAMINOPHEN

SUPPOSITORY; RECTAL

/TYLENOL/			
/MCNEIL/	/120MG/		/N17756/002/
	/650MG/		/N17756/001/
ə MCNEIL	120MG		N17756 002
ə	650MG		N17756 001

CHLORHEXIDINE GLUCONATE

SOLUTION; TOPICAL

EXIDINE			
/ə/XTTRIUM/	/2%/		/N19422/001/
			/DEC/17/1985/
XTTRIUM	2%		N19422 001
			DEC 17, 1985
MICRODERM			
JOHNSON AND JOHNSON	4%¤		N72255 001
			APR 15, 1991

SPONGE; TOPICAL

MICRODERM			
JOHNSON AND JOHNSON	4%¤		N72295 001
			FEB 28, 1991

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

	PSEUDOEPHEDRINE HCL/CHLORPHENIRAMINE MALEATE			
>DLT>	/ə/GRAHAM/LABS/	/8MG;120MG/		/N18844/001/
>DLT>				/MAR/20/1985/
>ADD>	GRAHAM LABS	8MG;120MG		N18844 001
>ADD>				MAR 20, 1985

CLOTRIMAZOLE

CREAM; TOPICAL

MYCELEX			
MILES	1%¤		N18183 002
			APR 01, 1991

CREAM; VAGINAL

>ADD>	MYCELEX-7			
>ADD>	MILES	1%¤		N18230 002
>ADD>				DEC 26, 1991

CLOTRIMAZOLE

SOLUTION; TOPICAL

	MYCELEX			
	MILES	1%¤		N18181 002
				APR 01, 1991

TABLET; VAGINAL

>ADD>	MYCELEX-7			
>ADD>	MILES	100MG¤		N18182 002
>ADD>				DEC 26, 1991

DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

DISOBROM			
GENEVA	6MG;120MG¤		N70770 001
			SEP 30, 1991

DOXYLAMINE SUCCINATE

TABLET; ORAL

>DLT>	/DOXY-SLEEP-AID/			
>DLT>	/PAR/	/25MG/		/N70156/001/
>DLT>				/JUL/02/1987/
>ADD>	ə PAR	25MG		N70156 001
>ADD>				JUL 02, 1987
	DOXYLAMINE SUCCINATE			
	COPLEY	25MG		N88900 002
				FEB 12, 1988

HYDROCORTISONE

OINTMENT; TOPICAL

/HC/(HYDROCORTISONE)/			
/C/AND/M/	/0.5%/		/N80481/001/
ə C AND M	0.5%		N80481 001

IBUPROFEN

TABLET; ORAL

	IBUPROFEN			
>ADD>	LUCHEM	200MG¤		N72901 001
>ADD>				DEC 19, 1991
>ADD>		200MG¤		N72903 001
>ADD>				DEC 19, 1991

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET; ORAL
ADVIL COLD AND SINUS
WHITEHALL 200MG;30MG N19771 001
SEP 19, 1989

/COADVIL/
/WHITEHALL/ /200MG;30MG/ /N19771/001/
/SEP/19,/1989/

INSULIN BIOSYNTHETIC HUMAN

INJECTABLE; INJECTION
NOVOLIN R
NOVO NORDISK 100UNITS/ML¤ N19938 001
JUN 25, 1991

INSULIN BIOSYNTHETIC HUMAN; INSULIN SUSP ISOPHANE BIOSYNTHETIC HUMAN

INJECTABLE; INJECTION
NOVOLIN 70/30
NOVO NORDISK 30UNITS/ML;70UNITS/ML¤ N19991 001
JUN 25, 1991

INSULIN PORK

INJECTABLE; INJECTION
INSULIN
/NOVO/NORDISK/ /40/UNITS/ML/ /N17926/001/
@ NOVO NORDISK 40 UNITS/ML N17926 001

INSULIN SUSP ISOPHANE BIOSYNTHETIC HUMAN

INJECTABLE; INJECTION
NOVOLIN N
NOVO NORDISK 100UNITS/ML¤ N19959 001
JUL 01, 1991

INSULIN ZINC SUSP BEEF

INJECTABLE; INJECTION
LENTE INSULIN
/NOVO/NORDISK/ /40/UNITS/ML/ /N17998/001/
@ NOVO NORDISK 40 UNITS/ML N17998 001

INSULIN ZINC SUSP BIOSYNTHETIC HUMAN

INJECTABLE; INJECTION
NOVOLIN L
NOVO NORDISK 100UNITS/ML¤ N19965 001
JUN 25, 1991

MICONAZOLE NITRATE

CREAM; VAGINAL
MONISTAT 7
JOHNSON RW 2%¤ N17450 002
FEB 15, 1991

SUPPOSITORY; VAGINAL
MONISTAT 7
JOHNSON RW 100MG¤ N18520 002
FEB 15, 1991

PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
SUDAFED 12 HOUR
BURROUGHS WELLCOME 120MG¤ N73585 001
OCT 31, 1991

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
TRIPROLIDINE AND PSEUDOEPHEDRINE HCL
KV 120MG;5MG¤ N72758 001
NOV 25, 1991

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE DIVISION OF BLOOD AND BLOOD PRODUCTS LIST
CUMULATIVE SUPPLEMENT NUMBER 12 / JAN '91 - DEC '91

CDP BLOOD BAG UNIT

INJECTABLE; INJECTION
CDP BLOOD BAG UNIT IN PLASTIC CONTAINER
BAXTER HLTHCARE — N900224
DEC 27, 1991

HETASTARCH 6% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
HESPAN IN PLASTIC CONTAINER
DUPONT MERCK
PHARM — 6GM/100ML;0.9GM/100ML — N890105
APR 04, 1991

PENTASTARCH 10% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
PENTASPAN IN PLASTIC CONTAINER
DUPONT MERCK
PHARM — 10GM/100ML;0.9GM/100ML — N890104
APR 04, 1991

RED CELL PRESERVATION SOLUTION SYSTEM

INJECTABLE; INJECTION
ADSOL IN PLASTIC CONTAINER
BAXTER HLTHCARE — N900223
DEC 27, 1991

ORPHAN DRUG PRODUCT DESIGNATIONS

SECTION 526 OF THE FEDERAL FOOD, DRUG, AND COSMETIC ACT CONTAINS PROVISIONS WHEREBY FDA MAY DESIGNATE A SPONSOR'S DRUG, ANTIBIOTIC, OR BIOLOGICAL PRODUCT AS A "DESIGNATED ORPHAN DRUG." SECTION 527 OF THE ACT ESTABLISHES A PROCESS WHEREBY A SPONSOR MAY RECEIVE SEVEN YEARS OF EXCLUSIVE APPROVAL STATUS IF THAT SPONSOR IS THE FIRST TO ACHIEVE NEW DRUG, ANTIBIOTIC, OR BIOLOGICAL PRODUCT APPROVAL FOR A DESIGNATED ORPHAN DRUG FOR THE DESIGNATED INDICATION(S). THE EXCLUSIVE APPROVAL MAY BE REVOKED BY WRITTEN CONSENT OF THE SPONSOR OR BY FDA ACTION AFTER FINDING THAT THE SPONSOR HOLDING EXCLUSIVE APPROVAL CANNOT ASSURE THE AVAILABILITY OF SUFFICIENT QUANTITIES OF THE DRUG TO MEET THE NEEDS OF PATIENTS WITH THE DESIGNATED ORPHAN INDICATION(S).

WHEN A PRODUCT IS GRANTED ORPHAN DRUG DESIGNATION, IT WILL APPEAR IN THIS SECTION. ONCE A BIOLOGICAL OR DRUG PRODUCT IS LICENSED/APPROVED FOR MARKETING, IT WILL BE LISTED IN THIS SECTION AND ASTERISKED, AS APPROPRIATE, TO DENOTE MARKETING/EXCLUSIVE APPROVAL STATUS. IN ADDITION, THE EXCLUSIVITY EXPIRATION DATE WILL BE DISPLAYED FOLLOWING THE APPROVED DESIGNATED INDICATION(S).

THE FOLLOWING DRUGS AND BIOLOGICALS HAVE BEEN GRANTED ORPHAN DRUG DESIGNATION PURSUANT TO SECTION 526 OF THE FOOD, DRUG, AND COSMETIC ACT AS AMENDED BY THE ORPHAN DRUG ACT [PUBLIC LAW 97-414].

ORPHAN DRUG PRODUCT DESIGNATIONS

BIOLOGICAL DESIGNATIONS

NAME OF BIOLOGICAL	DESIGNATED USE [EXCLUSIVITY EXPIRATION DATE]	SPONSOR NAME
GENERIC: ALPHA-GALACTOSIDASE A TRADE: CC-GALACTOSIDASE	TREATMENT OF ALPHA-GALACTOSIDASE A DEFICIENCY. (FABRY'S DISEASE).	DAVID H. CALHOUN, PH.D. CITY COLLEGE OF NEW YORK
GENERIC: ANTIVENOM (CROTALIDAE) PURIFIED (AVIAN) TRADE: NOT ESTABLISHED	TREATMENT OF ENVENOMATION BY POISONOUS SNAKES BELONGING TO THE CROTALIDAE FAMILY.	OPHIDIAN PHARMA
GENERIC: BOTULINUM TOXIN TYPE A TRADE: OCULINUM*/**	TREATMENT OF STRABISMUS ASSOCIATED WITH DYSTONIA IN ADULTS (PATIENTS 12 YEARS OF AGE AND ABOVE).*/** [DEC 29, 1996] TREATMENT OF BLEPHAROSPASM ASSOCIATED WITH DYSTONIA IN ADULTS (PATIENTS 12 YEARS OF AGE AND ABOVE).*/** [DEC 29, 1996] TREATMENT OF CERVICAL DYSTONIA. TREATMENT OF DYNAMIC MUSCLE CONTRACTURE IN PEDIATRIC CEREBRAL PALSY PATIENTS.	ALLERGAN
GENERIC: CHIMERIC M-T412 (HUMAN-MURINE) IGG MONOCLONAL ANTI-CD4 ANTIBODY TRADE: NOT ESTABLISHED	TREATMENT OF MULTIPLE SCLEROSIS.	CENTOCOR, INC

ORPHAN DRUG PRODUCT DESIGNATIONS

BIOLOGICAL DESIGNATIONS

NAME OF BIOLOGICAL	DESIGNATED USE [EXCLUSIVITY EXPIRATION DATE]	SPONSOR NAME
GENERIC: CLOSTRIDIUM BOTULINUM TYPE F NEUROTOXIN TRADE: NOT ESTABLISHED	TREATMENT OF SPASMODIC TORTICOLLIS. TREATMENT OF ESSENTIAL BLEPHAROSPASM.	PORTON PRODUCTS LIMITED
GENERIC: CRYPTOSPORIDIUM HYPERIMMUNE BOVINE COLOSTRUM IGG TRADE: NOT ESTABLISHED	TREATMENT OF DIARRHEA IN AIDS PATIENTS CAUSED BY INFECTION WITH CRYPTOSPORIDIUM PARVUM.	IMMUCELL CORPORATION
GENERIC: CYTOMEGALOVIRUS IMMUNE GLOBULIN INTRAVENOUS (HUMAN) TRADE: NOT ESTABLISHED	USE IN CONJUNCTION WITH GANCICLOVIR SODIUM FOR THE TREATMENT OF CYTOMEGALOVIRUS PNEUMONIA IN BONE MARROW TRANSPLANT PATIENTS.	MILES, INC
GENERIC: EPOETIN ALPHA (RECOMBINANT-HUMAN) TRADE: EPOGEN*/**	TREATMENT OF ANEMIA ASSOCIATED WITH HIV INFECTION OR HIV TREATMENT. [TREATMENT OF AZT-INDUCED ANEMIA IN HIV INFECTED PATIENTS.*/**] [DEC 31, 1997]	AMGEN
GENERIC: FILGRASTIM TRADE: NEUPOGEN	TREATMENT OF PATIENTS WITH ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) WHO, IN ADDITION, ARE AFFLICTED WITH CYTOMEGALOVIRUS RETINITIS (CMV RETINITIS) AND ARE BEING TREATED WITH GANCICLOVIR.	AMGEN, INC
GENERIC: HUMAN MONOCLONAL ANTIBODY AGAINST HEPATITIS B VIRUS TRADE: NOT ESTABLISHED	PROPHYLAXIS OF HEPATITIS B REINFECTION IN PATIENTS UNDERGOING LIVER TRANSPLANTATION SECONDARY TO END-STAGE CHRONIC HEPATITIS B INFECTION.	SANDOZ PHARMACEUTICALS CORPORATION
GENERIC: INSULIN-LIKE GROWTH FACTOR-1 TRADE: MYOTROPHIN	TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS.	CEPHALON, INC
GENERIC: INTERFERON (RECOMBINANT HUMAN, BETA) TRADE: R-IFN-BETA	SYSTEMIC TREATMENT OF METASTATIC RENAL CELL CARCINOMA. SYSTEMIC TREATMENT OF CUTANEOUS T-CELL LYMPHOMA. SYSTEMIC TREATMENT OF CUTANEOUS MALIGNANT MELANOMA. INTRALESIONAL AND/OR SYSTEMIC TREATMENT OF AIDS-RELATED KAPOSI'S SARCOMA. TREATMENT OF MULTIPLE SCLEROSIS.	BIOGEN

ORPHAN DRUG PRODUCT DESIGNATIONS

BIOLOGICAL DESIGNATIONS

NAME OF BIOLOGICAL	DESIGNATED USE [EXCLUSIVITY EXPIRATION DATE]	SPONSOR NAME
GENERIC: INTERLEUKIN-1 ALPHA, HUMAN RECOMBINANT TRADE: NOT ESTABLISHED	FOR THE PROMOTION OF EARLY ENGRAFTMENT IN BONE MARROW TRANSPLANTATION. FOR HEMATOPOIETIC POTENTIATION IN APLASTIC ANEMIA.	IMMUNEX CORPORATION
GENERIC: INTERLEUKIN-1 RECEPTOR ANTAGONIST, HUMAN RECOMBINANT TRADE: ANTRIL	TREATMENT OF JUVENILE RHEUMATOID ARTHRITIS.	SYNERGEN, INC
GENERIC: INTERLEUKIN-3, RECOMBINANT HUMAN TRADE: NOT ESTABLISHED	PROMOTION OF ERYTHROPOIESIS IN DIAMOND-BLACKFAN ANEMIA (CONGENITAL PURE CELL RED APLASIA).	IMMUNEX CORPORATION
GENERIC: LIPOSOME ENCAPSULATED RECOMBINANT INTERLEUKIN-2 TRADE: NOT ESTABLISHED	TREATMENT OF BRAIN AND CNS TUMORS.	ONCOTHERAPEUTICS, INC
GENERIC: MONOCLONAL ANTIBODY PM-81 TRADE: NOT ESTABLISHED	ADJUNCTIVE TREATMENT OF ACUTE MYELOGENOUS LEUKEMIA.	MEDAREX, INC
GENERIC: MUCOID EXOPOLYSACCHARIDE PSEUDOMONAS HYPERIMMUNE GLOBULIN TRADE: MEPIG	TREATMENT OF PULMONARY INFECTIONS DUE TO PSEUDOMONAS AERUGINOSA IN PATIENTS WITH CYSTIC FIBROSIS.	UNIVAX BIOLOGICS, INC
GENERIC: MYELIN TRADE: NOT ESTABLISHED	TREATMENT OF MULTIPLE SCLEROSIS.	AUTOIMMUNE, INC
GENERIC: POLY I: POLY $C_{12}U$ TRADE: AMPLIGEN	TREATMENT OF RENAL CELL CARCINOMA.	HEM RESEARCH, INC
GENERIC: RECOMBINANT HUMAN DEOXYRIBONUCLEASE (RHDNASE) TRADE: NOT ESTABLISHED	TO REDUCE MUCOUS VISCOSITY AND ENABLE CLEARANCE OF AIRWAY SECRETIONS IN PATIENTS WITH CYSTIC FIBROSIS.	GENENTECH, INC

ORPHAN DRUG PRODUCT DESIGNATIONS

BIOLOGICAL DESIGNATIONS

NAME OF BIOLOGICAL		DESIGNATED USE [EXCLUSIVITY EXPIRATION DATE]	SPONSOR NAME
GENERIC:	RECOMBINANT SECRETORY LEUCOCYTE PROTEASE INHIBITOR	TREATMENT OF CONGENITAL ALPHA-1 ANTITRYPSIN DEFICIENCY. TREATMENT OF CYSTIC FIBROSIS.	SYNERGEN, INC
TRADE:	NOT ESTABLISHED		
GENERIC:	RICIN (BLOCKED) CONJUGATED MURINE MCA (ANTI-B4)	FOR THE EX-VIVO PURGING OF LEUKEMIC CELLS FROM THE BONE MARROW OF NON-T CELL ACUTE LYMPHOCYTIC LEUKEMIA PATIENTS WHO ARE IN COMPLETE REMISSION.	IMMUNOGEN, INC
TRADE:	NOT ESTABLISHED		
GENERIC:	RICIN (BLOCKED) CONJUGATED MURINE MCA (N901)	TREATMENT OF SMALL CELL LUNG CANCER.	IMMUNOGEN, INC
TRADE:	NOT ESTABLISED		
GENERIC:	SARGRAMOSTIM	TREATMENT OF NEUTROPENIA ASSOCIATED WITH BONE MARROW TRANSPLANTS IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA, HODGKIN'S DISEASE AND ACUTE LYMPHOBLASTIC LEUKEMIA. [MAR 5, 1998]	IMMUNEX
TRADE:	LEUKINE*/**		
GENERIC:	SDZ MSL-109	PROPHYLAXIS OF CYTOMEGALOVIRUS DISEASE IN PATIENTS UNDERGOING SOLID ORGAN TRANSPLANTATION. TREATMENT OF CYTOMEGALOVIRUS RETINITIS IN PATIENTS WITH ACQUIRED IMMUNODEFICIENCY SYNDROME.	SANDOZ PHARMACEUTICALS CORP
TRADE:	NOT ESTABLISHED		
GENERIC:	THYMOSIN ALPHA-1	ADJUNCTIVE TREATMENT OF CHRONIC ACTIVE HEPATITIS B.	ALPHA 1 BIOMEDICALS, INC
TRADE:	NOT ESTABLISHED		

ORPHAN DRUG PRODUCT DESIGNATIONS

DRUG DESIGNATIONS

NAME OF DRUG	DESIGNATED USE [EXCLUSIVITY EXPIRATION DATE]	SPONSOR NAME
GENERIC: ALGLUCERASE TRADE: CEREDASE*/**	REPLACEMENT THERAPY IN PATIENTS WITH GAUCHER'S DISEASE TYPE I. [APR 5, 1998]	GENZYME
GENERIC: AMPHOTERICIN B LIPID COMPLEX TRADE: NOT ESTABLISHED	TREATMENT OF CRYPTOCOCCAL MENINGITIS.	BRISTOL MYERS SQUIBB COMPANY
GENERIC: BERACTANT TRADE: SURVANTA*/**	PREVENTION OF NEONATAL RESPIRATORY DISTRESS SYNDROME (RDS).*/** [JUL 1, 1998] TREATMENT OF NEONATAL RESPIRATORY DISTRESS SYNDROME (RDS).*/** [JUL 1, 1998]	ROSS
GENERIC: BACLOFEN TRADE: NOT ESTABLISHED	TREATMENT OF INTRACTABLE SPASTICITY DUE TO MULTIPLE SCLEROSIS OR SPINAL CORD INJURY.	INFUSAID, INC
GENERIC: CALCIUM GLUCONATE GEL TRADE: H-F GEL	EMERGENCY TOPICAL TREATMENT OF HYDROGEN FLUORIDE (HYDROFLUORIC ACID) BURNS.	LTR PHARMACEUTICALS, INC
GENERIC: CYCLOSPORINE 2% OPHTHALMIC OINTMENT TRADE: SANDIMMUNE	TREATMENT OF PATIENTS AT HIGH RISK OF GRAFT REJECTION FOLLOWING PENETRATING KERATOPLASTY. USE IN CORNEAL MELTING SYNDROMES OF KNOWN OR PRESUMED IMMUNOLOGIC ETIOPATHOGENESIS INCLUDING MOOREN'S ULCER.	SANDOZ PHARMACEUTICALS CORP
GENERIC: CYSTEAMINE HCL TRADE: NOT ESTABLISHED	TREATMENT OF NEPHROPATHIC CYSTINOSIS.	WARNER-LAMBERT COMPANY
GENERIC: DAPSONE TRADE: DAPSONE	PROPHYLAXIS OF PNEUMOCYSTIS CARINII PNEUMONIA.	JACOBUS PHARMACEUTICAL COMPANY
GENERIC: DEFEROXAMINE AND DEXTRAN TRADE: BIO-RESCUE	TREATMENT OF ACUTE IRON POISONING.	BIOMEDICAL FRONTIERS, INC
GENERIC: DESMOPRESSIN ACETATE TRADE: DDAVP HIGH CONCENTRATION	TREATMENT OF MILD HEMOPHILIA A AND VON WILLEBRAND'S DISEASE.	RORER PHARMACEUTICAL CORP

ORPHAN DRUG PRODUCT DESIGNATIONS

DRUG DESIGNATIONS

NAME OF DRUG	DESIGNATED USE [EXCLUSIVITY EXPIRATION DATE]	SPONSOR NAME
GENERIC: DEXRAZOXONE TRADE: ZINECARD	PREVENTION OF CARDIOMYOPATHY ASSOCIATED WITH DOXORUBICIN ADMINISTRATION.	ADRIA LABORATORIES
GENERIC: DRONABINOL TRADE: MARINOL	STIMULATION OF APPETITE AND PREVENTION OF WEIGHT LOSS IN PATIENTS WITH A CONFIRMED DIAGNOSIS OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS).	UNIMED, INC
GENERIC: ETIDRONATE DISODIUM TRADE: DIDRONEL	PREVENTION OF DEGENERATIVE METABOLIC BONE DISEASE OCCURRING IN PATIENTS WHO REQUIRE LONG TERM (6 MONTHS OR GREATER) TOTAL PARENTERAL NUTRITION. TREATMENT OF DEGENERATIVE METABOLIC BONE DISEASE OCCURRING IN PATIENTS WHO REQUIRE LONG TERM (6 MONTHS OR GREATER) TOTAL PARENTERAL NUTRITION.	MGI PHARMA, INC
GENERIC: FLUDARABINE PHOSPHATE TRADE: FLUDARA*/**	TREATMENT OF REFRACTORY B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA. [APR 18, 1998]	BERLEX
GENERIC: FOSPHENYTOIN TRADE: NOT ESTABLISHED	ACUTE TREATMENT OF PATIENTS WITH STATUS EPILEPTICUS OF THE GRAND MAL TYPE.	WARNER-LAMBERT COMPANY
GENERIC: GALLIUM NITRATE TRADE: GANITE*/**	TREATMENT OF HYPERCALCEMIA OF MALIGNANCY. [JAN 17, 1998]	FUJISAWA
GENERIC: GENTAMICIN IMPREGNATED PMMA BEADS ON SURGICAL WIRE TRADE: SEPTOPAL	TREATMENT OF CHRONIC OSTEOMYELITIS OF POST-TRAUMATIC, POSTOPERATIVE OR HEMATOGENOUS ORIGIN.	E. MERCK, DARMSTADT
GENERIC: GM 6001 TRADE: NOT ESTABLISHED	TREATMENT OF CORNEAL ULCERS.	GLYCOMED, INC
GENERIC: HALOFANTRINE TRADE: HALFAN	TREATMENT OF MILD TO MODERATE ACUTE MALARIA CAUSED BY SUSCEPTIBLE STRAINS OF P. FACIPARUM AND P. VIVAX.	SMITHKLINE BEECHAM PHARMACEUTICALS
GENERIC: HISTRELIN TRADE: NOT ESTABLISHED	TREATMENT OF ACUTE INTERMITTENT PORPHYRIA, HEREDITARY COPROPORPHYRIA, AND VARIEGATE PORPHYRIA.	KARL E. ANDERSON, M.D. UNIVERSITY OF TEXAS

ORPHAN DRUG PRODUCT DESIGNATIONS

DRUG DESIGNATIONS

NAME OF DRUG	DESIGNATED USE [EXCLUSIVITY EXPIRATION DATE]	SPONSOR NAME
GENERIC: HISTRELIN ACETATE TRADE: SUPPRELIN*/**	TREATMENT OF CENTRAL PRECOCIOUS PUBERTY. [DEC 24, 1998]	RW JOHNSON
GENERIC: IDARUBICIN HCL TRADE: IDAMYCIN	TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN PEDIATRIC PATIENTS.	ADRIA
GENERIC: KETOCONAZOLE TRADE: NIZORAL	FOR USE WITH CYCLOPORIN A TO DIMINISH THE NEPHROTOXICITY INDUCED BY CYCLOSPORIN IN ORGAN TRANSPLANTATION.	PHARMEDIC COMPANY
GENERIC: LEUCOVORIN CALCIUM TRADE: LEUCOVORIN CALCIUM*/**	FOR USE IN COMBINATION WITH 5-FLUOROURACIL FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER. (USE IN COMBINATION WITH 5-FLUOROURACIL TO PROLONG SURVIVAL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED COLORECTAL CANCER.*/** [DEC 12, 1998])	LEDERLE
GENERIC: L-BACLOFEN TRADE: NEURALGON	TREATMENT OF INTRACTABLE SPASTICITY ASSOCIATED WITH SPINAL CORD INJURY OR MULTIPLE SCLEROSIS.	MERICON INDUSTRIES, INC
GENERIC: L-LEUCOVORIN CALCIUM TRADE: ISOVORIN	USE IN CONJUNCTION WITH HIGH-DOSE METHOTREXATE IN THE TREATMENT OF OSTEOSARCOMA.	LEDERLE LABORATORIES
GENERIC: LODOXAMIDE TROMETHAMINE TRADE: ALOMIDE	TREATMENT OF VERNAL KERATOCONJUNCTIVITIS.	ALCON LABORATORIES, INC
GENERIC: METRONIDAZOLE TRADE: METROGEL	TREATMENT OF PERIORAL DERMATITIS.	CURATEK PHARMACEUTICALS
GENERIC: NIFEDIPINE TRADE: NOT ESTABLISHED	TREATMENT OF INTERSTITIAL CYSTITIS.	MEDICAL CENTER JONATHAN FLEISCHMANN, M.D. CLEVELAND METROHEALTH
GENERIC: OFLOXACIN TRADE: NOT ESTABLISHED	TREATMENT OF BACTERIAL CORNEAL ULCERS.	ALLERGAN, INC

ORPHAN DRUG PRODUCT DESIGNATIONS

DRUG DESIGNATIONS

NAME OF DRUG	DESIGNATED USE [EXCLUSIVITY EXPIRATION DATE]	SPONSOR NAME
GENERIC: OM 401 TRADE: DREPANOL	PROPHYLACTIC TREATMENT OF SICKLE CELL DISEASE.	OMEX INTERNATIONAL, INC
GENERIC: OXANDROLONE TRADE: OXANDRIN	ADJUNCTIVE THERAPY FOR AIDS PATIENTS SUFFERING FROM HIV-WASTING SYNDROME.	GYNEX, INC
GENERIC: PENTOSTATIN TRADE: NIPENT*/**	TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA. TREATMENT OF HAIRY CELL LEUKEMIA. (SINGLE AGENT TREATMENT FOR ADULT PATIENTS WITH ALPHA-INTERFERON-REFRACTORY HAIRY CELL LEUKEMIA.*/** [OCT 11, 1998])	PARKE-DAVIS
GENERIC: POLOXAMER 331 TRADE: PROTOX	INITIAL THERAPY OF TOXOPLASMOSIS IN PATIENTS WITH ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS).	BURROUGHS WELLCOME COMPANY
GENERIC: PRAMIRACETAM SULFATE TRADE: NOT ESTABLISHED	FOR THE MANAGEMENT OF COGNITIVE DYSFUNCTION AND ENHANCEMENT OF ANTIDEPRESSANT ACTIVITY ASSOCIATED WITH ELECTROCONVULSIVE THERAPY.	CAMBRIDGE NEUROSCIENCE, INC
GENERIC: RECOMBINANT BETA-GLUCOCEREBROSIDASE TRADE: NOT ESTABLISHED	FOR REPLACEMENT THERAPY IN PATIENTS WITH TYPES I, II, AND III GAUCHER'S DISEASE.	GENZYME CORPORATION
GENERIC: RECOMBINANT HUMAN SUPEROXIDE DISMUTASE TRADE: NOT ESTABLISHED	PREVENTION OF BRONCHOPULMONARY DYSPLASIA IN PREMATURE NEONATES WEIGHING LESS THAN 1500 GMS.	BIO TECHNOLOGY GENERAL CORP
GENERIC: RIBAVIRIN TRADE: VIRAZOLE	TREATMENT OF HEMORRHAGIC FEVER WITH RENAL SYNDROME.	ICN PHARMACEUTICALS, INC

ORPHAN DRUG PRODUCT DESIGNATIONS

DRUG DESIGNATIONS

NAME OF DRUG	DESIGNATED USE [EXCLUSIVITY EXPIRATION DATE]	SPONSOR NAME
GENERIC: SERMORELIN ACETATE TRADE: GEREF	TREATMENT OF AIDS-ASSOCIATED CATABOLISM/WEIGHT LOSS.	SERONO
GENERIC: SOMATROPIN TRADE: SAIZEN	TREATMENT OF AIDS-ASSOCIATED CATABOLISM/WEIGHT LOSS.	SERONO LABORATORIES, INC
GENERIC: SUCCIMER TRADE: CHEMET*/**	TREATMENT OF LEAD POISONING IN CHILDREN.*/** [JAN 30, 1998] TREATMENT OF MERCURY INTOXICATION.	MCNEIL
GENERIC: SUCRALFATE TRADE: NOT ESTABLISHED	TREATMENT OF ORAL ULCERATIONS AND DYSPHAGIA IN PATIENTS WITH EPIDERMOLYSIS BULLOSA.	NASKA PHARMCAL CO
GENERIC: TESTOSTERONE PROPIONATE TRADE: NOT ESTABLISHED	TREATMENT OF VULVAR DYSTROPHIES.	STAR PHARMACEUTICALS, INC
GENERIC: TESTOSTERONE SUBLINGUAL TRADE: NOT ESTABLISHED	TREATMENT OF CONSTITUTIONAL DELAY OF GROWTH AND PUBERTY IN BOYS.	GYNEX, INC
GENERIC: TIRATRICOL TRADE: TRIACANA	USE IN COMBINATION WITH LEVO-THYROXINE TO SUPPRESS THYROID STIMULATING HORMONE (TSH) IN PATIENTS WITH WELL-DIFFERENTIATED THYROID CANCER WHO ARE INTOLERANT TO ADEQUATE DOSES OF LEVO-THYROXINE ALONE.	MEDGENIX GROUP
GENERIC: TOREMIFENE TRADE: NOT ESTABLISHED	HORMONAL THERAPY OF METASTATIC CARCINOMA OF THE BREAST.	ADRIA LABORATORIES, INC
GENERIC: URSODEOXYCHOLIC ACID TRADE: ACTIGALL	MANAGEMENT OF THE CLINICAL SIGNS AND SYMPTOMS ASSOCIATED WITH PRIMARY BILIARY CIRRHOSIS.	CIBA GEIGY
GENERIC: URSODEOXYCHOLIC ACID TRADE: URSOFALK	TREATMENT OF PATIENTS WITH PRIMARY BILIARY CIRRHOSIS.	INTERFALK U.S., INC
GENERIC: 3,4-DIAMINOPYRIDINE TRADE: DYNAMINE	TREATMENT OF HEREDITARY MOTOR AND SENSORY NEUROPATHY TYPE I (CHARCOT-MARIE-TOOTH DISEASE).	MAYO CLINIC

ORPHAN DRUG PRODUCT DESIGNATIONS

DRUG DESIGNATIONS

NAME OF DRUG	DESIGNATED USE [EXCLUSIVITY EXPIRATION DATE]	SPONSOR NAME
GENERIC: 6-METHYLENANDROSTA-1,4-DIENE-3,17-DIONE TRADE: NOT ESTABLISHED	HORMONAL THERAPY OF METASTATIC CARCINOMA OF THE BREAST.	ADRIA LABORATORIES, INC
GENERIC: 566C80 TRADE: NOT ESTABLISHED	PREVENTION OF PNEUMOCYSTIS CARINII PNEUMONIA (PCP) IN HIGH-RISK, HIV-INFECTED PATIENTS DEFINED BY ONE OR BOTH OF THE FOLLOWING CRITERIA: (1) A HISTORY OF ONE OR MORE EPISODES OF PCP, (2) A PERIPHERAL CD4+ (T4 HELPER/INDUCER) LYMPHOCYTE COUNT LESS THAN OR EQUAL TO 200/MM^3.	BURROUGHS WELLCOME COMPANY

DRUG PRODUCTS WHICH MUST DEMONSTRATE IN VIVO BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO DECEMBER 1991 ADDITIONS

BIOPHARMACEUTIC GUIDANCE AVAILABILITY

THE FOLLOWING IS A LIST OF GUIDANCES AVAILABLE FOR IN VIVO BIOEQUIVALENCE STUDIES AND IN VITRO DISSOLUTION TESTING AVAILABLE FROM THE DIVISION OF BIOEQUIVALENCE, HFD-650, MPN-2 ROOM 278, 5600 FISHERS LANE, ROCKVILLE, MD 20857. COMMENTS AND SUGGESTIONS CONCERNING THESE GUIDANCES ARE ENCOURAGED AND SHOULD BE SENT TO THE DIVISION OF BIOEQUIVALENCE.

REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 11TH EDITION FOR A FULL LISTING OF BIOPHARMACEUTIC GUIDANCE AVAILABILITY DATA. ONLY NEW DATA WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

DRUG NAME (DOSAGE FORM)	DATE	REVISED DATE
ESTROGENS, CONJUGATED (TABLET)	AUG 21, 1991	

ANDA SUITABILITY PETITIONS

THE FOLLOWING ARE TWO LISTS OF PETITIONS FILED UNDER SECTION 505(j)(2)(C) OF THE ACT WHERE THE AGENCY HAS DETERMINED THAT THE REFERENCED PRODUCT: (1) IS SUITABLE FOR SUBMISSION AS AN ANDA (PETITIONS APPROVED) OR (2) IS NOT SUITABLE FOR SUBMISSION AS AN ANDA (PETITIONS DENIED). THE DETERMINATION THAT AN ANDA WILL BE APPROVED IS NOT MADE UNTIL THE ANDA ITSELF IS SUBMITTED AND REVIEWED BY THE AGENCY. A COPY OF EACH PETITION IS LISTED BY DOCKET NUMBER ON PUBLIC DISPLAY IN FDA'S DOCKETS MANAGEMENT BRANCH, HFA-305, ROOM 4-62, 5600 FISHERS LANE, ROCKVILLE, MD 20857.

REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 11TH EDITION FOR A FULL LISTING OF ANDA SUITABILITY PETITIONS DATA. ONLY NEW DATA WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

PETITIONS APPROVED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE CAPSULE; ORAL	325MG 50MG 40MG 30MG	91 P-069/ CP2	KING & SPAULDING	NEW COMBINATION	APPROVED DEC 10, 1991
CARBAMAZEPINE SUSPENSION; ORAL	200MG/5ML	89 P-0399/CP	GUIDELINES	NEW DOSAGE FORM	APPROVED MAY 16, 1991
CLOBETASOL PROPIONATE LOTION; TOPICAL	0.05%	90 P-0198/ CP1	KROSS	NEW DOSAGE FORM	APPROVED MAR 14, 1991
CYCLOPHOSPHAMIDE INJECTABLE; INJECTION	100MG/VIAL	90 P-0250/ CP1	PHARMACHEMIE	NEW DOSAGE FORM	APPROVED MAY 07, 1991
CYCLOPHOSPHAMIDE INJECTABLE; INJECTION	200MG/VIAL	90 P-0250/ CP2	PHARMACHEMIE	NEW DOSAGE FORM	APPROVED MAY 07, 1991
CYCLOPHOSPHAMIDE INJECTABLE; INJECTION	500MG/VIAL	90 P-0250/ CP3	PHARMACHEMIE	NEW DOSAGE FORM	APPROVED MAY 07, 1991
CYCLOPHOSPHAMIDE INJECTABLE; INJECTION	1GM/VIAL	90 P-0250/ CP4	PHARMACHEMIE	NEW DOSAGE FORM	APPROVED MAY 07, 1991
CYTARABINE INJECTABLE; INJECTION	20MG/ML (100ML/CONTAINER)	86 P-0428/ CP005	ADRIA	NEW DOSAGE FORM	APPROVED OCT 28, 1991

ANDA SUITABILITY PETITIONS

PETITIONS APPROVED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
DOPAMINE HYDROCHLORIDE INJECTABLE; INJECTION	5MG/ML	90 P-0137/ CP1	ABBOTT	NEW STRENGTH	APPROVED APR 10, 1991
ESTRADIOL FILM, EXTENDED RELEASE; TRANSDERMAL	0.067MG/24HR	90 P-0125/ CP1	NOVEN PHARMS	NEW STRENGTH	APPROVED MAR 14, 1991
ESTRADIOL FILM, EXTENDED RELEASE; TRANSDERMAL	0.084MG/24HR	90 P-0125/ CP2	NOVEN PHARMS	NEW STRENGTH	APPROVED MAR 14, 1991
ETOPOSIDE INJECTABLE; INJECTION	20MG/ML (25ML/VIAL)	91 P-0041/ CP1	ADRIA	NEW STRENGTH	APPROVED MAY 22, 1991
LEUCOVORIN CALCIUM INJECTABLE; INJECTION	EQ 200MG BASE/VIAL	91 P-0235/ CP1	CETUS	NEW STRENGTH	APPROVED DEC 10, 1991
NIFEDIPINE CAPSULE, EXTENDED RELEASE; ORAL	30MG 60MG 90MG	90 P-0436/ CP1	KV	NEW DOSAGE FORM	APPROVED OCT 23, 1991
PANCURONIUM BROMIDE INJECTABLE; INJECTION	0.1MG/ML	91 P-0006/ CP1	LYPHOMED	NEW STRENGTH	APPROVED OCT 28, 1991
TECHNETIUM TC99 MEDRONATE KIT INJECTABLE; INJECTION	N/A	91 P-0040/ CP1	ABARIS	NEW STRENGTH	APPROVED OCT 28, 1991
TERFENADINE CAPSULE; ORAL	60MG	91 P-0087 CP1	ARTHUR A. CHECCHI	NEW DOSAGE FORM	APPROVED OCT 28, 1991
THEOPHYLLINE TABLET, EXTENDED RELEASE; ORAL	800MG	91 P-0209/ CP1	PURDUE FREDERICK	NEW STRENGTH	APPROVED DEC 10, 1991

ANDA SUITABILITY PETITIONS

PETITIONS DENIED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
ALBUTEROL SULFATE CAPSULE, EXTENDED RELEASE; ORAL	EQ 4MG BASE	89 P-0207/CP	PARTICLE DYNAMICS	NEW DOSAGE FORM	DENIED DEC 13, 1991
FUROSEMIDE INJECTABLE; INJECTION	1MG/ML	90 P-0313/ CP1	LYPHOMED	NEW STRENGTH	DENIED OCT 28, 1991

EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE EXCLUSIVITY COLUMN, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 11TH EDITION FOR A FULL LISTING OF EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). ONLY NEW CODES WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

REFERENCES
NEW DOSING SCHEDULE

D-17	400MG EVERY 12 HOURS FOR THREE DAYS FOR UNCOMPLICATED URINARY TRACT INFECTIONS

REFERENCES
NEW INDICATION

I-55	HYPERTENSION
I-56	EROSIVE GASTROESOPHAGEAL REFLUX DISEASE
I-57	SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER
I-58	INITIAL TREATMENT OF ADVANCED OVARIAN CARCINOMA IN COMBINATION WITH OTHER APPROVED CHEMOTHERAPEUTIC AGENTS
I-59	ENDOSCOPICALLY DIAGNOSED ESOPHAGITIS, INCLUDING EROSIVE AND ULCERATIVE ESOPHAGITIS, AND ASSOCIATED HEARTBURN DUE TO GASTROESOPHAGEAL REFLUX DISEASE
I-60	SINGLE APPLICATION TREATMENT OF HEAD LICE IN CHILDREN TWO MONTHS TO TWO YEARS IN AGE
I-61	FEMALE ANDROGENETIC ALOPECIA
I-62	PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
I-63	ONCE DAILY TREATMENT AS INITIAL THERAPY IN THE TREATMENT OF HYPERTENSION
I-64	PREVENTION OF SUPRAVENTRICULAR ARRHYTHMIAS
I-65	PREVENTION OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS
I-66	UNCOMPLICATED GONORRHEA

REFERENCES
PATENT USE CODE

U-44	RELIEF OF NAUSEA AND VOMITING
U-45	TREATMENT OF INFLAMMATION AND ANALGESIA
U-46	TREATMENT OF PANIC DISORDER
U-47	STIMULATION OF THE RELEASE OF GROWTH HORMONE
U-48	ANALGESIA

EXCLUSIVITY TERMS

REFERENCES
PATENT USE CODE

U-49	SYMPTOMATIC CANCER-RELATED HYPERCALCEMIA
U-50	USE IN TREATING INFLAMMATORY DERMATOSES
U-51	BLOOD POOL IMAGING, INCLUDING FIRST PASS AND GATED EQUILIBRIUM IMAGING AND FOR DETECTION OF SITES OF GASTROINTESTINAL BLEEDING
U-52	TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER SIX MONTHS OF AGE) WITH ADVANCED HIV INFECTION
U-53	HYPERCALCEMIA OF MALIGNANCY
U-54	REVERSAL AGENT OR ANTAGONIST OF NONDEPOLARIZING NEUROMUSCULAR BLOCKING AGENTS
U-55	TREATMENT OF PAIN
U-56	AID TO SMOKING CESSATION

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	20089 001	ACYCLOVIR; ZOVIRAX	4199574	APR 22, 1997			
						I-45	APR 26, 1993
	20089 002	ACYCLOVIR; ZOVIRAX	4199574	APR 22, 1997			
						I-45	APR 26, 1993
	20057 003	ALGLUCERASE; CEREDASE				NCE	APR 05, 1996
						ODE	APR 05, 1998
	18276 001	ALPRAZOLAM; XANAX	4508726	APR 02, 2002	U-46		
	18276 002	ALPRAZOLAM; XANAX	4508726	APR 02, 2002	U-46		
	18276 003	ALPRAZOLAM; XANAX	4508726	APR 02, 2002	U-46		
	18276 004	ALPRAZOLAM; XANAX	4508726	APR 02, 2002	U-46		
			3980789	SEP 14, 1993			
	19926 001	ALTRETAMINE; HEXALEN				ODE	DEC 26, 1997
	19155 001	AMMONIUM LACTATE; LAC-HYDRIN	4105783	OCT 26, 1995			
	18700 001	AMRINONE LACTATE; INOCOR	4072746	APR 23, 1998	U-7	NCE	JUL 31, 1994
	19677 001	ATROPINE SULFATE; ENLON-PLUS	4952586	AUG 28, 2007	U-54	NC	NOV 06, 1994
	19678 001	ATROPINE SULFATE; ENLON-PLUS	4952586	AUG 28, 2007	U-54	NC	NOV 06, 1994
	19851 001	BENAZEPRIL HYDROCHLORIDE; LOTENSIN	4410520	OCT 18, 2000		NCE	JUN 25, 1996
	19851 002	BENAZEPRIL HYDROCHLORIDE; LOTENSIN	4410520	OCT 18, 2000		NCE	JUN 25, 1996
	19851 003	BENAZEPRIL HYDROCHLORIDE; LOTENSIN	4410520	OCT 18, 2000		NCE	JUN 25, 1996
	19851 004	BENAZEPRIL HYDROCHLORIDE; LOTENSIN	4410520	OCT 18, 2000		NCE	JUN 25, 1996
	20032 001	BERACTANT; SURVANTA	4397839	AUG 10, 2000		NCE	JUL 01, 1996
>ADD>	19845 001	BETAXOLOL HYDROCHLORIDE; BETOPTIC S	4911920	MAR 27, 2007			
>ADD>	19890 001	BUTORPHANOL TARTRATE; STADOL				NDF	DEC 12, 1994
	18709 001	CAPTOPRIL; CAPOZIDE 25/15				I-63	OCT 24, 1994
	18709 002	CAPTOPRIL; CAPOZIDE 25/25				I-63	OCT 24, 1994
	18709 003	CAPTOPRIL; CAPOZIDE 50/25				I-63	OCT 24, 1994
	18709 004	CAPTOPRIL; CAPOZIDE 50/15				I-63	OCT 24, 1994
	19856 001	CARBIDOPA; SINEMET CR	4900755	MAY 23, 2006			
			4832957	MAY 23, 2006			
			3830827	AUG 20, 1991			
						NDF	MAY 30, 1994
	19880 001	CARBOPLATIN; PARAPLATIN	4140707	AUG 25, 1998		I-58	JUL 05, 1994
	19880 002	CARBOPLATIN; PARAPLATIN	4140707	AUG 25, 1998		I-58	JUL 05, 1994
	19880 003	CARBOPLATIN; PARAPLATIN	4140707	AUG 25, 1998		I-58	JUL 05, 1994
	20044 001	CETYL ALCOHOL; EXOSURF NEONATAL	4312860	NOV 23, 2001		NC	AUG 02, 1993
	17920 002	CIMETIDINE; TAGAMET	3950333	APR 13, 1993		I-56	MAR 07, 1994
	17920 003	CIMETIDINE; TAGAMET	3950333	APR 13, 1993		I-56	MAR 07, 1994
	17920 004	CIMETIDINE; TAGAMET	3950333	APR 13, 1993		I-56	MAR 07, 1994
	17920 005	CIMETIDINE; TAGAMET	3950333	APR 13, 1993		I-56	MAR 07, 1994
	17924 001	CIMETIDINE HYDROCHLORIDE; TAGAMET	3950333	APR 13, 1993		I-56	MAR 07, 1994
	17939 002	CIMETIDINE HYDROCHLORIDE; TAGAMET				I-65	NOV 13, 1994

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	19849 001	DAPIPRAZOLE HYDROCHLORIDE; REV-EYES	4252721	JAN 06, 2002		NCE	DEC 31, 1995
>DLT>	19849 001	DAPIPRAZOLE HYDROCHLORIDE; REV-EYES	4252721	FEB 24, 1998		NCE	DEC 31, 1995
	19082 001	DEZOCINE; DALGAN	4605671	AUG 12, 2003			
			4001331	JAN 04, 1996		NCE	DEC 29, 1994
			3836670	SEP 09, 1991	U-48		
	19082 002	DEZOCINE; DALGAN	4605671	AUG 12, 2003			
			4001331	JAN 04, 1996		NCE	DEC 29, 1994
			3836670	SEP 09, 1991	U-48		
	19082 003	DEZOCINE; DALGAN	4605671	AUG 12, 2003			
			4001331	JAN 04, 1996		NCE	DEC 29, 1994
			3836670	SEP 09, 1991	U-48		
	20037 001	DICLOFENAC SODIUM; VOLTAREN	4960779	OCT 02, 2007			
			3652762	MAR 28, 1991		NDF	MAR 28, 1994
	20154 002	DIDANOSINE; VIDEX	4861759	AUG 29, 2006	U-52	NCE	OCT 09, 1996
	20154 003	DIDANOSINE; VIDEX	4861759	AUG 29, 2006	U-52	NCE	OCT 09, 1996
	20154 004	DIDANOSINE; VIDEX	4861759	AUG 29, 2006	U-52	NCE	OCT 09, 1996
	20154 005	DIDANOSINE; VIDEX	4861759	AUG 29, 2006	U-52	NCE	OCT 09, 1996
	20155 003	DIDANOSINE; VIDEX	4861759	AUG 29, 2006	U-52	NCE	OCT 09, 1996
	20155 004	DIDANOSINE; VIDEX	4861759	AUG 29, 2006	U-52	NCE	OCT 09, 1996
	20155 005	DIDANOSINE; VIDEX	4861759	AUG 29, 2006	U-52	NCE	OCT 09, 1996
	20155 006	DIDANOSINE; VIDEX	4861759	AUG 29, 2006	U-52	NCE	OCT 09, 1996
	20156 001	DIDANOSINE; VIDEX	4861759	AUG 29, 2006	U-52	NCE	OCT 09, 1996
	20027 001	DILTIAZEM HYDROCHLORIDE; CARDIZEM				NDF	OCT 24, 1994
	20027 002	DILTIAZEM HYDROCHLORIDE; CARDIZEM				NDF	OCT 24, 1994
>ADD>	20062 002	DILTIAZEM HYDROCHLORIDE; CARDIZEM CD				NP	DEC 27, 1994
>ADD>	20062 003	DILTIAZEM HYDROCHLORIDE; CARDIZEM CD				NP	DEC 27, 1994
>ADD>	20062 004	DILTIAZEM HYDROCHLORIDE; CARDIZEM CD				NP	DEC 27, 1994
	18723 001	DIVALPROEX SODIUM; DEPAKOTE	4988731	JAN 29, 2008			
	18723 002	DIVALPROEX SODIUM; DEPAKOTE	4988731	JAN 29, 2008			
	18723 003	DIVALPROEX SODIUM; DEPAKOTE	4988731	JAN 29, 2008			
	19680 001	DIVALPROEX SODIUM; DEPAKOTE	4988731	JAN 29, 2008			
	19794 001	DIVALPROEX SODIUM; DEPAKOTE CP	4988731	JAN 29, 2008			
	19794 002	DIVALPROEX SODIUM; DEPAKOTE CP	4988731	JAN 29, 2008			
	19946 001	DOXACURIUM CHLORIDE; NUROMAX	4701460	OCT 20, 2004		NCE	MAR 07, 1996
	19668 001	DOXAZOSIN MESYLATE; CARDURA	4188390	FEB 12, 1999		NCE	NOV 02, 1995
	19668 002	DOXAZOSIN MESYLATE; CARDURA	4188390	FEB 12, 1999		NCE	NOV 02, 1995
	19668 003	DOXAZOSIN MESYLATE; CARDURA	4188390	FEB 12, 1999		NCE	NOV 02, 1995
	19668 004	DOXAZOSIN MESYLATE; CARDURA	4188390	FEB 12, 1999		NCE	NOV 02, 1995

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	19616 004	ENOXACIN; PENETREX	4442101	APR 10, 2001			
>ADD>			4359578	NOV 16, 1999		NCE	DEC 31, 1996
>ADD>			4352803	OCT 05, 1999	U-36		
>ADD>	19616 005	ENOXACIN; PENETREX	4442101	APR 10, 2001			
>ADD>			4359578	NOV 16, 1999		NCE	DEC 31, 1996
>ADD>			4352803	OCT 05, 1999	U-36		
	19080 001	ESTAZOLAM; PROSOM	3987052	OCT 19, 1995			
	19080 002	ESTAZOLAM; PROSOM	3987052	OCT 19, 1995			
	19081 002	ESTRADIOL; ESTRADERM				I-62	OCT 24, 1994
	19081 003	ESTRADIOL; ESTRADERM				I-62	OCT 24, 1994
	19653 001	ETHINYL ESTRADIOL; ORTHO CYCLEN-21	4027019	MAY 31, 1996		NC	DEC 29, 1992
	19653 002	ETHINYL ESTRADIOL; ORTHO CYCLEN-28	4027019	MAY 31, 1996		NC	DEC 29, 1992
	18922 002	ETODOLAC; LODINE	4076831	FEB 28, 1997	U-45		
			3939178	FEB 17, 1993		NCE	JAN 31, 1996
	18922 003	ETODOLAC; LODINE	4076831	FEB 28, 1997	U-45		
			3939178	FEB 17, 1993		NCE	JAN 31, 1996
	19834 001	FELODIPINE; PLENDIL	4264611	APR 28, 1998		NCE	JUL 26, 1996
	19834 002	FELODIPINE; PLENDIL	4262611	APR 28, 1998		NCE	JUL 26, 1996
	18830 001	FLECAINIDE ACETATE; TAMBOCOR				I-64	OCT 23, 1994
	18830 003	FLECAINIDE ACETATE; TAMBOCOR				I-64	OCT 23, 1994
	18830 004	FLECAINIDE ACETATE; TAMBOCOR				I-64	OCT 23, 1994
	19949 001	FLUCONAZOLE; DIFLUCAN	4404216	OCT 16, 2003		NCE	JAN 29, 1995
	19949 002	FLUCONAZOLE; DIFLUCAN	4404216	OCT 16, 2003		NCE	JAN 29, 1995
	19949 003	FLUCONAZOLE; DIFLUCAN	4404216	OCT 16, 2003		NCE	JAN 29, 1995
	19950 001	FLUCONAZOLE; DIFLUCAN	4404216	OCT 16, 2003		NCE	JAN 29, 1995
	20038 001	FLUDARABINE PHOSPHATE; FLUDARA	4357324	NOV 02, 1999		NCE	APR 18, 1996
						ODE	APR 18, 1998
>ADD>	20073 001	FLUMAZENIL; MAZICON	4316839	FEB 23, 1999		NCE	DEC 20, 1996
	20101 001	FLUOXETINE HYDROCHLORIDE; PROZAC	4314081	FEB 02, 2001		NCE	DEC 29, 1992
	19957 001	FLUTICASONE PROPIONATE; CUTIVATE	4335121	MAR 16, 2002			
	19958 001	FLUTICASONE PROPIONATE; CUTIVATE	4335121	MAR 16, 2002			
	20068 001	FOSCARNET SODIUM; FOSCAVIR				NCE	SEP 27, 1996
	19915 002	FOSINOPRIL SODIUM; MONOPRIL	4384123	MAY 17, 2000			
			4337201	JUN 29, 1999		NCE	MAY 16, 1996
	19915 003	FOSINOPRIL SODIUM; MONOPRIL	4384123	MAY 17, 2000			
			4337201	JUN 29, 1999		NCE	MAY 16, 1996
	19961 002	GALLIUM NITRATE; GANITE	4529593	JAN 17, 2005	U-49	NCE	JAN 17, 1996
						ODE	JAN 17, 1998

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	19967 001	HALOBETASOL PROPIONATE; ULTRAVATE	4619921	DEC 17, 2004		NCE	DEC 17, 1995
	19968 001	HALOBETASOL PROPIONATE; ULTRAVATE	4619921	DEC 17, 2004		NCE	DEC 17, 1995
>ADD>	19836 001	HISTRELIN; SUPPRELIN	4244946	JAN 13, 1998		NCE	DEC 24, 1996
>ADD>						ODE	DEC 24, 1998
>ADD>	19836 002	HISTRELIN; SUPPRELIN	4244946	JAN 13, 1998		NCE	DEC 24, 1996
>ADD>						ODE	DEC 24, 1998
>ADD>	19836 003	HISTRELIN; SUPPRELIN	4244946	JAN 13, 1998		NCE	DEC 24, 1996
>ADD>						ODE	DEC 24, 1998
	19784 001	IBUPROFEN; RUFEN				NDF	SEP 19, 1992
	19580 001	IOTROLAN; OSMOVIST	4239747	DEC 16, 1999		NCE	DEC 07, 1994
	19580 002	IOTROLAN; OSMOVIST	4239747	DEC 16, 1999		NCE	DEC 07, 1994
>ADD>	19091 001	ISOSORBIDE MONONITRATE; ISMO				NCE	DEC 30, 1996
>ADD>	19546 001	ISRADIPINE; DYNACIRC	4466972	AUG 21, 2003	U-3	NCE	DEC 20, 1995
>DLT>	19546 001	ISRADIPINE; DYNACIRC	4466972	AUG 21, 2001	U-3	NCE	DEC 20, 1995
>ADD>	19546 002	ISRADIPINE; DYNACIRC	4466972	AUG 21, 2003	U-3	NCE	DEC 20, 1995
>DLT>	19546 002	ISRADIPINE; DYNACIRC	4466972	AUG 21, 2001	U-3	NCE	DEC 20, 1995
>ADD>	19645 001	KETOROLAC TROMETHAMINE; TORADOL	4089969	MAY 16, 1997	U-55		
>ADD>	19698 001	KETOROLAC TROMETHAMINE; TORADOL	4089969	MAY 16, 1997	U-55		
>ADD>	19698 002	KETOROLAC TROMETHAMINE; TORADOL	4089969	MAY 16, 1997	U-55		
	18686 001	LABETALOL HYDROCHLORIDE; NORMODYNE	4012444	AUG 02, 1998		NCE	AUG 01, 1994
	18687 001	LABETALOL HYDROCHLORIDE; NORMODYNE	4012444	AUG 02, 1998		NCE	AUG 01, 1994
	18687 002	LABETALOL HYDROCHLORIDE; NORMODYNE	4012444	AUG 02, 1998		NCE	AUG 01, 1994
	18687 003	LABETALOL HYDROCHLORIDE; NORMODYNE	4012444	AUG 02, 1998		NCE	AUG 01, 1994
	18687 004	LABETALOL HYDROCHLORIDE; NORMODYNE	4012444	AUG 02, 1998		NCE	AUG 01, 1994
	18716 001	LABETALOL HYDROCHLORIDE; TRANDATE	4012444	AUG 02, 1998		NCE	AUG 01, 1994
	18716 002	LABETALOL HYDROCHLORIDE; TRANDATE	4012444	AUG 02, 1998		NCE	AUG 01, 1994
	18716 003	LABETALOL HYDROCHLORIDE; TRANDATE	4012444	AUG 02, 1998		NCE	AUG 01, 1994
	18716 004	LABETALOL HYDROCHLORIDE; TRANDATE	4012444	AUG 02, 1998		NCE	AUG 01, 1994
	19425 001	LABETALOL HYDROCHLORIDE; TRANDATE	4012444	AUG 02, 1998		NCE	AUG 01, 1994
>ADD>	08107 001	LEUCOVORIN CALCIUM; LEUCOVORIN CALCIUM				ODE	DEC 12, 1998
>ADD>	08107 002	LEUCOVORIN CALCIUM; LEUCOVORIN CALCIUM				ODE	DEC 12, 1998
>ADD>	08107 004	LEUCOVORIN CALCIUM; LEUCOVORIN CALCIUM				ODE	DEC 12, 1998
>ADD>	08107 005	LEUCOVORIN CALCIUM; LEUCOVORIN CALCIUM				ODE	DEC 12, 1998
	20035 001	LEVAMISOLE HYDROCHLORIDE; ERGAMISOL	4584305	JUN 19, 2004	U-42	NCE	JUN 18, 1995
	20088 001	LEVONORGESTREL; NORPLANT SYSTEM	3850911	NOV 26, 1991		NP	DEC 10, 1993
>ADD>	20105 001	LIOTHYRONINE SODIUM; TRIOSTAT				NDF	DEC 31, 1994
	19753 001	MORICIZINE HYDROCHLORIDE; ETHMOZINE	3864487	FEB 04, 1994		NCE	JUN 19, 1995
	19753 002	MORICIZINE HYDROCHLORIDE; ETHMOZINE	3864487	FEB 04, 1994		NCE	JUN 19, 1995
	19753 003	MORICIZINE HYDROCHLORIDE; ETHMOZINE	3864487	FEB 04, 1994		NCE	JUN 19, 1995

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	19886 001	NAFARELIN ACETATE; SYNAREL	4234571	NOV 18, 1999		NCE	FEB 13, 1995
>ADD>	20076 001	NICOTINE; HABITROL	4597961	JUL 01, 2003	U-56		
>ADD>	20076 002	NICOTINE; HABITROL	4597961	JUL 01, 2003	U-56		
>ADD>	20076 003	NICOTINE; HABITROL	4597961	JUL 01, 2003	U-56		
	18612 001	NICOTINE POLACRILEX; NICORETTE	3901248	AUG 26, 1992		NCE	JAN 13, 1994
	19684 001	NIFEDIPINE; PROCARDIA XL	4783337	SEP 16, 2003		I-55	SEP 06, 1992
			4765989	SEP 16, 2003		D-2	SEP 06, 1992
	19684 002	NIFEDIPINE; PROCARDIA XL	4783337	SEP 16, 2003		I-55	SEP 06, 1992
			4765989	SEP 16, 2003		D-2	SEP 06, 1992
	19684 003	NIFEDIPINE; PROCARDIA XL	4783337	SEP 16, 2003		I-55	SEP 06, 1992
			4765989	SEP 16, 2003		D-2	SEP 06, 1992
>ADD>	20064 001	NITROFURANTOIN; MACROBID				NDF	DEC 24, 1994
	19508 001	NIZATIDINE; AXID	4382090	MAY 03, 2000	U-18	I-59	JUL 26, 1994
	19508 002	NIZATIDINE; AXID	4382090	MAY 03, 2000	U-18	I-59	JUL 26, 1994
>ADD>	19384 002	NORFLOXACIN; NOROXIN	4639458	JAN 27, 2004		I-66	NOV 26, 1994
>ADD>						D-17	NOV 26, 1994
	19757 001	NORFLOXACIN; CHIBROXIN	4551456	NOV 05, 2002			
			4146719	MAR 27, 1998		NDF	JUN 17, 1994
	19735 001	OFLOXACIN; FLOXIN	4382892	MAY 10, 2002			
	19735 002	OFLOXACIN; FLOXIN	4382892	MAY 10, 2002			
	19735 003	OFLOXACIN; FLOXIN	4382892	MAY 10, 2002			
	19715 001	OLSALAZINE SODIUM; DIPENTUM	4559330	AUG 04, 2004		NCE	JUL 31, 1995
	19810 001	OMEPRAZOLE; PRILOSEC	4255431	MAR 10, 2000		I-57	JUN 12, 1994
	20007 001	ONDANSETRON HYDROCHLORIDE; ZOFRAN	4753789	JUN 28, 2005	U-44	NCE	JAN 04, 1996
			4695578	JAN 03, 2005			
	20036 001	PAMIDRONATE DISODIUM; AREDIA	4711880	DEC 08, 2004		NCE	OCT 31, 1996
			3962432	JUN 08, 1993	U-53		
	20122 001	PENTOSTATIN; NIPENT	3923785	DEC 02, 1992		ODE	OCT 11, 1998
						NCE	OCT 11, 1996
	18631 001	PENTOXIFYLLINE; TRENTAL	3737433	APR 03, 1997		NCE	AUG 30, 1994
	19456 001	PINACIDIL; PINDAC	RE31244	NOV 08, 1996	U-3	NCE	DEC 28, 1994
	19456 002	PINACIDIL; PINDAC	RE31244	NOV 08, 1996	U-3	NCE	DEC 28, 1994
	19797 001	POLYETHYLENE GLYCOL 3350; NULYTELY				NP	APR 22, 1994
	19898 002	PRAVASTATIN SODIUM; PRAVACHOL	4346227	AUG 24, 1999		NCE	OCT 31, 1996
	19898 003	PRAVASTATIN SODIUM; PRAVACHOL	4346227	AUG 24, 1999		NCE	OCT 31, 1996
	19568 001	PREDNICARBATE; DERMATOP	4242334	DEC 30, 1997	U-50	NE	SEP 23, 1994
	19627 001	PROPOFOL; DIPRIVAN	4056635	NOV 01, 1996		NCE	OCT 02, 1994
	19664 001	PSEUDOEPHEDRINE HYDROCHLORIDE; SELDANE-D	3878217	APR 15, 1994		NC	AUG 19, 1994

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	19885 001	QUINAPRIL HYDROCHLORIDE; ACCUPRIL	4743450	MAY 10, 2005			
			4344949	AUG 17, 1999	U-3	NCE	NOV 19, 1996
	19885 002	QUINAPRIL HYDROCHLORIDE; ACCUPRIL	4743450	MAY 10, 2005			
			4344949	AUG 17, 1999	U-3	NCE	NOV 19, 1996
	19885 003	QUINAPRIL HYDROCHLORIDE; ACCUPRIL	4743450	MAY 10, 2005			
			4344949	AUG 17, 1999	U-3	NCE	NOV 19, 1996
	19885 004	QUINAPRIL HYDROCHLORIDE; ACCUPRIL	4743450	MAY 10, 2005			
			4344949	AUG 17, 1999	U-3	NCE	NOV 19, 1996
>ADD>	19901 001	RAMIPRIL; ALTACE	4587258	JAN 29, 2005		NCE	JAN 28, 1996
>DLT>	19901 001	RAMIPRIL; ALTACE	4587258	MAY 06, 2003		NCE	JAN 28, 1996
>ADD>	19901 002	RAMIPRIL; ALTACE	4587258	JAN 29, 2005		NCE	JAN 28, 1996
>DLT>	19901 002	RAMIPRIL; ALTACE	4587258	MAY 06, 2003		NCE	JAN 28, 1996
>ADD>	19901 003	RAMIPRIL; ALTACE	4587258	JAN 29, 2005		NCE	JAN 28, 1996
>DLT>	19901 003	RAMIPRIL; ALTACE	4587258	MAY 06, 2003		NCE	JAN 28, 1996
>ADD>	19901 004	RAMIPRIL; ALTACE	4587258	JAN 29, 2005		NCE	JAN 28, 1996
>DLT>	19901 004	RAMIPRIL; ALTACE	4587258	MAY 06, 2003		NCE	JAN 28, 1996
	19863 001	SERMORELIN ACETATE; GEREF	4703035	DEC 28, 2004	U-47	NCE	DEC 28, 1995
			4517181	MAY 14, 2002		NCE	DEC 28, 1995
>ADD>	19839 001	SERTRALINE HYDROCHLORIDE; ZOLOFT	4536518	AUG 20, 2002		NCE	DEC 30, 1996
>ADD>	19839 002	SERTRALINE HYDROCHLORIDE; ZOLOFT	4536518	AUG 20, 2002		NCE	DEC 30, 1996
>ADD>	19839 003	SERTRALINE HYDROCHLORIDE; ZOLOFT	4536518	AUG 20, 2002		NCE	DEC 30, 1996
>ADD>	19839 004	SERTRALINE HYDROCHLORIDE; ZOLOFT	4536518	AUG 20, 2002		NCE	DEC 30, 1996
>ADD>	19766 001	SIMVASTATIN; ZOCOR	4444784	APR 24, 2001		NCE	DEC 23, 1997
>ADD>	19766 002	SIMVASTATIN; ZOCOR	4444784	APR 24, 2001		NCE	DEC 23, 1997
>ADD>	19766 003	SIMVASTATIN; ZOCOR	4444784	APR 24, 2001		NCE	DEC 23, 1997
>ADD>	19766 004	SIMVASTATIN; ZOCOR	4444784	APR 24, 2001		NCE	DEC 23, 1997
						NCE	JAN 30, 1996
	19998 002	SUCCIMER; CHEMET				ODE	JAN 30, 1998
	19981 001	TECHNETIUM TC-99M RED BLOOD CELL KIT; ULTRATAG	4755375	JUL 05, 2005	U-51	NC	JUN 10, 1994
	19785 001	TECHNETIUM TC-99M SESTAMIBI KIT; CARDIOLITE	4452774	SEP 09, 2004		NCE	DEC 21, 1995
	19785 002	TECHNETIUM TC-99M SESTAMIBI KIT; CARDIOLITE	4452774	SEP 09, 2004		NCE	DEC 21, 1995
	18163 001	TEMAZEPAM; RESTORIL				D-17	OCT 25, 1994
						NS	OCT 25, 1994
	18163 002	TEMAZEPAM; RESTORIL				D-17	OCT 25, 1994
						NS	OCT 25, 1994
	18163 003	TEMAZEPAM; RESTORIL				D-17	OCT 25, 1994
						NS	OCT 25, 1994
	19979 001	TICLOPIDINE HYDROCHLORIDE; TICLID	4591592	MAY 27, 2003			
			4051141	SEP 27, 1994		NCE	OCT 31, 1996
	19979 002	TICLOPIDINE HYDROCHLORIDE; TICLID	4591592	MAY 27, 2003		NCE	OCT 31, 1996
			4051141	SEP 27, 1994			
	19798 001	TRIAMCINOLONE ACETONIDE; NASACORT				NR	JUL 11, 1994

*U.S. Government Printing Office: 1992 — 312-211/40006

New 12th Edition

APPROVED DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

12TH EDITION

Superintendent of Documents Subscriptions Order Form

Order Processing Code
* 6126

Charge your order. It's easy!

MasterCard VISA

☐ **Yes,** please send me the following indicated subscriptions:

__ subscriptions of **APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS**, ADP, and the monthly Cumulative Supplements, for $95.00 per year.

1. The total cost of my order is $_____. All prices include regular domestic postage and handling and are subject to change. International customers please add 25%.

Please Type or Print

2. _____
(Company or personal name)

_____
(Additional address/attention line)

_____
(Street address)

_____
(City, State, ZIP Code)

(_____) _____
(Daytime phone including area code)

3. **Please choose method of payment.**

☐ Check payable to Superintendent of Documents

☐ GPO Deposit Account ☐☐☐☐☐☐☐ – ☐

☐ VISA or MasterCard

☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐

_____
(Credit card expiration date)

Thank you for your order!

_____
(Signature)

(10/91)

4. **Mail To:** Superintendent of Documents, Government Printing Office, Washington, DC 20402-9371.
To **FAX** your charge order, call (202) 512-0019.
To charge your subscription call (202) 783-3238.